---
document_datetime: 2025-01-27 11:48:26
document_pages: 116
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/ahzantive-epar-public-assessment-report_en.pdf
document_name: ahzantive-epar-public-assessment-report_en.pdf
version: success
processing_time: 167.572556
conversion_datetime: 2025-12-15 01:17:26.512805
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
14 November 2024 EMA/CHMP/565845/2024

Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Ahzantive

International non-proprietary name: aflibercept

Procedure No. EMEA/H/C/006607/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                              | ..............................................6                                                           |
|-------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier....................................................................................      | 6                                                                                                         |
| 1.2. Legal basis, dossier content and multiples                                                                         | ............................................................. 6                                           |
| 1.3. Information on Paediatric requirements.................................................................            | 7                                                                                                         |
| 1.4. Information relating to orphan market exclusivity                                                                  | ................................................... 7                                                     |
| 1.4.1. Similarity                                                                                                       | ....................................................................................................... 7 |
| 1.5. Scientific advice................................................................................................. | 7                                                                                                         |
| 1.6. Steps taken for the assessment of the product                                                                      | ....................................................... 8                                                 |
| 2. Scientific discussion                                                                                                | ................................................................................8                         |
| 2.1. About the product                                                                                                  | .............................................................................................. 8          |
| 2.2. Type of Application and aspects on development                                                                     | .................................................... 9                                                    |
| 2.3. Quality aspects                                                                                                    | .................................................................................................. 9      |
| 2.3.1. Introduction                                                                                                     | ................................................................................................... 9     |
| 2.3.2. Active substance                                                                                                 | ............................................................................................. 9           |
| 2.3.3. Finished medicinal product..............................................................................         | 15                                                                                                        |
| 2.3.4. Discussion on chemical, and pharmaceutical aspects ..........................................                    | 21                                                                                                        |
| 2.3.5. Conclusions on the chemical, pharmaceutical and biological aspects                                               | ..................... 23                                                                                  |
| 2.3.6. Recommendations for future quality development                                                                   | .............................................. 24                                                         |
| 2.4. Non-clinical aspects..........................................................................................     | 24                                                                                                        |
| 2.4.1. Introduction .................................................................................................   | 24                                                                                                        |
| 2.4.2. Pharmacology...............................................................................................      | 24                                                                                                        |
| 2.4.3. Pharmacokinetics ..........................................................................................      | 24                                                                                                        |
| 2.4.4. Toxicology....................................................................................................   | 25                                                                                                        |
| 2.4.5. Ecotoxicity/environmental risk assessment........................................................                | 26                                                                                                        |
| 2.4.6. Discussion on non-clinical aspects....................................................................           | 26                                                                                                        |
| 2.4.7. Conclusion on the non-clinical aspects..............................................................             | 26                                                                                                        |
| 2.5. Clinical aspects ................................................................................................  | 27                                                                                                        |
| 2.5.1. Introduction                                                                                                     | ................................................................................................. 27      |
| 2.5.2. Clinical pharmacology                                                                                            | .................................................................................... 27                   |
| 2.5.3. Discussion on clinical pharmacology .................................................................            | 31                                                                                                        |
| 2.5.4. Conclusions on clinical pharmacology ...............................................................             | 33                                                                                                        |
| 2.5.5. Clinical efficacy                                                                                                | ............................................................................................. 34          |
| 2.5.6. Discussion on clinical efficacy ..........................................................................       | 68                                                                                                        |
| 2.5.7. Conclusions on the clinical efficacy...................................................................          | 75                                                                                                        |
| 2.5.8. Clinical safety                                                                                                  | ............................................................................................... 75        |
| 2.5.9. Discussion on clinical safety ............................................................................       | 93                                                                                                        |
| 2.5.10. Conclusions on the clinical safety                                                                              | ..................................................................102                                     |
| 2.6. Risk Management                                                                                                    | Plan.....................................................................................103              |
| 2.6.1. Safety concerns                                                                                                  | ...........................................................................................103            |
| 2.6.2. Pharmacovigilance plan.................................................................................103       |                                                                                                           |
| 2.6.3. Risk minimisation measures...........................................................................103         |                                                                                                           |
| 2.6.4. Conclusion...................................................................................................107 |                                                                                                           |
| 2.7. Pharmacovigilance...........................................................................................108    |                                                                                                           |

<div style=\"page-break-after: always\"></div>

| 2.7.1. Pharmacovigilance system.............................................................................108       |
|-----------------------------------------------------------------------------------------------------------------------|
| 2.7.2. Periodic Safety Update Reports submission requirements ...................................108                  |
| 2.8. Product information.........................................................................................108  |
| 2.8.1. User consultation..........................................................................................108 |
| 2.8.2. Additional monitoring....................................................................................108   |
| 3. Biosimilarity assessment.....................................................................108                   |
| 3.1. Comparability exercise and indications claimed....................................................108            |
| 3.2. Results supporting biosimilarity.........................................................................109     |
| 3.3. Uncertainties and limitations about biosimilarity ..................................................111          |
| 3.4. Discussion on biosimilarity................................................................................112   |
| 3.5. Extrapolation of safety and efficacy....................................................................113      |
| 3.6. Additional considerations..................................................................................114   |
| 3.7. Conclusions on biosimilarity and benefit risk balance ............................................114            |
| 4. Recommendations...............................................................................114                  |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADA Anti-drug antibody ADCC Antibody-dependent cell mediated cytotoxicity ADR Adverse drug reaction AE Adverse event AESI Adverse event of special interest AMD Age-related macular degeneration ANCOVA Analysis of covariance ATC Anatomical therapeutic chemical ATE Arterial thromboembolic events BCVA Best corrected visual acuity BLA Biologics licence application BLI Biolayer interferometry BMI Body mass index CD Circular dichroism CDC Complement dependent cytotoxicity CFP Colour fundus photography CI Confidence interval Cmax Maximum serum concentration CNV Choroidal neovascularisation CQA Critical quality attributes CSR Clinical study report CTAD Citrate-theophylline-adenosine-dipyridamole CTD Common technical document DME Diabetic macular oedema DR Diabetic retinopathy DRE Disease-related event ECL Electrochemiluminescence EMA European Medicines Agency ETDRS  Early Treatment Diabetic Retinopathy Study FA Fluorescein angiography FAS Full analysis set FCP Foveal centre point FCS Foveal centre subfield FDA Food and Drug Administration FP Fundus photography GCP Good clinical practice GLP Good laboratory practice GMP Good manufacturing practice ICF Informed consent form Ig Immunoglobulin IgG Immunoglobulin G IOP Intraocular pressure IQR Interquartile range ISI Integrated Summary of Immunogenicity IVT Intravitreal L Liter LC-MS  Liquid chromatography-mass spectrometry LloQ Lower limit of quantification LOQ Limit of quantification LS Least squares MAR Missing at random mCNV  Myopic choroidal neovascularisation MedDRA Medical Dictionary for Regulatory Activities MMRM  Mixed model repeated measurements MNAR Missing not at random MNV Macular neovascularisation MoA Mechanism of action MSD Meso scale discovery N Total number of patients in the analysis set n Number of patients with non-missing assessments NAb Neutralising antibody

<div style=\"page-break-after: always\"></div>

nAMD Neovascular AMD n.c. Not calculable NEI VFQ-25 National Eye Institute Visual Function Questionnaire 25 nmiss Number of patients with missing values/assessments OCT Optical coherence tomography PD Pharmacodynamics PDE Pigment epithelium detachment PI Prescribing information PK Pharmacokinetics PKS Plasma concentration analysis set PlGF Placental growth factor PMDA Pharmaceuticals and Medical Devices Agency PPS Per protocol set PT Preferred term Ref. Reference RDTS   Repeat-dose toxicology study RMP Reference medicinal product ROW Rest of world RVO Retinal vein occlusion SAE Serious adverse event SAF Safety analysis set SAP Statistical analysis plan SD Standard deviation SD-OCT Spectral Domain Optical Coherence Tomography SE Standard error SmPC Summary of product characteristics SOC System organ class TEAE Treatment emergent adverse event ULN Upper limit of normal US Unites States VA Visual acuity VEGF Vascular endothelial growth factor VEGFR  Vascular endothelial growth factor receptor vs. Versus ∆ Difference

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Klinge Biopharma GmbH submitted on 25 April 2024 an application for marketing authorisation to the European Medicines Agency (EMA) for Ahzantive, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 22 July 2021.

The applicant applied for the following indication:

Ahzantive is indicated for adults for the treatment of

- neovascular (wet) age-related macular degeneration (AMD) (see section 5.1)
- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1)
- visual impairment due to diabetic macular oedema (DME) (see section 5.1)
- visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1).

## 1.2. Legal basis, dossier content and multiples

## The legal basis for this application refers to:

Article 10(4) of Directive 2001/83/EC - relating to applications for a biosimilar medicinal products.

The application submitted is composed of administrative information, complete quality data, appropriate non-clinical and clinical data for a similar biological medicinal product.

This application is submitted as a multiple of Baiama simultaneously being under initial assessment in accordance with Article 82.1 of Regulation (EC) No 726/2004.

The chosen reference product is:

Medicinal product which is or has been authorised in accordance with Union provisions in force for not less than 10 years in the EEA:

- Product name, strength, pharmaceutical form: Eylea 40 mg/mL solution for injection
- Marketing authorisation holder: Bayer AG
- Date of authorisation: 22-11-2012
- Marketing authorisation granted by: Union
- Marketing authorisation number: EU/1/12/797/001-002

Medicinal product authorised in the Union/Members State where the application is made or European reference medicinal product:

- Product name, strength, pharmaceutical form: Eylea 40 mg/mL solution for injection
- Marketing authorisation holder: Bayer AG
- Date of authorisation: 22-11-2012
- Marketing authorisation granted by: Union
- Marketing authorisation number: EU/1/12/797/001-002

<div style=\"page-break-after: always\"></div>

Medicinal product which is or has been authorised in accordance with Union provisions in force and to which bioequivalence has been demonstrated by appropriate bioavailability studies:

- Product name, strength, pharmaceutical form: Eylea 40 mg/mL solution for injection

- Marketing authorisation holder: Bayer AG

- Date of authorisation: 22-11-2012

- Marketing authorisation granted by: Union

- Marketing authorisation number(s): EU/1/12/797/001-002

- Bioavailability study number(s): FYB203-03-01

## 1.3. Information on paediatric requirements

Not applicable

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## 1.5. Scientific advice

The applicant received the following scientific advice on the development relevant for the indication subject to the present application:

| Date         | Reference                 | SAWP co-ordinators                                          |
|--------------|---------------------------|-------------------------------------------------------------|
| 25 July 2019 | EMEA/H/SA/4194/1/2019/III | Prof Andrea Laslop, Dr Rune Kjeken and Dr Kerstin Wickström |

The scientific advice pertained to the following quality, non-clinical, and clinical aspects:

- Quality: analytical similarity assessment plan, preliminary analytical similarity data, quality attributes, release and stability testing, analytical assessments, grouping
- Non-clinical: PK and toxicology studies
- Clinical: PK study, direct entry into patients, confirmatory efficacy and safety study (overall study design, safety parameter, immunogenicity assessment, population, proposed primary endpoint, therapeutic equivalence, secondary endpoints, statistical evaluation, sample size, interim analysis, adaptation of sample size).

<div style=\"page-break-after: always\"></div>

## 1.6. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Tomas Radimersky

Co-Rapporteur:  Christian Gartner

CHMP Peer reviewer(s): N/A

| The application was received by the EMA on                                                                                                                                                | 25 April 2024     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The procedure started on                                                                                                                                                                  | 28 May 2024       |
| The CHMP Rapporteurs' first assessment report was circulated to all CHMP and PRAC members on                                                                                              | 28 August 2024    |
| The PRAC Rapporteur's first assessment report was circulated to all PRAC and CHMP members on                                                                                              | 03 September 2024 |
| The PRAC agreed on the PRAC assessment overview and advice to CHMP during the meeting on                                                                                                  | 05 September 2024 |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                                                   | 19 September 2024 |
| The applicant submitted the responses to the CHMP list of outstanding issues on                                                                                                           | 10 October 2024   |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs joint assessment report on the responses to the list of outstanding issues to all CHMP and PRAC members on                  | 29 October 2024   |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs updated joint assessment report on the responses to the list of outstanding issues to all CHMP and PRAC members on          | 07 November 2024  |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Ahzantive on | 14 November 2024  |

## 2. Scientific discussion

## 2.1. About the product

Ahzantive (also referred to as FYB203) 40 mg/mL solution for injection in a vial has been developed as a biosimilar to the reference product Eylea (INN: aflibercept; EMEA/H/C/002392).

Aflibercept is in the pharmaceutical group 'ophthalmologicals / antineovascularisation agents' (ATC code: S01LA05).

Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptor 1 and 2 extracellular domains fused to the Fc portion of human immunoglobulin G1. It acts as a soluble decoy receptor that binds VEGF-A and PlGF with higher affinity than their natural receptors, and thereby can inhibit the binding and activation of these cognate VEGF receptors.

The claimed therapeutic indications for Ahzantive are: in adults for the treatment of

<div style=\"page-break-after: always\"></div>

- neovascular (wet) age-related macular degeneration (AMD) (see section 5.1),
- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),
- visual impairment due to diabetic macular oedema (DME) (see section 5.1),
- visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1).

The indication of treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease in preterm infants - granted to Eylea 40 mg/mL solution for injection in pre-filled syringe - is not claimed.

## 2.2. Type of application and aspects on development

Scientific advice: during the development of FYB203 a written scientific advice was obtained from the European Medicines Agency (EMA).

## 2.3. Quality aspects

## 2.3.1. Introduction

FYB203 ( aflibercept aflibercept company code) was developed as biosimilar to Eylea (aflibercept) as reference product.

The finished product is presented as a solution for injection in vial containing 40 mg/ml of Aflibercerpt as active substance.

Other ingredients are: polysorbate 20 (E 432), histidine hydrochloride monohydrate (for pH adjustment), histidine (for pH adjustment), sodium chloride, sucrose and water for injections.

The product is available in a vial (type I glass) with a stopper (elastomeric butyl rubber). Each vial contains an extractable volume of at least 0.1 mL. Pack size of 1 vial.

## 2.3.2. Active substance

## 2.3.2.1. General information

The active substance (INN: aflibercept; company code FYB203) is a recombinant fusion protein consisting of human vascular endothelial growth factor (VEGF) receptor-1 (VEGFR-1) and VEGF receptor-2 (VEGFR-2) extracellular domains fused to the Fc portion of human IgG1 and is produced in Chinese hamster ovary (CHO) cells.

FYB203 active substance is a colourless to pale yellow solution, containing 36.0-44.0 mg/mL of aflibercept. The solution is stored frozen at ≤ -60°C.

FYB203 is a homodimeric recombinant fusion glycoprotein. Each molecule of aflibercept consists of the extracellular domain 2 (D2) of human vascular endothelial growth factor receptor (VEGFR- 1 D2) and domain 3 (D3) of VEGFR-2 (VEGFR-2 D3), fused to the Fc domain of human immunoglobulin G1 (IgG1).

Aflibercept acts as a soluble decoy receptor that binds VEGF-A, VEGF-B and P1GF and thereby can inhibit the binding and activation of their natural receptors. Pharmacological inhibition of VEGF-A has been demonstrated to be effective at preventing angiogenesis and vascular leakage associated with various

<div style=\"page-break-after: always\"></div>

eye diseases. Inhibition of VEGF-A is aflibercept´s main mechanism of action and it is identical for all indications for which Eylea is licensed or approved. The biological activity of FYB203 active substance is monitored via the cell-based iLite potency assay.

The major structural characteristics of FYB203 active substance are summarised below.

Molecular formula: C4318H6788N1164O1304S32

Number of amino acids: 864 in total, the polypeptide chains of each molecule unit consist of 432 amino acids

Number of disulfide bridges: 8 intra-chain bonds, 2 inter-chain bonds

Theoretical molecular weight: Unglycosylated protein: 96.9 kDa, Glycosylated protein: 115 kDa

Isoelectric point value 5.8-8.3

Molecular absorption (280 nm):  Specific extinction coefficient of aflibercept: 1.155 L*g -1 *cm -1

The  nomenclature,  chemical  description  and  the  company  code  (FYB203)  of  aflibercept  are  clearly defined.  The  FYB203  structure  consist  of  a  homodimeric  recombinant  fusion  glycoprotein  of  864  AS length with each built of the extracellular D2 domain of human VEGF-1 receptor and D3 domain of human VEGFR-2 receptor fused to the Fc domain of human IgG1. Disulfide bonds, glycosylation and the mode of action of aflibercept are described in detail.

## 2.3.2.2. Manufacture, process controls and characterisation

All manufacturing and testing sites are covered by valid GMP certificates. Active substance manufacturing sites are appropriately listed in the dossier and responsibilities of individual quality control testing sites are specified.

## Description of manufacturing process and process controls

The  active  substance  manufacturing  process  has  been  adequately  described.  The  FYB203  active substance manufacturing process is a standard process for recombinant protein production, starting with a single vial of working cell bank, expansion in shake flasks, wave bags, seed bioreactors and a cultivation in production bioreactor. The downstream process consists of chromatographic, filtrations and additional steps for virus removal/inactivation and formulation of bulk active substance. filling and freezing. Limits for  the  process  parameters  and  in-process  controls  are  derived  from  process  characterisation  and development activities.

The  ranges  of  critical  process  parameters  and  the  routine  in-process  controls  (IPCs)  along  with acceptance criteria, including controls for microbial purity and endotoxin, are described for each step. The applicant provided a detailed description of the manufacturing process steps that is accompanied by flow  charts  and  tables  listing  process  parameters  and  IPCs  with  their  classification  and  acceptable ranges/acceptance criteria/action limits. Information on Critical process parameter (CPP), Key process parameters  (KPP),  Critical  performance  attributes  (CPA)  and  Key  performance  attributes  (KPA)  is included. Acceptance criteria, action limits and/or additional alert limits, as applicable to critical/key and non-key  in-process  controls  are  also  presented.  The  active  substance  manufacturing  process  is considered acceptable.

## Control of materials

Sufficient information on raw materials used in the active substance manufacturing process has been submitted. Compendial raw materials are tested in accordance with the corresponding monograph, while specifications (including test methods) for non-compendial raw materials are presented in the dossier. No human or animal derived materials are used in the active substance manufacturing process and

<div style=\"page-break-after: always\"></div>

acceptable documents have been provided for raw materials of biological origin used in the establishment of cell substrate.

Comprehensive testing of MCB and WCB in line with ICH Q5D and Q1A (R1) was performed with respect to the cell banks' identity, purity, viability, viral safety and genetic properties. Characterisation reports for the MCB, WCB and LIVCA cell banks were provided, as well as the testing reports for unprocessed bulk, and the applicant has established periodic testing of the cell banks during storage.

Raw materials and consumables are appropriately tested when released into the production process.

## Control of critical steps and intermediates

The manufacturing process is well described and its control strategy, which includes input and output process parameters and in-process controls, is clearly defined. A comprehensive overview of critical in-process  controls  and  critical  in-process  tests  performed  throughout  the  FYB203  active  substance manufacturing process is given. Acceptable information has been provided on the control system in place to monitor and control the active substance manufacturing process with regard to critical, as well as noncritical operational parameters and in-process tests. Limits are provided for both process parameters and IPCs (justified by process characterisation) and the consequences for failing to meet them are clearly described. In the main, the PPs and IPCs and their respective ranges/limits are considered adequate. Actions taken if limits are exceeded are specified.

## Process validation

The  FYB203  active  substance  manufacturing  process  has  been  validated  adequately.  Overall,  the validation criteria are acceptable.

Process performance qualification and validation activities included process consistency (PPQ), in vitro cell age study, impurity clearance study, process hold study, membrane and chromatographic column performance,  extractables  and  leachables  evaluation,  active  substance  transport  validation  and reprocessing/  repeated  filtration  evaluation.  Process  consistency  validation  (PV)  is  based  on  the commercial  manufacturing  process,  using  a  sufficient  number  of  consecutive  batches.  Following  the process validation, the process was further refined using the available manufacturing scale data.

It has been demonstrated that differences in charge forms and sialylation do not impact the potency of the finished product. Additional detailed data and discussion support the appropriateness of the process characterisation strategy.

## Impurities

Validation  of  process-related  impurities  and  product-related  impurities  was  performed  by  their measurement at the individual process steps of the PPQ runs. Impurities were consistently reduced to acceptable low levels/below the LOQ/LOD. Elemental impurities and their possible sources were tested and found below the respective PDE and were therefore considered negligible.

## Hold-times

The  maximum  acceptable  hold  times  were  validated  with  respect  to  microbial  and  physicochemical stability.

## Membrane and column performance

Resin lifetimes and potential carry-over, and re-usability have been investigated. The membrane and resin  lifetimes  were  first  investigated  for  a  defined  number  of  use  cycles  by  performing  prospective studies at small-scale using qualified scale-down models (SDM) loaded with representative material from

<div style=\"page-break-after: always\"></div>

manufacturing scale batches. Further, in order to confirm the resin and membrane lifetime established at small-scale, a concurrent validation study at manufacturing scale is performed.

## No carry-over was observed

## In-vitro cell age

Following  the  ICH  Q5D  recommendations,  an in  vitro cell  age  (IVCA)  study  was  carried  out  for  the commercial scale FYB203 active substance manufacturing process to confirm the genetic stability and adventitious agents safety of the production cells at the end of production (EoP). Furthermore, a smallscale IVCA study was designed and performed to demonstrate genetic stability and consistent process performance and product quality over an extended cultivation period.

## Qualification of scale-down models

Scale-down models (were appropriately qualified and offsets were determined for some of the product quality attributes at certain steps so that the comparability of the results from the small-scale models to the manufacturing scale could be established.

## Extractables and leachables

Based  on  a  comprehensive  risk  assessment  for  extractables  and  leachables  a  product-specific extractables study was performed for the identified high-risk equipment. A toxicological risk assessment was subsequently performed for the identified extractables above the analytical evaluation threshold, which did not reveal any safety concerns for patients.

## Shipping validation

Data  supporting  shipment  of  the  active  substance  from  the  manufacturing  site  to  finished  product manufacturing site have been provided and are considered acceptable.

## Reprocessing and repeated filtration

Limited to refiltration in the event of equipment/technical failure at the bioburden reduction filtration, virus filtration and final filtration steps. Lack of impact on product quality was demonstrated in smallscale studies and an adequate protocol for concurrent validation of reprocessing was provided.

## Manufacturing process development

The applicant has provided an extensive description of the activities performed in the course of the manufacturing process development (together with data from supportive studies) and it is acknowledged that the batch release data support the comparability of the relevant batches. A number of changes in the  manufacturing  process  were  introduced  only  after  the  validation  campaign.  These  are  generally justified or involve tightening of applied limits. The presented approach to process characterisation was deemed well described and acceptable.

The  development  of  the  FYB203  active  substance  manufacturing  process  was  initiated  in  one manufacturing site at laboratory scale. Consequently, the process was transferred to the commercial manufacturing site, where confirmation runs were executed, which were followed by scale-up to pilot scale (for preclinical supply) and eventually a commercial scale process. The commercial process was further modified, which was established to support the clinical development and commercial production. Initial GMP batches were followed by process validation batches.

## Quality by Design (QbD)

The manufacturing process has been evaluated using a combination of conventional univariate studies and elements of quality by design (QbD) process characterisation (PC) is a systematic re-evaluation of

<div style=\"page-break-after: always\"></div>

development data  and  includes  experiments  aimed  at  evaluating  and  confirming  process  parameter criticality and acceptable ranges (AR) for the final manufacturing process. The overall goal of PC is to assess  and  subsequently  ensure  robustness  of  the  process,  which  finally  is  capable  of  consistently delivering a product that is safe and efficacious.

PC was conducted in accordance with current ICH requirements including QbD principles. PC included systematic evaluation of representative small scale and manufacturing scale data, risk assessments, and laboratory scale studies.

As a major outcome of PC, a robust process with performance and product quality within defined ranges was established.

The main deliverables of PC were:

- Classification of the process parameters into critical, key, and non-key as well as definition of the respective acceptable ranges.
-  Development  of  a  control  strategy  including  justifications  for  in-process  controls  (IPC) classifications into critical, key, and non-key.

The presented approach to process characterisation was deemed well described and acceptable.

## Characterisation

The FYB203 active substance has been sufficiently characterised by physicochemical and biological stateof-the-art methods revealing that the active substance has the expected structure of a recombinant fusion protein. The characterisation overall is sufficiently detailed, and results/observations are discussed in the dossier. Where multiple batches are analysed by the same method, the results appear consistent across the batches, save small differences attributable to method variability. A detailed description of experiments focused on the investigation of the charge forms, glycosylation and their impact on potency is  presented, demonstrating the determining role of sialylation of the abundance of acidic forms and confirming that neither charge forms nor sialylation have observable effect on potency of the finished product.

## Impurities

The applicant has identified product-related impurities as well as process-related impurities.

## 2.3.2.3. Specification

The proposed release specification for FYB203 Active substance includes compendial tests for colour, clarity  of  solution,  pH  and  osmolality.  Microbial  purity  including  bioburden  (TAMC  and  TYMC)  and Endotoxins  respectively.  Non-compendial  tests  comprise  polysorbate  20  content,  identity,  quantity, potency, purity and process-related impurities as well as product related impurities

To derive acceptance criteria for release specifications, the applicant uses a combination of data from clinical trial material and PPQ batches. As the resulting acceptance criteria can be considered sufficiently tight, reflecting both the results of the clinical trial material and the capabilities of the manufacturing process, no objection is raised concerning the general approach and the majority of the acceptance criteria are considered justified.

## Analytical methods

The analytical methods used have been adequately described and appropriately validated in accordance with ICH guidelines.

<div style=\"page-break-after: always\"></div>

Panel of tests contains pharmacopoeial and in-house methods. References for Ph.Eur. monographs and sufficient descriptions of in-house methods were provided.

## Validation of analytical procedures

Verification summaries for Ph.Eur. methods were provided, as well as validation summaries for in-house methods. Validations of analytical procedures were conducted in compliance with principles laid out in ICH Q2(R1).

## Batch analysis

Batch analysis data of commercial scale batches of the FYB203 active substance were provided. The results are within the specifications and confirm consistency of the manufacturing process.

The presented batch release results are within specifications valid at the time of release and show good consistency of the manufacturing process output.

## Reference materials

For routine release testing a two-tiered reference standard system is established. The stated criteria for qualification of the reference standards are considered adequate and potential drift in potency of the PRS is  deemed  to  be  well  controlled.  Furthermore,  the  applicant  has  provided  detailed  results  for  the replicates measured at reference standard qualifications.

## 2.3.2.4. Stability

The  stability  results  indicate  that  the  FYB203  active  substance  is  sufficiently  stable  and  justify  the proposed shelf life in the proposed container.

A  number  of  batches  manufactured  from  the  commercial  process  were  stored  in  commercially representative primary containers, The stability studies are in line with ICH Q5C.

Stability of FYB203 active substance batches was investigated under long-term, accelerated, and stress conditions according to the ICH guidelines. Additionally, a freeze-thaw study was performed.

Most  parameters  tested  are  the  same  as  for  release  where  the  same  analytical  methods  and specifications apply. In support of the proposed shelf-life, long-term stability data stability studies were performed in representative batches. Overall, the stability data support the proposed shelf-life. As it has been shown that unprotected aflibercept is susceptible to photo-degradation, the applicant has confirmed that the active substance is stored protected from light.

No trends are observed in the long-term storage conditions. In accelerated and stressed studies the stability is demonstrated. Photostability studies were performed demonstrating that the active substance is susceptible to photo-degradation and hence should be stored protected from light.

A post-approval stability protocol was provided, together with a stability commitment of placing one batch of FYB203 active substance on stability each year which is acceptable. Overall, the studies have been carried out in accordance with current regulatory guidelines.

Any  confirmed  out-of-specification  result,  or  significant  negative  trend,  should  be  reported  to  the Rapporteur and EMA.

<div style=\"page-break-after: always\"></div>

## 2.3.3. Finished medicinal product

## 2.3.3.1. Description of the product and Pharmaceutical development

FYB203 finished product is a sterile solution for intravitreal injection with 40 mg/mL aflibercept in a single-use vial. With the exception of active substance, all components are compendial to Ph. Eur.

For  FYB203  finished  product,  an  alternative  formulation  was  developed  compared  to  the  reference product  Eylea  differing  in  the  buffer  system  used.  This  alternative  formulation  is  based  on  wellestablished compendial excipients L-histidine / L-histidine HCl monohydrate, sodium chloride, sucrose and polysorbate 20.

The container closure system for FYB203 finished product consists of a 2R borosilicate Type I glass vial and a butyl rubber stopper sealed by an aluminium crimp cap with a plastic flip-off cap attached.

The FYB203 finished product solution in vials is sterilised by use of sterile filtration. FYB203 finished product is a temperature-susceptible proteinaceous solution and thus a terminal sterilisation process with moist heat is not feasible. The method of sterilisation is sufficiently justified.

Process characterisation studies were performed to evaluate some of the process parameters. Results from process characterisation studies were further verified during process validation.

The toxicological assessment revealed no specific, highly potent extractables for the primary packaging of FYB203 finished product vials. The material complies with Ph. Eur. and EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product. FYB203 40 mg/mL vials have been designed to deliver the same therapeutic dose of aflibercept as the reference medicinal product ( RMP) Eylea. Thus, a dose of 0.05 mL must be ensured for the intravitreal (IVT) injection, meaning that a deliverable volume of 0.05 mL must be guaranteed to deliver 2 mg aflibercept with one IVT injection .

The product should be supplied as a vial only. According to the SmPC, for preparation and intravitreal injection the following medical devices for single use are needed. A 5-micron sterile filter needle (18gauge x 1½-inch), a 1-mL sterile Luer-lock syringe and a 30 G x ½-inch sterile injection needle are needed for the intravitreal injection. These medical devices are considered as referenced. Representative components were used for in-use compatibility study on the device combination.

There are no novel excipients used in the finished product formulation.

## 2.3.3.2. Manufacture of the product and process controls

The  finished  product  is  manufactured  by  standard  process  covering  thawing  and  pooling  of  active substance,  bioburden  reduction  filtration,  sterile  filtration,  filling  and  stoppering,  crimping,  visual inspection, and packaging for shipment. Representative flow diagram was provided including IPCs. The manufacturing process has been validated. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The in-process controls are adequate.

Reprocessing for finished product is not considered.

Finished product manufacturing sites are appropriately listed in the dossier and responsibilities of the individual quality control sites are specified. A flow-chart indicating all manufacturing and control sites involved in the manufacturing process and control of the medicinal product was submitted.

All sites are covered by valid MIA/GMP certificates.

<div style=\"page-break-after: always\"></div>

## Process controls

An  input  process  parameter  whose  variation  has  an  impact  on  a  CQA  is  defined  as  critical  process parameter  (CPP).  Operating  ranges  (OR)  and  acceptable  ranges  (AR)  were  considered  for  process parameters. An output parameter whose variability has the potential to affect a CQA in the final product is  defined  as  critical  in-process  control  (CIPC).  Acceptance  criterion  or  action  limit  and  optionally  an additional  alert  limit  was  considered  for  process  controls.  The  proposed  control  classification  seems reasonable. The criticality assessment of the operational parameters and process controls is supported by FMEA evaluation. Hold times are clearly identified and controlled. Suitability of endotoxin testing and bioburden testing was demonstrated. The batch numbering system in place ensures uniqueness and traceability of manufactured batches.

## Process validation

The  manufacturing  process  has  been  validated.  Process  validation  covers  all  finished  product manufacturing steps and was performed following a classical approach. All PPQ batches met in-process controls  and  acceptance  criteria.  The  provided  data  demonstrates  that  when  operating  within  the proposed ranges, the performance controls meet relevant quality criteria. An ongoing process verification programme is implemented in order to maintain the process in validated state.

## Hold time validation

Holding times for commercial manufacturing process are covered by hold time validation studies. Filling and crimping time is covered by performed media-fill runs. Results from physicochemical and microbial stability analyses are presented. Samples were analysed for certain quality attributes to demonstrate the physico-chemical and microbial stability of the interim finished product stages.

## Filter validation

The filter validation demonstrated that the sterile filter is suitable for manufacturing.

## Media fill

The aseptic filling operations were validated via media fill runs. A bracketing approach is applied to validate aseptic filling operations.

## Transport validation

The suitability of the transport was determined using a transport simulation study. After simulation the pallets  and  all  packaging  levels  have  been  optically  checked  for  defects  caused  by  exposure  to  the selected  stress  conditions.  After  transport  simulation  study  the  analytical  testing  of  finished  product samples  was  performed.  No  impacts  on  product  quality  were  noted  following  mechanical  stress, indicating  that  the  shipping  system  can  maintain  product  integrity  during  the  transportation.  The applicant is asked to provide corresponding results upon availability. Details of the temperature excursion studies as well as to the approved shipping container(s) have been provided upon request

## Comparability studies

Comparability  studies  between  different  manufacturing  sites  at  finished  product  were  performed. Analytical comparability study assessing IPC results, extended characterisation data, release data, and stability profiles at different storage conditions was performed

<div style=\"page-break-after: always\"></div>

## 2.3.3.3. Product specification

The release specifications include tests for identity, potency, purity, microbial purity as well as general attributes that were assessed using compendial methods. The limits are sufficiently justified and are considered adequate to control the quality of FYB203 drug product.

The limits are sufficiently justified and are considered adequate to control the quality of FYB203 drug product.

The sequential approach to define release and shelf-life specifications is described. The overall risk of a potential release of elemental impurities into the drug product caused by the sources like drug substance, excipients,  process  equipment  with  direct  product  contact  and  primary  packaging  components  is assessed as low and an establishment of a special control strategy to control the elemental impurities in FYB203 finished product vials is not required. All processes for manufacturing FYB203 finished product vials  are  under  control  regarding  the  level  of  elemental  impurities.  Any  future  change  made  to  the processes will be subjected to change control processes and the potential impact will be evaluated.

A risk evaluation concerning the presence of nitrosamine impurities in the finished product has been performed considering all suspected and actual root causes in line with the 'Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine impurities in human medicinal products' (EMA/369136/2020). Based on the information provided it is accepted that a negligible potential safety risk for FYB203 active substance or the related finished product was identified. Therefore, no additional control measures are deemed necessary.

## Analytical methods

The  analytical  methods  used  have  been  adequately  described  and  (non-compendial  methods) appropriately validated in accordance with ICH guidelines.

## Analytical procedures

Majority  of  analytical  procedures  used  are  the  same  as  described  in  active  substance  section,  with addition of usual methods used for finished products, e.g. extractable volume test or container closure integrity test Sufficient descriptions were provided, comments regarding equipment or reagent changes remain the same as described in active substance section. Unique method identifiers are included for all methods, in order to maintain a clear link between specifications, methods and methods validations.

Validations of analytical procedures were conducted in compliance with principles laid out in ICH Q2(R1).

## Batch analysis

Batch analysis  data  of  finished  product  were  provided.  The  results  are  within  the  specifications  and confirm consistency of the manufacturing process.

Batch release results are presented in the dossier. Presented batch release data all met specifications and no significant changes between batches are observed.

## Reference materials

For analysis of FYB203 finished product the same reference standards as for FYB203 active substance are used.

<div style=\"page-break-after: always\"></div>

## 2.3.3.4. Stability of the product

Based on available stability data, the shelf-life of 24 months and storage at 2°C-8°C conditions as stated in the SmPC are acceptable.

A number of finished product batches were placed on stability studies. Stability studies are performed at the intended long-term storage temperature (5 ± 3°C), accelerated conditions (25 ± 2°C/60 ± 5% RH), and stressed conditions (40 ± 2°C/75 ± 5% RH). The container used in the stability studies is same as proposed  for  the  routine  storage.  All  vials  were  stored  inverted  to  simulate  worst-case  conditions. Stability  testing  protocols  are  provided  for  all  tested  storage  conditions  and  are  according  to  ICH guidelines.

The  majority  of  parameters  tested  during  stability  are  the  same  as  for  release  (colour,  clarity,  pH, subvisible particles, activity and sterility, where the same analytical methods and specifications apply. Only few quality attributes have different release and shelf-life specifications although the same testing procedures are used.

Stability data covering the shelf-life were provided. All results met acceptance criteria decreasing trends were  observed  for  some  purity  parameters.  At  accelerated  and  stressed  storage  conditions  the degradation trends are more significant. The proposed shelf-life of 24 months at 2°C-8°C based on the available stability data which is acceptable

Out-of-fridge  stability  studies  were  performed  to  cover  potential  temperature  excursions  during manufacturing and sample handling. The provided data met acceptance criteria and no impact on the stability  behaviour  is  observed.  Stability  data  for  one  clinical  finished  product  batch  storage  is  now available.  Therefore,  it  is  concluded  that  the  proposed  possibility  defined  in  the  SmPC  to  store  the unopened vial outside the refrigerator below 25°C for up to 24 hours is covered with worst-case stability data and could be accepted.

Formulation robustness study data are also presented in this section. Solutions with different formulation variants of finished product were placed on stability at 5°C ± 3°C and at 25°C ± 2°C. All quality attributes assessed up to the current timepoint are well within the specification limits.

Additionally, the impact of agitation stress and photo stress on finished product was evaluated during the forced degradation study as a part of analytical similarity assessment. Based on the results it is concluded that agitation stress does not affect product quality, whereas photo stress has an impact on product stability. Therefore, it is stated in the SmPC that finished product has to be stored in the original package in order to protect from light.

The  post-approval  stability  protocol  and  stability  commitment  was  provided.  One  batch  of  finished product will be placed on stability each year.

In accordance with EU GMP guidelines, any confirmed out-of-specification result, or significant negative trend, should be reported to the Rapporteur and EMA.

## 2.3.3.5. Adventitious agents

Multiple  complementing  measures  are  implemented  to  ensure  product  safety  in  terms  of  potential contamination by non-viral and viral adventitious agents. The measures include selection and testing of materials, testing of cell banks, testing of microbial attributes as in-process controls and at release, implementation  and  validation  of  dedicated  virus  clearance  steps  and  steps  contributing  to  virus reduction. In addition, microbial quality is ensured by process design (microbial reduction filtrations, sterile filtration, aseptic processing) and adequate sanitisation procedures.

<div style=\"page-break-after: always\"></div>

## Materials of biological origin and testing of cell banks and intermediates

Materials  of  biological  origin  were  identified  and  listed.  No  raw  materials  of  animal  or  human  origin are/were  used  during  manufacture  of  FYB203  active  substance/finished  product.  Origin  of  biological materials was provided and for animal derived materials, the source countries were identified and the applicant performed detailed assessment regarding safety from the perspective of potential non-viral and  viral  contamination.  For  all  reagents  with  bovine  constituents  used  during  development,  the geographic  origin  can  be  traced  to  countries  with  a  negligible  TSE  risk  or  are  certified  to  fulfil  the requirements laid down  in Note for Guidance EMEA/410/01, rev. 3NoOverall, the extensive characterisation  testing  of  production  cell  banks  demonstrated  the  absence  of  microbial  and  viral contamination.

## Virus clearance studies

Virus  clearance  capacity  of  the  manufacturing  process  has  been  assessed  in  virus  clearance  studies Overall, the performed validation study was performed in line with the applicable guidelines using process parameters representing  the  worst-case  scenario  in  routine  GMP  production  and  data  demonstrated sufficient  viral  clearance  capability  of  the  purification  process  In  summary,  the  risk  of  potential contamination and transmission of bacterial, viral, or TSE agents is adequately controlled and negligible

## 2.3.3.6. GMO

## Not applicable

## 2.3.3.7. Biosimilarity

The biosimilar development has been performed following principles of the Guideline on similar biological medicinal  products  containing  biotechnology-derived  proteins  as  active  substance:  quality  issues (EMA/CHMP/BWP/247713/2012).  Analytical  similarity  of  FYB203  was  assessed  in  a  comprehensive exercise with EU-authorised and US-licensed Eylea products. Conclusions of the EMA scientific advice (EMA/CHMP/SAWP/398725/2019)  with  regard  to  criticality  ranking  of  quality  attributes,  statistical approach for data evaluation, sampling of batches, panel of comparability exercises, reporting of Nglycan  structure  groups,  determination  of  extinction  coefficient  and  discussion  on  the  observed differences in quality attributes were taken into consideration in the biosimilar development and are addressed in the dossier.

## CQA assessment

As part of initial development efforts, the criticality of the relevant quality attributes was performed following risk ranking approach as per ICH Q9. Standardised approach concerning evaluation of impact and uncertainty was applied and impact factor was established based on effect of each attribute on biological activity/efficacy, PK/PD, immunogenicity and safety. For some quality attributes describing identity  and  potency  as  well  as  for  general  finished  product  attributes  and  some  process-related impurities, the impact on efficacy, PK/PD, safety or immunogenicity is well established. For those quality attributes, a default criticality is assigned independent of the product specificities. The information on the CQA assessment and its outcome that includes detailed assessment examples for some criticality categories  (low,  moderate,  high,  very  high)  is  satisfactory.  Overall,  criticality  ratings  and  their justification is supported.

## Data evaluation approach

Quality  attributes  with  quantitative  data  with  very  high  to  moderate  criticality  were  subjected  to quantitative  comparison  between  FYB203  and  Eylea  EU  reference  product.  Pre-defined  limits  were

<div style=\"page-break-after: always\"></div>

applied for data, such as retention time and molecular mass. Low and very low ranked CQAs or qualitative data  was  evaluated  by  visual  comparison  (e.g.  spectral  overlays).  For  very  high  to  high  criticality attributes subjected to quantitative evaluation of results a tighter similarity criterion might have been considered to strengthen the conclusion based on statistical evaluation however, the evaluation approach and  provided  comprehensive  justifications  is  in  line  with  the  current  guidance  as  described  in  the Reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development (EMA/CHMP/138502/2017) and is deemed acceptable.

## Analytical methods and tested batches

Panel  of  analytical  methods  employed  in  analytical  similarity  assessment  is  considered  sufficiently comprehensive

Methods used in similarity exercises are categorised as leading, orthogonal or methods for additional characterisation. All procedures were sufficiently described. Description of used equipment, reagents and solutions, sample preparation, method workflow steps, equipment setup and parameters of the method were provided as applicable. Data reporting, approach to results evaluation were described and system suitability testing were described. All analytical methods were appropriately qualified and the provided results  demonstrate  suitability  for  the  intended  purpose.  Qualification  reports  were  provided  for  all methods  subjected  to  qualification  and  the  provided  data  summarizing  the  method  parameters  are considered acceptable.

In  general,  all  available  independent  FYB203  finished  product  batches  and  an  independent  active substance batch were tested by leading methods, while a reduced number of FYB203 batches were tested by  orthogonal  and  additional  characterisation  methods.  All  batches  used  for  purpose  of  analytical similarity were produced at the proposed commercial active substance manufacturing site by the current commercial scale active substance process. FYB203 finished product batches included in the analytical exercise were manufactured at commercial scale at the proposed commercial production site. Batches tested in analytical similarity study were used in non-clinical and clinical studies and finished product batches were produced from active substance PPQ material. The batch sampling strategy is considered clear  and  tested  batches  are  considered  representative  for  the  proposed  commercial  manufacturing process.

Generally,  a  sufficient  number  of  batches  was  employed  for  analytical  characterisation  to  study  the quality profile of the EU-authorised Eylea reference product. In addition, analytical data for US-licensed Eylea are shown as supportive data. EU-sourced RMP lots as well as US-sourced originator lots were sourced over a time span of several years. It is agreed that the number of lots sourced over these long time periods will provide a robust estimate of variability of the RMPs.

<div style=\"page-break-after: always\"></div>

## Analytical similarity exercise

To evaluate the similarity of FYB203 in comparison to Eylea EU, an analytical similarity assessment was performed consisting of the initial characterisation, forced degradation study and stability study under accelerated and stress conditions.

Brief summary of the identified peptide fragments from individual digestion techniques was provided. Based on the data it is concluded that the higher order structure of the products is highly similar.

Molecular  heterogeneity  was  characterised  for  size  and  charge  heterogeneity  as  well  as  for  further modifications. Results indicate similar structural, size, and charge heterogeneity, in further functional characterisation it was demonstrated that differences in N-glycosylation profile do not have impact on relevant biological properties and potency. Furthermore, in relation to the available non-clinical data and with references to the available literature it was sufficiently justified that the differences identified in the N-glycosylation profile do not have impact on pharmacokinetic properties in the context of intravitreal administration. Characterisation of the potential Fc-mediated effector functions and biding affinities is considered adequate, and results are considered similar to the EU-Eylea reference product.

Comparative  stress  stability  studies  were  performed  under  various  conditions  (agitation,  photolytic stress, oxidation, acidic and basic pH and glycation stress) to evaluate degradation pathways Results demonstrated  similar  degradation  pathways  and  degradation  rates  in  tested  quality  attributes  In dedicated comparative freeze-thaw study performed showed no significant changes of stability indicating quality  attributes  were  observed.  In  conclusion,  it  is  agreed  that  the  overall  response  to  product degrading stress conditions was well comparable for FYB203 and its reference product Eylea. Observed trends and kinetics were in good agreement among all products for all stress conditions.

A  comprehensive  analytical  exercise  was  performed  to  evaluate  FYB203  similarity  with  EU-Eylea reference medicinal product in all relevant physical and chemical attributes and functional characteristics. In addition to initial characterisation study, comparative forced degradation study and stability study under accelerated and stress conditions were performed and study results provide supportive information with regard to totality of evidence. Overall, the FYB203 is considered similar to the Eylea reference medicinal product in majority of physical and chemical attributes and biological properties. Differences have  been  identified  in  N-glycosylation  profile  with  regard  to  overall  fucosylation,  galactosylation, mannosylation and sialylation content. Also, lower levels of oxidation and deamidation were observed in FYB203. These findings contributed to different relative content and distribution of charged variants and lower Fc γ RIIIA affinity. Nonetheless, it has been justified that this heterogeneity does not significantly impact  the  primary  or  potential  secondary  mechanism  of  action  of  aflibercept  as  generally  robust functional characterisation supports the similarity between FYB203 and EU-Eylea. Also, it is concluded that observed differences do not have impact on safety and immunogenicity of the FYB203. Potential impact of differences in N-glycosylation profile to pharmacokinetic properties is not expected in regard to the intravitreal application which is supported by scientifically sound discussion. Available non-clinical data for all tested FYB203 batches showed a high degree of similarity to treatment with Eylea in the relevant ocular matrices (vitreous humor, aqueous humor, retina/choroid tissue) which further support this conclusion. All residual uncertainty with regard to demonstration of analytical similarity has been sufficiently  resolved.  FYB203  is  considered  similar  to  EU-Eylea  in  relevant  physical  and  chemical attributes and functional characteristics and identified differences in quality profile are not expected to affect clinical performance.

## 2.3.4. Discussion on chemical, and pharmaceutical aspects

Information on development, manufacture and control of the active substance and finished product has been  presented  in  a  satisfactory  manner.  The  results  of  tests  carried  out  indicate  consistency  and

<div style=\"page-break-after: always\"></div>

uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## Active substance

FYB203 has been developed as biosimilar product to EYLEA. The provided data support the comparability of the relevant historical batches to the commercial manufacturing process and a comparability exercise presented in line with the ICH Q5E, complete with clear summary tables of the relevant manufacturing process was included in the dossier.

The  process  validation  at  commercial  scale  is  deemed  successful  overall.  The  active  substance specifications and limits are considered justified in general, and it is accepted that tightening of the sialylation acceptance criteria is not warranted given absence of its impact on potency or safety and the negligible  impact  of  sialylation  of  aflibercept  on  pharmacokinetics  with  intravitreal  administration. Validation of analytical procedures were conducted in compliance with principles laid out in ICH Q2(R1). Validation summaries have been provided for all declared testing sites.

For  routine  release  testing  a  two-tier  reference  standard  system  is  established.  The  applicant  has provided  a  clear  overview  of  the  history  of  reference  standards  (RS)  and  qualification  criteria.  The applicant  has  also  provided  results  for  individual  replicates  from  the  qualification  of  the  reference standards. The qualification criteria and overall approach to RS management are deemed to sufficiently control potential drift in potency.

The proposed shelf-life at ≤ -60°C is supported by long-term stability data from representative batches fully  covering  at  least  the  proposed  shelf-life,  additional  long-term  and  accelerated  and  stressedconditions stability data.

## Finished product

FYB203 finished product is developed as a proposed biosimilar to the reference product Eylea in the dosage form of solution for intravitreal injection in a single-use vial. It was sufficiently demonstrated that the target fill volume is sufficient for the desired deliverable volume of 0.05 mL. Based on the results of  formulation  development,  finally  chosen  formulation  differs  from  the  formulation  of  Eylea  by replacement of the sodium phosphate buffering system with a L-histidine/L-histidine HCl monohydrate buffering system.

Process  characterisation  studies  were  performed,  and  results  were  further  verified  during  process validation on consecutive PPQ batches. Process validation covers all finished product manufacturing steps and was performed following a classical approach. The provided data demonstrates that when operating within the proposed ranges, the performance controls meet relevant quality criteria. Holding times for commercial  manufacturing  process  including  the  cumulative  hold  times  are  covered  by  hold  time validation studies. Sufficient level of details is provided on filters.

The finished product specifications and limits are considered justified. Acceptable panel of tests, their validations and verifications, with majority of shared methods and raised concerns with active substance, was presented.

The proposed shelf-life 24 months at 2°C - 8°C is acceptable based on the provided stability data. Also, the proposed possibility to store the unopened vial outside the refrigerator for up to 24 hours is supported with stability data covering the worst-case scenario.

## Biosimilarity

A  comprehensive  analytical  exercise  using  a  broad  panel  of  orthogonal  state-of-the  art  analytical techniques was performed to evaluate FYB203 similarity with EU-Eylea reference medicinal product in

<div style=\"page-break-after: always\"></div>

all relevant physical and chemical attributes and functional characteristics. Analysis covered primary and higher order structure, product related substances and impurities, variants related to cysteine chemistry, charge, isoaspartate formation, glycosylation, or molecular size, and finished product related attributes. Functional activity was compared by a large panel of binding assays and cell-based biological assays covering the mode of action for the targeted indications as well as Fc-related functions. Based on the provided information it is concluded that the analytical methods are suitable for the intended purpose. In addition, results for US-Eylea were presented. Batches/lots analysed can be expected to sufficiently reflect product variability of both the proposed biosimilar and the reference product. The FYB203 batches have been manufactured according to the intended active substance commercial process.

For quantitative data the applicant applied quality ranges based on RMP data. Low and very low ranked CQAs which result in qualitative data were, in general, evaluated visually. The evaluation approach and provided comprehensive justifications is in line with the current guidance as described in the Reflection paper  on  statistical  methodology  for  the  comparative  assessment  of  quality  attributes  in  drug development (EMA/CHMP/138502/2017) and is deemed acceptable. All individual test results of  the analytical similarity exercise are provided.

In addition to the initial characterisation study, a comparative forced degradation study and a stability study  under  accelerated  and  stress  conditions  were  performed  and  study  results  provide  supportive information with regard to totality of evidence.

Overall, the differences between FYB203 and EU-Eylea reference medicinal product have been identified in  N-glycosylation  profile  with  regard  to  overall  fucosylation,  galactosylation,  mannosylation  and sialylation  content.  Also,  lower  levels  of  oxidation  and  deamidation  was  observed  in  FYB203.  These findings contributed to different relative content and distribution of charged variants and lower Fc γ RIIIA affinity.  Nonetheless,  it  has  been  justified  that  this  heterogeneity  does  not  significantly  impact  the primary  or  potential  secondary  mechanism  of  action  of  aflibercept  as  generally  robust  functional characterisation supports the similarity between FYB203 and EU-Eylea. Potential impact of differences in N-glycosylation profile to pharmacokinetic properties in ocular matrices is not expected in regard to the intravitreal application which is supported by scientifically sound discussion. Available non-clinical data for all tested FYB203 batches showed a high degree of similarity to treatment with Eylea in the relevant ocular  matrices  (vitreous  humor,  aqueous  humor,  retina/choroid  tissue)  which  further  support  this conclusion.  All  residual  uncertainty  with  regards  to  demonstration  of  analytical  similarity  has  been sufficiently  resolved.  FYB203  is  considered  similar  to  EU-Eylea  in  relevant  physical  and  chemical attributes and functional characteristics and identified differences in quality profile are not expected to affect clinical performance.

## Adventitious agents

The risk for transmission of adventitious agents is adequately controlled and minimised by complementary measures implemented at various stages of the manufacturing process.

## 2.3.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

<div style=\"page-break-after: always\"></div>

## 2.3.6. Recommendations for future quality development

N/A

## 2.4. Non-clinical aspects

## 2.4.1. Introduction

Ahzantive (FYB203) has been developed as a proposed biosimilar to Eylea (INN: aflibercept). Aflibercept is a glycosylated, disulfide-stabilised homodimeric recombinant fusion protein consisting of domain 2 of human  vascular  endothelial  growth  factor  receptor  1  (VEGFR-1 D2)  and  domain  3  of  VEGFR-2 (VEGFR-2 D3) fused to the Fc domain of human IgG1. The molecular weight of the intact deglycosylated aflibercept  molecule,  as  measured  by  mass  spectrometry,  is  96.9 kDa.  Aflibercept  has  five  Nglycosylation sites on each polypeptide chain which can be occupied with carbohydrates and exhibit some degree of heterogeneity, including heterogeneity in terminal sialic acid residues.

The intended route of FYB203 administration is intravitreal (IVT) injection.

In  the  Non-clinical  Overview  (NCO)  the  applicant  claimed  identical  qualitative  and  quantitative composition of FYB203 to the RMP (EU Eylea) in contrary to other sections of NCO in which the applicant claimed alternative formulation. The applicant corrected the discrepancy declaring identical qualitative and quantitative composition of FYB203 to the RMP (EU-Eylea). Furthermore, the applicant provided conducted non-GLP pilot in vivo formulation study to complement the overall data package.

## 2.4.2. Pharmacology

The applicant provided detailed description of the in vitro studies conducted.

No in  vivo studies were conducted for primary pharmacology assessment. Secondary pharmacology, pharmacodynamic drug-drug interaction, and safety pharmacology studies were deemed not necessary for FYB203 as respective data from these experiments would not add relevant nonclinical information for the proposed biosimilar. Overall approach and omission of in vivo studies is adequate.

## 2.4.3. Pharmacokinetics

The applicant conducted two in vivo pharmacokinetic studies to demonstrate similarity of PK profile of aflibercept (FYB203) to originator EU-Eylea at four different compartments i.e., vitreous humor, aqueous humor, retina/choroid tissue and plasma.

Validated ELISA and MSD assays were used to determine drug levels in vitreous humor, aqueous humor, retina/choroid tissue, and plasma of NZW rabbits. Although immunogenicity data in animal models is not regarded representative of the human situation, anti-drug antibodies were analysed in the plasma of NZW rabbits using a validated MSD assay.

In a first GLP-compliant study, the biosimilar candidate FYB203 was tested side-by-side to EU-approved Eylea.  The  PK  profile  of  FYB203  in  the  relevant  ocular  matrices  (vitreous  humor,  aqueous  humor, retina/choroid tissue), showed a high degree of similarity to treatment with Eylea, whereas in plasma of rabbits treated with FYB203 levels of free aflibercept were approximately 2-fold lower when compared to rabbits treated with EU-Eylea.

<div style=\"page-break-after: always\"></div>

The aim of the second GLP PK study in rabbits was to evaluate and compare the ocular and systemic pharmacokinetics  of  3  different  FYB203  batches  manufactured  under  varying  growth  condition  with different levels of sialylation, and EU-approved Eylea. Again, drug levels in vitreous humor, aqueous humor, and retina/choroid tissue revealed similar ocular PK for all FYB203 batches tested and EU-Eylea, whereas  in  plasma  FYB203  levels  were  decreased  when  compared  to  Eylea.  For  a  FYB203  batch manufactured  at  pilot  scale  with  a  sialylation  degree  most  similar  to  Eylea,  plasma  levels  were comparable to those of EU-approved Eylea.

Overall, the applicant concluded that the presence of more terminal galactose and GlcNAc (linked to lower levels of sialic acid) in FYB203 may explain the different PK properties in plasma exhibiting faster clearance from the blood via the liver compared to the originator Eylea. This was not fully accepted as the PK profile also shows variation in Tmax (e.g., non-linear PK in 48-72 hours in second study) across batches.

Generally,  the  PK  of  aflibercept  after  IVT  administration  are  well  described  and  no in  vivo data  is warranted  for  biosimilar  products  like  FYB203  in  accordance  with  currently  effective  guidance. Nevertheless, two PK studies in rabbit were conducted and study reports submitted. Due to the fact that such in  vivo studies  are  regarded  as  insensitive  to  support  biosimilarity,  these  data  are  regarded  of supportive value only. In addition to support similarity on the PK level, different formulations for FYB203 were tested in one of the two studies to define the final formulation to be used for further FYB203 development.

However, all FYB203 batches with differences in receptor domain sialylation showed a high degree of similarity in target binding and potency. The applicant therefore argued that differences in sialylation did not impact potency or target binding as demonstrated by functional assays (see under Quality, Analytical similarity). Taking provided arguments altogether, the PK differences based on non-clinical PK studies are not considered as concern for biosimilarity.

## 2.4.4. Toxicology

## 2.4.4.1. Repeat dose toxicity

The applicant provided one repeat-dose toxicology study that was performed to evaluate the toxicological effects of repeated IVT injections of FYB203, in comparison with EU approved Eylea over a 5-week period in  albino  NZW  rabbits.  The  study  was  performed  in  compliance  with  the  OECD  Principles  of  Good Laboratory Practice (GLP) regulations.

Published data (del Amo et al, 2015) and the derived pharmacokinetic parameters indicate that the rabbit is a useful animal model in intravitreal nonclinical studies. However, because the volume of the vitreous humor of NZW rabbits (approx. 1 mL) is smaller than that of humans (approx. 4 mL), the intraocular drug concentration in rabbit eyes after a single dose is higher than in human eyes. In addition, systemic exposure following intravitreal administration of aflibercept is higher in rabbits than in humans due to weight differences. These facts had to be taken into account.

Overall, the applicant conducted an extensive in  vivo non-clinical  programme for FYB203 biosimilars which is not in line with the current guidelines emphasizing avoidance of in vivo studies due to availability of  more  sensitive in vitro methods  for  comparability  assessment.  In  addition  to  two in  vivo pharmacokinetic studies, an in vivo 1-month repeat-dose toxicology study (2 applications on D1 and D15) with toxicokinetic and recovery groups was conducted with FYB203 manufactured at the intended commercial scale.

<div style=\"page-break-after: always\"></div>

The toxicology study with inclusion of toxicokinetic measurements also support the notion that FYB203 Tech Batch and EU-Eylea cannot be considered as biosimilar in terms of free plasma aflibercept. However, repeated dose toxicity studies are usually not recommended  for similar biological products (EMA/CHMP/BMWP/403543/2010) and observed differences are not expected to have impact on clinical efficacy and safety supported by in vitro functional biosimilarity assessment and low systemic exposures to free plasma aflibercept FYB203 in patients. Clinical data supersede over non-clinical studies provided and no further non-clinical studies are warranted.

## 2.4.5. Ecotoxicity/environmental risk assessment

Adequate justification for absence of ERA has been provided. Monoclonal antibodies are unlikely to pose a significant risk to the environment. Environmental risk assessment studies are therefore not required in accordance with EMEA/CHMP/SWP/4447/00.

## 2.4.6. Discussion on non-clinical aspects

Comparability data and in vitro functional characterisation ( in vitro binding and potency assays) data were submitted. Please refer to the respective section of this assessment report and the Quality sections for discussion and conclusion on the similarity data for FYB203. The provided data supports similarity of FYB203 and the RMP.

In  vivo studies  conducted  demonstrated  similar  ocular  pharmacokinetic  between  tested  products whereas in plasma FYB203 levels were lower when compared to Eylea. Yet, the applicant claimed in vitro functional biosimilarity. In accordance with stepwise approach, in vitro studies were conducted first, and a decision then was made that in vivo studies were required to demonstrate that the use of an alternative formulation has no impact on the similarity of PK parameters. Considering the observed differences in free plasma aflibercept, the applicant introduced manufacturing changes to increase sialylation levels, however difference in PK profile although in a reduced extent was still observed between products. The applicant was requested to justify extensive non-clinical testing strategy and clarify manufacturing and functional comparability between batches used for in vitro biosimilarity assessment and in clinical studies (see section 3).

Section 4.6 and 5.3 of the proposed SmPC are in line with the approved product information for Eylea.

The applicant concluded from the generated RDTS data that analysis of ocular tolerance and systemic toxicity in rabbits treated with FYB203 or EU-approved Eylea support the claim of similarity of FYB203 with regard to safety.

In particular, the RDT data submitted by the applicant is acknowledged and the discussion provided by can  be  followed.  However,  toxicity  data  in  the  context  of  a  biosimilar  development  are  regarded  of supportive value only and no conclusions on similarity can be drawn due to general lack of sensitivity of in vivo (animal) models in regard to biosimilarity assessment.

## 2.4.7. Conclusion on the non-clinical aspects

There are no concerns arising from the functional biosimilarity exercise (see Quality section) triggering the  need  for  further  investigations  and  the  difference  in  free  plasma  concentration  of  aflibercept  in provided in vivo PK and toxicology studies in rabbits has not been considered an issue. The applicant revised the documentation to declare identical qualitative and quantitative composition of FYB203 to the RMP (EU-Eylea). The updated documentation clarified that the formulation comprises well-established compendial excipients for intraocular use. No further assessment of these excipients has been considered

<div style=\"page-break-after: always\"></div>

necessary.  Additionally,  the  applicant  provided  the in  vivo pharmacokinetic  study  with  different formulations. Based on the data provided, it was reasonable to conclude that the observed differences in  the in  vivo pharmacokinetics (PK) of free aflibercept in plasma may be attributed to variations in formulation  in  comparison  to  RMP  (EU-Eylea)  and  differences  in  affinity  for  the  asialoglycoprotein receptor (ASGPR), which is influenced by varying sialylation levels among the products. Nevertheless, the applicant has demonstrated that these differences do not affect the efficacy of DP with formulation 2, as confirmed by in vitro biosimilarity studies, nor do they impact its safety, as supported by in vivo GLP animal studies following intravitreal (IVT) administration.

The applicant has also provided an overview table detailing the batches used in non-clinical development, The  overview  reveals  that  the  non-clinical  batches  were  not  a  priori  tested  in in  vitro studies  for glycosylation  and  biological  functions.  As  a  cautionary  note  for  potential  future  developments,  the applicant was strongly urged to follow a stepwise approach, ensuring that in vitro studies are thoroughly conducted before initiating any in vivo studies, if they are deemed necessary.

Overall, nonclinical in vivo data in the context of a biosimilar development are regarded of supportive value only as no conclusions on similarity can be drawn due to general lack of sensitivity of in  vivo (animal) models in regard to biosimilarity assessment.

## 2.5. Clinical aspects

## 2.5.1. Introduction

## GCP aspects

The clinical trials were performed in accordance with GCP as claimed by the applicant.

As stated by the applicant in the clinical overview (section 2.5.1.4.1) only one clinical study (MAGELLAN-AMD) has been conducted, then the tabular overview of clinical studies has not been provided. This is endorsed by the assessor.

## 2.5.2. Clinical pharmacology

## 2.5.2.1. Pharmacokinetics

## Bioanalytical methods for pharmacokinetics: Free and total aflibercept assays

Two separate validated ligand-binding assays, one to measure total (free + bound to VEGF) aflibercept and  the  other  for  measuring  free  (active,  not  bound  to  VEGF)  aflibercept  in  human  plasma,  were developed  and  validated  in accordance  with  the  Guideline  on  bioanalytical  method  validation (EMEA/CHMP/EWP/192217/2009).  Based  on  the  provided  method  validation  documentation  it  is concluded that both methods are suitable for their intended use. The bioanalytical similarity assessment was performed. Detailed analytical reports have been provided for testing of the clinical samples. Instudy  method  performance  was  demonstrated  by  back-  calculated  calibration  standards,  inter-batch precision and accuracy of QC samples and ISR. Study samples were analysed without exceeding the validated short-term, long-term or freeze-thaw stability periods. In summary, the presented data do not indicate any issue related to testing of the clinical samples.

<div style=\"page-break-after: always\"></div>

## Bioanalytical methods for immunogenicity testing: ADA and NAb assays

Two validated methods to monitor the relative humoral immune response to FYB203 vs. EU-approved Eylea were employed: bridging electrochemiluminescence (ECL) assay to detect ADA and competitive ligand-binding assay to detect NAb with capacity to block binding of aflibercept to the target, VEGFA165. A multi-tiered approach for immunogenicity assays was applied including ADA screening assay, ADA confirmatory assay for samples screened positive, followed by titre estimation and NAb assay. Taken together,  the  adopted  three-tiered  approach  for  determination  of  ADAs  was  well  described  and developed. It  is  considered  state  of  the  art  and  valid  for  its  intended  use.  The  presented  assay  for determination of neutralising properties was well described and established. It was setup correctly and validated.

Overall, the immunogenicity assays were characterised by very good sensitivity and a low risk of false negative results.

The  bioanalytical  methods  for  pharmacokinetics  (total  and  free  aflibercept  in  human  plasma)  and immunogenicity  testing  (ADA  and  NAb  assays)  have  been  considered  reliable,  well  developed  and validated and suitable for intended use. No concerns on bioanalytics have been identified.

## Bioequivalence

No PK studies were conducted in healthy volunteers for ethical and safety reasons. The results of the assessment of comparative systemic free and total aflibercept exposure that were included as a safety endpoint in a subgroup of 57 patients within the confirmatory comparative clinical safety and efficacy study.

## Study FYB203-03-01

The objective of the PK sub-group analysis was to compare systemic exposure of both total and free aflibercept by measurement of plasma concentration 48 hours following a first and third intravitreal (IVT) administration  of  either  FYB203  or  EU-approved  Eylea  at  a  dose  of  2  mg  (0.05  mL  of  a  40  mg/mL solution) in patients with subfoveal nAMD or wet AMD.

<!-- image -->

ADA =Anti-drug antibody; EOS =End of Study; IMP =Investigational Medicinal Product; ICF =informed consent form; PC = plasma concentration; V = visit; W = week.

** PK Subgroup only.

Figure 1: Design of confirmatory efficacy &amp; safety study, FYB203-03-01

<div style=\"page-break-after: always\"></div>

Blood  samples  were  collected  for  measurement  of  plasma  concentrations  of  systemic  free  and  total aflibercept at Week 0 (Visit 1) prior to 1st IVT dose, 48 hours after 1st IVT dose (Visit 1a), and at 48 hours after the 3rd IVT dose (Visit 3a).

Free  as  well  as  total  aflibercept  were  measured  and  evaluated  by  the  applicant.  Free  aflibercept  is anticipated to be the active drug and levels of free aflibercept are considered more important, however total aflibercept levels add additional information on total levels and possibly differences in accumulation.

The number of patients included in the PK analysis is considered adequate, demographic characteristics were comparable between treatment groups and the method of selection of patients in the PK subset has been clarified.

## Results:

Free and total aflibercept were assessed and compared in a subgroup of 57 patients (26 for Eylea and 31 for FYB203) at selected study sites at baseline prior to first IVT dose, 48 hours after first IVT dose (Visit 1a) and at 48 hours after the third IVT dose (Visit 3a). Systemic concentrations were assessed close to the predicted maximum concentration [Cmax] (based on estimated Tmax). Comparisons are based on descriptive statistics.

Table 1: Systemic total and free aflibercept plasma concentrations until week 8 by treatment group (ng/mL) (PKS, N=57)

| eCRF Visit and Statistic                       | FYB203 (N=31)                                  | Eylea (N=26)    |
|------------------------------------------------|------------------------------------------------|-----------------|
| Total aflibercept plasma concentration (ng/mL) | Total aflibercept plasma concentration (ng/mL) |                 |
| Vla (V1 + 48h)                                 |                                                |                 |
| n                                              | 31                                             | 26              |
| Geom. Mean                                     | 54.731                                         | 42.000          |
| Geom. CV (%)                                   | 51.169                                         | 102.113         |
| Geom. Mean 95.0% CI                            | 45.858-65.322                                  | 29.854-59.089   |
| P10-P90                                        | 30.100-85.200                                  | 17.700-87.600   |
| Week 8,V3a (V3+48h)                            |                                                |                 |
| 11                                             | 31                                             | 25              |
| Geom. Mean                                     | 118.282                                        | 116.821         |
| Geom. CV (%)                                   | 26.569                                         | 24.443          |
| Ge0m. Mean 95.0% CI                            | 107.477-130.174                                | 105.764-129.035 |
| P10-P90                                        | 79.500-164.000                                 | 86.200-163.000  |
| Free aflibercept plasma concentration (ng/mL)  | Free aflibercept plasma concentration (ng/mL)  |                 |
| Vla (V1 + 48h)                                 |                                                |                 |
| n                                              | 31                                             | 26              |
| Geom. Mean                                     | 21.667                                         | 14.235          |
| Geom. CV (%)                                   | 58.922                                         | 119.312         |
| Ge0m. Mean 95.0% CI                            | 17.735-26.470                                  | 9.735-20.817    |
| P10-P90                                        | 10.300-40.600                                  | 6.600-31.600    |
| Week 8,V3a (V3+48h)                            |                                                |                 |
| n                                              | 31                                             | 26              |
| Geom. Mean                                     | 22.773                                         | 20.512          |
| Geom. CV (%)                                   | 55.552                                         | 59.891          |
| Ge0m. Mean 95.0% CI                            | 18.828-27.545                                  | 16.402-25.652   |
| P10-P90                                        | 10.600-42.700                                  | 8.860-41.200    |

CI = confidence interval, CV = coefficient of variation, eCRF = electronic case report form,

Geom. Mean = geometric mean, h = hours, N = number of patients per group, n/nmiss = number of nonmissing/missing assessments, PKS = Plasma concentration analysis set, P10/P90 = 10th /90t percentile, V = visit

Because none of the 57 patients in the PK subgroup developed ADA during the 56-week study period it was not possible to perform the planned analysis of the relationship of ADA status to systemic exposure.

<div style=\"page-break-after: always\"></div>

In the absence of ADA formation, the geometric mean and 95% CI for the aflibercept (both total and free) concentrations measured 48 hours after the third IVT injection were similar for the FYB203 and Eylea treatment groups, supporting a conclusion of similar systemic exposure following repeated IVT administration in nAMD patients.

## 2.5.2.2. Pharmacodynamics

No dedicated PD study have been conducted as part of the clinical biosimilarity exercise and none is considered necessary.

## Mechanism of action

The only known mechanism of action of aflibercept is its binding to VEGF-A and PlGF thereby inhibiting the binding and activation of VEGFR-1 and VEGFR-2, present on the surface of endothelial cells.

Aflibercept  exerts  inhibitory  effects  on  angiogenesis  and  stabilizing  actions  on  vessel  permeability through  the  blocking  of  VEGF-A.  IVT  injection  permits  direct  targeting  of  the  areas  of  abnormal neovascularisation in the retina.

## Immunological events

ADA formation against aflibercept was evaluated in serum in all patients before they received the IVT injections at baseline, Week 4, Week 16, Week 24, Week 40, at Week 56/early termination, and in addition, in patients participating in the PK subgroup one week after the first dose (baseline) and 48 hours after the third dose (Week 8).

The results provide compelling evidence of absence of clinically impactful ADA or NAb formation for either FYB203  or  Eylea,  consistent  with  very  low  incidence  (1.9%  of  FYB203-treated  nAMD  patients)  and minimal ADA titres detected, which is also in line with the accumulated clinical experience for Eylea.

Table 2: ADA / Nab prevalence and ADA titre in study FYB2023-03-01 - SAF

<!-- image -->

| Category          | Sample timepoint   | Sample timepoint   | Sample timepoint   | Sample timepoint   | Sample timepoint   | Sample timepoint   |
|-------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| Category          | Week 0/ Baseline   | Week 4             | Week 16            | Week 24            | Week 40            | Week 56            |
| FYB203(N=215)     | FYB203(N=215)      | FYB203(N=215)      | FYB203(N=215)      | FYB203(N=215)      | FYB203(N=215)      | FYB203(N=215)      |
| No. of patients # | 213                | 209                | 195                | 195                | 184                | 194                |
| No. ADA positive  | 4                  | 2                  | 3                  | 4                  | 5                  | 5                  |
| % ADA positive    | 1.9                | 1.0                | 1.5                | 2.1                | 2.7                | 2.6                |
| Median titer *    | 0.75               | 0.75               | 1.0                | 1.0                | 2.00               | 2.00               |
| Min/Max titer *   | 0.5- 1.0           | 0.5-1.0            | 1.0- 4.0           | 0.5 - 4.0          | 1.0 -16.0          | 1.0 -50.0          |
| No.NAbpositive    | 0                  | 0                  | 0                  | 0                  | 2                  | 3                  |
| % NAb positive    | 0.0                | 0.0                | 0.0                | 0.0                | 1.1                | 1.5                |
| Eylea (N=218)     | Eylea (N=218)      | Eylea (N=218)      | Eylea (N=218)      | Eylea (N=218)      | Eylea (N=218)      | Eylea (N=218)      |
| No. of patients # | 204                | 201                | 191                | 193                | 189                | 192                |
| No. ADA positive  | 3                  | 1                  | 1                  | 1                  | 2                  | 2                  |
| % ADA positive    | 1.5                | 0.5                | 0.5                | 0.5                | 1.1                | 1.0                |
| Median titer *    | 0.5                | 1.0                | 1.0                | 1.0                | 1.00               | 1.50               |
| Min/Max titer *   | 0.5- 1.0           | 1.0-1.0            | 1.0-1.0            | 1.0-1.0            | 1.0 -1.0           | 1.0 -2.0           |
| No. NAb positive  | 0                  | 0                  | 0                  | 0                  | 0                  | 0                  |
| % NAb positive    | 0.0                | 0.0                | 0.0                | 0.0                | 0.0                | 0.0                |

# = number of patients with non-missing assessment; SAF = Safety Analysis Set

* ADA titer values do not include the MRD of 18

<div style=\"page-break-after: always\"></div>

Table 3: Number and percentage of patients with treatment-induced / treatment-boosted positive ADA until Week 56 - SAF

| Statistic                           | FYB203 (N=215)   | FYB203 (N=215)   | Eylea (N=218)   | Eylea (N=218)   | DifferenceFYB203- Eylea   | DifferenceFYB203- Eylea   |
|-------------------------------------|------------------|------------------|-----------------|-----------------|---------------------------|---------------------------|
|                                     | n                | (%)              |                 | (%)             | Estimate (%)              | 95% CI (%)                |
| Number of evaluable patients        | 213              | (100.0)          | 204             | (100.0)         |                           |                           |
| Patients with treatment-induced ADA | 4                | (1.9)            | 2               | (1.0)           | 0.9                       | [1.4 ; 3.2]               |
| Patients with treatment-boosted ADA | 0                | (0.0)            | 0               | (0.0)           | NA                        | [NA ; NA]                 |

ADA = Anti-Drug Antibody; NA = Not Applicable; 95% CI = 95% Farrington-Manning Confidence Intervals; n = number of patients within the specified category; % = number of patients within the specified category / total number of patients with non-missing assessment; N = total number of patients in analysis set; SAF = Safety Analysis Set

ADA incidence from baseline to Week 56 was very low, consistent with published results for Eylea: treatment-emergent (corresponding to the definition of 'treatment-induced') ADA was detected in only 4 out of 213 (1.9%) evaluable patients in the FYB203 group compared to 2 out of 204 (1.0%) in the Eylea group. NAb was detected in 3 patients in the FYB203 treatment group; no patients treated with Eylea had a NAb positive result.

Four out of 213 (1.9%) evaluable patients in the FYB203 group were ADA positive at baseline compared to 3 out of 204 (1.5%) in the Eylea group, consistent with an expected false positive rate of 1% in the confirmatory ADA assay. Treatment with FYB203 or Eylea did not boost the ADA signals in any of these patients.

## Impact of immunogenicity on PK:

No conclusion could be drawn regarding the impact of ADA / NAb formation on plasma drug levels because none of the 57 patients in the PK subgroup developed ADA or NAb during the 56-week study period.

## Impact of immunogenicity on efficacy:

The low number of patients with ADA or NAb positive results at any time during the 56-week study period precluded  a  definitive  analysis  of  the  impact,  if  any,  of  treatment-induced  ADA  /  NAb  on  efficacy parameters. Nevertheless, detection of ADA or NAb was not associated with any discernible downward inflexion in the efficacy response (BCVA, FCP or FCS) vs. time profiles for individual patients relative to earlier timepoints. Moreover, the profiles for ADA / NAb positive patients were fully contained within the range observed for ADA / NAb negative patients in each treatment group.

## Impact of immunogenicity on safety:

No  drug  hypersensitivity  or  anaphylaxis-type  or  ocular  inflammatory  TEAEs  of  special  interest  were reported  up  to  Week  56  in  patients  with  ADA  positive  status  at  any  time  during  the  study  period. Therefore, it was concluded that neither FYB203 nor Eylea induced adverse events that could potentially be related to immunogenicity.

## 2.5.3. Discussion on clinical pharmacology

## Pharmacokinetics

No dedicated human PK study was conducted, instead the comparability was evaluated in supportive PK analysis in the subset of patients enrolled in phase III study FYB203-03-01. This approach is acceptable in this case as aflibercept is applied intravitreally and PK comparison of systemic exposure is not suitable given the negligible and variable systemic concentrations.

<div style=\"page-break-after: always\"></div>

The design of the PK subgroup analysis, including the number nAMD patients for evaluation of aflibercept plasma  concentration  and  the  sampling  timepoints  was  discussed  during  EMA  Scientific  Advice (EMEA/H/SA/4194/1/2019/III) and the applicant followed the recommendations.

Free  as  well  as  total  aflibercept  were  measured  and  evaluated  by  the  applicant.  Free  aflibercept  is anticipated to be the active drug and levels of free aflibercept are considered more important, however total aflibercept levels add additional information on total levels and possibly differences in accumulation.

A total of 57 patients were included in the PK subgroup (31 in FYB203 and 26 in Eylea group) and PK data were analysed only descriptively. All samples at baseline were below the lower limit of quantification in both treatment arms for free and total aflibercept. Out of the 60 patients who were recruited into the PK sub-study, there were 3 patients with positive baseline levels for total aflibercept detected and these 3 patients were excluded from the PK analysis. Predose plasma concentrations were measured only at Week 0.

The number of patients included in the PK analysis is considered adequate, demographic characteristics were comparable between treatment groups.

The post-dose plasma levels at Week 0 and at Week 8 were evaluated only on Day 2 (48 h) after IVT injection.  It  would  have  been  preferable  to  conduct  daily  sampling  on  at  least  two  days  around  the expected Tmax, since Cmax can occur at any time from Day 1 to Day 3 after administration, however this issue is not further pursued. The levels of free aflibercept were in the similar range as previously reported.

At  Week 0, plasma concentrations of free aflibercept were slightly higher in the FYB203 group (GM 21.667 ng/mL) compared to Eylea group (GM 14.235 ng/mL), but with large variability (CV 58.9% vs 119.3%).

At Week 8, plasma concentrations of free aflibercept were comparable between treatment groups FYB203 group (GM 22.773 ng/mL) compared to Eylea group (GM 20.512 ng/mL), with reduced but still high variability (CV 55.6% vs 59.9%).

After the first dose the total aflibercept concentrations were somewhat higher with FYB203 compared to Eylea (geom. mean 54.731 ng/mL and 42.000 ng/mL, respectively), however the variability was larger for Eylea compared to FYB203 (geom. CV 102.113% and 51.169%, respectively). After the third dose, the total aflibercept concentrations (and variability) levelled out between treatments.

There was no accumulation of free aflibercept after the third dose as compared to after the first dose (as expected); measured concentrations were generally in the expected range, and very low, attesting that no relevant systemic exposure exists. Total aflibercept concentrations were higher than free aflibercept concentrations, as expected. Total aflibercept concentrations were higher after the third dose compared to after the first dose, reflecting accumulation (as expected).

The systemic exposure was similar between FYB203 and Eylea treatment groups.

## Pharmacodynamics

No dedicated PD study have been conducted and none is considered necessary.

The analytical similarity assessment revealed minor differences between FYB203 and Eylea for some forms of glycosylation (FYB203 showing a higher amount of Asn68 non-glycosylation and lower amount of mannosylation, afucosylation and a tendency for lower sialylation). It is agreed that the glycosylation process is inherently variable and thus some variability for individual products as well as differences between products are to be expected. As glycosylation may in theory affect efficacy, PK/PD as well as

<div style=\"page-break-after: always\"></div>

immunogenicity,  the  applicant  provided  a  justification  as  to  why  these  differences  are  not  clinically relevant.

- VEGFR part:

It has been reported that glycosylation has no effect on target binding (TGA, 2012; Barleon et al., 1997). This was confirmed in all the functional assays investigating the mechanism of action (MoA) of aflibercept (similarity  data  presented  in  Analytical  similarity  section).  Furthermore,  charge  variant  fractionation experiments using free-flow electrophoresis showed that fractions differing in their glycosylation profile were highly comparable in their potency and additionally desialylated FYB203 displayed no changes in neutralisation of its targets (refer to quality section).

Theoretically, differences in binding to the mannose receptor and ASGPR could have an impact on PK. However, aflibercept is injected directly into the eye and ocular PK is driven mainly by protein size as the ASGPR is primarily expressed on hepatocytes (Berger et al., 2012; Roggenbuck et al., 2012,). This was confirmed as different levels in sialylation varying by about 7 % in the receptor domain had no impact on ocular PK in rabbits.

- Fc part:

As it was shown that ADCC and CDC are not part of aflibercept's MoA (refer to quality Assessment and section Analytical similarity characterisation), differences known to affect effector function (e.g. afucose levels) will not translate into any biological effects. Also, ASGPR cannot bind to the Fc part (Maverakis et al., 2015) and is not relevant for ocular PK and therefore galactosylation and sialylation levels of the Fc part have no impact on PK.

In summary, it has been shown that differing glycosylation profiles do not have an impact on FYB203 function.

The explanation is pharmacologically plausible.

## Immunogenicity

The percentage of ADA-positive patients from the first IP administration through Week 56 was generally low in both treatment arms and ranged between 1.0% and 2.7% in the FYB203 group and between 0.5% and 1.5% for the Eylea overall treatment group. There were 2 patients at week 40 and 3 patients at week 56 who were Nab positive in FYB203 arm and no patient with positive Nab was observed in Eylea arm. The percentage of ADA-positive patients was slightly higher with FYB203 compared to Eylea across all timepoints up to Week 56 and the number of patients with treatment-induced ADA is also slightly higher in FYB203 arm - 4 patients vs 2 patients in Eylea arm. No treatment-boosted ADAs were observed in either treatment group. Based on the provided data and due to overall low incidence of ADAs, the impact of immunogenicity on efficacy and safety is very limited and no concerns arise regarding the impact of immunogenicity on efficacy and safety. Information on the risk of immunogenicity is described in sections 4.4 and 4.8 of SmPC in line with the reference medicinal product.

## 2.5.4. Conclusions on clinical pharmacology

Based  on  the  data  in  nAMD  patients  no  significant  differences  in  systemic  exposure  were  observed between FYB203 and Eylea treatment groups. The results are considered supportive of biosimilarity.

The incidence of ADA was low in both study arms and throughout the study and ranged between 1.0% and 2.7% in the FYB203 group and between 0.5% and 1.5% for the Eylea treatment group and most of the subjects were ADA negative. There were 3 patients at week 56 who were Nab positive in FYB203 arm and no patient with positive Nab was observed in Eylea arm.

<div style=\"page-break-after: always\"></div>

The incidence of ADA-positive patients was slightly higher in the FYB203 treatment group during the study, but the total number of patients was very low in both study groups and no clinically relevant impact of immunogenicity on efficacy and safety was seen in the study.

## 2.5.5. Clinical efficacy

Table 4: Summary of the study FYB203-03-01

| Study ID      | Enrolment status Start date Total enrolment/ enrolment goal        | Design Control type                                                                     | Study & control drugs Dose, route of administration and duration Regimen                                         | Population Main inclusion/ exclusion criteria   |
|---------------|--------------------------------------------------------------------|-----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| FYB203- 03-01 | Completed Randomised Set Total (RAN): N=434 FYB203: 215 Eylea: 219 | Randomised, double-masked, parallel group, multicentre study Active Control/ Comparator | 2 mg (0.05 mL) every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks up to Week 48 | Patients with neovascular AMD                   |

## 2.5.5.1. Main study(ies)

## Study FYB203-03-01

This study was a parallel-group, randomised, active-controlled, double-masked, multi-centre study to demonstrate therapeutic equivalence of FYB203 to Eylea and to compare the safety and immunogenicity in subjects with neovascular age-related macular degeneration (nAMD).

ADA = anti-drug antibody, EOS = end of study, ICF =informed consent form, IMP = investigational medicinal product, PC = plasma concentration, V = visit, W = week

<!-- image -->

Figure 2: Schematic outline of the study FYB203-03-01

## Methods

Subjects were randomised in a 1:1 ratio to receive either FYB203 or EU-approved Eylea at a dose of 2 mg (0.05 mL of a 40 mg/mL solution). The treatment consisted of 1 IVT injection every 4 weeks for 3 consecutive doses starting at Baseline (Visit 1) through Week 8 (Visit 3) followed by 1 IVT injection every

<div style=\"page-break-after: always\"></div>

8 weeks over a period of approximately 48 weeks (Visit 8), resulting in a total of 8 IVT injections per subject.

Four hundred (400) subjects were planned to be randomised. A total of 712 subjects were screened in the study of which 434 subjects were randomised. After consent withdrawal by 1 subject randomised to Eylea, 433 subjects started treatment with FYB203 (215) and Eylea (218). A total of 196 subjects in the FYB203 group and 206 subjects in the Eylea group completed the study until Week 56.

## Study Participants

The study was conducted in 9 countries, where 77 sites screened at least 1 patient. In total, 72 sites in 9 countries randomised at least 1 patient: Bulgaria (4 sites), Czech Republic (9 sites), Hungary (8 sites), Israel (6 sites), Italy (5 sites), Japan (14 sites), Poland (9 sites), Russia (9 sites) and Ukraine (8 sites).

## Main Inclusion criteria

Subjects  had  to  provide  written  informed  consent,  be  at  least  50  years  old,  and  suffer  from  newly diagnosed, angiographically documented, treatment-naïve CNV lesion secondary to nAMD in the study eye with a BCVA between 20/40 and 20/200 Snellen equivalent. Further, subjects had to have an FCP retinal thickness between ≥300 μm and &lt;800 μm in the study eye and a BCVA of at least 20/200 Snellen equivalent in the fellow eye. Participants had to agree to follow the contraception guidance with exception of post-menopausal women.

## Main Exclusion criteria

Subjects were not allowed to participate if they had prior or current ocular treatment, any prior antiVEGF treatment in either eye, any investigational products to treat ocular diseases other than nAMD within 30 days or 5 half-lives prior to randomisation, any medical history of vitrectomy, macular surgery or other surgical intervention for AMD in the study eye, any history of IVT treatment with corticosteroids or device implantation within 6 months prior to Screening in the study eye. Further, they could not participate if they had particular CNV lesion characteristics or particular current ocular conditions or if they had any diagnosis and signs of nAMD requiring IVT treatment with an anti-VEGF agent within the Screening period or throughout the study in the fellow eye.

## Treatments

After randomisation at the Baseline Visit, the subjects received either FYB203 or EU-approved Eylea at a dose of 2 mg (0.05 mL of a 40 mg/mL solution) at Baseline (Visit 1), Week 4 (Visit 2), Week 8 (Visit 3), Week 16 (Visit 4), Week 24 (Visit 5), Week 32 (Visit 6), Week 40 (Visit 7) and Week 48 (Visit 8). The IVT injections were performed by the unmasked IVT administrator. Only a qualified ophthalmologist experienced in IVT injections administered the injection.

<div style=\"page-break-after: always\"></div>

Table 5: Summary of treatments in the study FYB203-03-01

|             | FYB203 (experimental product, proposed biosimilar aflibercept)   | Eylea (reference aflibercept, EU- approved)                                     |
|-------------|------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Trade name  | Not applicable                                                   | Eylea                                                                           |
| Vials       | Vial containing 100 μL, equivalent to 4 mg aflibercept           | Vial containing 100 pL, equivalent to 4 mg aflibercept                          |
| Dose        | 2 mg in a glass vial designed to deliver 50 μL solution          | 2 mg in a glass vial or prefilled syringe designed to deliver 50 μL of solution |
| Route       | IVT                                                              | IVT                                                                             |
| Formulation | Solution for injection                                           | Solution for injection                                                          |
| Strength    | 40 mg/mL solution                                                | 40 mg/mL solution                                                               |

IVT= imtravitreal

## Prohibited Prior Therapy and Treatment

- Any treatment with any investigational products to treat ocular diseases other than nAMD within 30 days or 5 half-lives prior to randomisation, whichever is longer.
-  Prior  treatment  with  anti-VEGF  agents  (e.g.,  bevacizumab,  aflibercept,  ranibizumab)  or  any investigational products to treat AMD, in either eye.
- IVT or periocular injections of corticosteroids or device implantation in the study eye within 6 months prior to randomisation.
-  Prior  treatment  with  verteporfin  (photodynamic  therapy),  transpupillary  thermotherapy,  radiation therapy, or retinal laser treatment (e.g., focal laser photocoagulation) in the study eye.
- Prior vitrectomy, macular surgery or other surgical intervention for AMD in the study eye.
- Any other intraocular surgery (including cataract surgery) in the study eye within 3 months prior to randomisation.

## Prohibited Concomitant Therapy and Treatment

- Any IVT anti-VEGF treatment except IMP (FYB203 or Eylea)
- Systemic anti-VEGF agents (e.g., bevacizumab)
- Systemic medications known to be toxic to the lens, retina, or optic nerve including deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines, vigabatrin, and ethambutol
- IVT injection of corticosteroid (e.g., triamcinolone acetonide), IVT device implantation, or periocular injections of corticosteroid
- Treatment involving macula with photodynamic therapy with verteporfin, transpupillary thermotherapy, radiation therapy, or retinal laser treatment (e.g., focal laser photocoagulation)
- Ocular investigational products to treat nAMD
- Systemic investigational products to treat nAMD
- Ocular investigational products to treat ocular diseases other than nAMD

## Objectives

The primary objective of this study was to evaluate and compare functional changes in best corrected visual  acuity  (BCVA)  by  Early  Treatment  Diabetic  Retinopathy  Study  (ETDRS)  letters  at  Week  8  of treatment with FYB203 or Eylea compared to Baseline.

## The secondary objectives were to evaluate and compare:

- changes in foveal centre point (FCP) retinal thickness
- changes in FCP retinal thickness and changes in foveal central subfield (FCS) retinal thickness over time

<div style=\"page-break-after: always\"></div>

- functional changes of the retina by BCVA over time the proportion of patients who gained or lost ≥5, 10, and 15 ETDRS letters compared to Baseline
- the absence of disease activity (fluid-free macula) over time
- change in total lesion size
- systemic free and total aflibercept concentrations in a subgroup of up to 60 patients (up to 30 per group)
- change in vision-related functioning and well-being measured by National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25)
- the immunogenic profile (anti-drug antibodies [ADAs]) in serum
- local and systemic AEs and SAEs

## Outcomes/endpoints

| Population               | Patients with nAMD who were randomized to receive either FYB203 or Eylea and who received at least 1 dose of investigational medicinal product, i.e., the FAS.   |
|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment condition      | FYB203 vs Eylea (at least 1 IVT injection with a dose of 2 mg).                                                                                                  |
| Endpoint                 | Absolute change from Baseline to Week 8 in BCVA by ETDRS letters: CHG BCVA,Week 8 = BCVA Week 8 - BCVA Base , using analysis visits.                             |
| Population-level summary | Difference in means between FYB203 and Eylea treatment groups.                                                                                                   |

## Intercurrent events and strategy to handle them

All intercurrent events were handled according to the treatment policy strategy, i.e., all values of interest were analyzed whether or not the intercurrent event occurs. The following intercurrent events were considered: 1) discontinuation of treatment, 2) discontinuation of study (including death of the patient) related to safety of the IMP without any post-Baseline assessment of the BCVA, 3) discontinuation of study (including death of the patient) unrelated to safety of the IMP without any post-Baseline assessment of the BCVA and 4) major protocol deviations, which impacted the BCVA assessment until Week 8 as defined during the data review meeting (DRM).

Secondary endpoints were:

- Change from Baseline (Visit 1) in FCP retinal thickness to Week 4 (Visit 2) (defined as key secondary endpoint for the 'EU analysis')
- Changes of FCP retinal thickness and FCS retinal thickness over the whole study from Baseline (Visit 1) to Week 24 (Visit 5), Week 40 (Visit 7) and Week 56 (Visit 9)
- Change of BCVA by ETDRS letters over the whole study from Baseline (Visit 1) to Week 24 (Visit 5), Week 40 (Visit 7) and Week 56 (Visit 9)
- Proportion of patients who gained or lost ≥5, 10, or 15 ETDRS letters from Baseline (Visit 1) to Week 24 (Visit 5), Week 40 (Visit 7) and Week 56 (Visit 9)
- Percentage of patients with fluid-free macula at each visit, i.e., Baseline (Visit 1), Week 4 (Visit 2), Week 8 (Visit 3), Week 16 (Visit 4), Week 24 (Visit 5), Week 32 (Visit 6), Week 40 (Visit 7), Week 48 (Visit 8) and Week 56 (Visit 9)
- Change from Baseline (Visit 1) in total lesion size to Week 24 (Visit 5), Week 40 (Visit 7) and Week 56 (Visit 9)
- Systemic concentrations of free and total aflibercept in a PK subgroup at selected sites at Baseline (Visit 1) and close to predicted maximum concentration [Cmax] (based on estimated time to maximum concentration [tmax])
- o 48 hours after 1 st  dose (Visit 1a) and

<div style=\"page-break-after: always\"></div>

- o 48 hours after the 3 rd  dose (Visit 3a)
- Change from Baseline (Visit 1) in vision-related functioning and well-being measured by NEI VFQ-25 to Week 24 (Visit 5), Week 40 (Visit 7) and Week 56 (Visit 9)
- Number of patients with ADAs over time, i.e., at Baseline (Visit 1), 7 days after the first injection (Visit 1b, for PK subgroup only), Week 4 (Visit 2), 48 hours after the 3 rd  injection (Visit 3a, for PK subgroup only), Week 16 (Visit 4), Week 24 (Visit 5), Week 40 (Visit 7) and Week 56 (Visit 9)
- Frequency of local and systemic AEs and SAEs

## Sample size

The total sample size of approximately 400 patients for the 'EU analysis' was calculated on the basis of a 1:1 randomisation ratio and a standard deviation (SD) of 9.0 ETDRS letters in BCVA. An equivalence test of means using two 1-sided tests with sample sizes of 180 in each treatment group (360 patients in total)  achieves 90.0% power at a 2.5% significance level when no difference between the means is assumed, the SD is 9.0 letters, and the equivalence interval is [-3.5; 3.5] letters.

Further, the change of FCP retinal thickness at Week 4 (Visit 2) compared to Baseline Visit (Visit 1), was planned to be evaluated as a key secondary endpoint for EU/Japan regulatory submissions. The sample size of 200 patients in each treatment group (400 patients in total) provides a power of 82.8% at a 2.5% significance level (e.g. a two-sided 95% CI) when the true difference between the means is 0, the SD is 135 μm and the equivalence interval is [ -45.0; 45.0] μm. The equivalence margin of 45.0 μm was c hosen in light of the Treat &amp; Extend (T&amp;E) regimen established for the treatment of nAMD with Eylea. Based on the ARIES study (NCT02581891), re-treatment / shortening of dosing intervals could be suspended as long as the subretinal fluid did not exceed 50 μm in thickness (in addition to the absence of intraretinal fluid and the absence of new neovascularisation or haemorrhage) (Mitchell et al. 2021). Therefore, the predefined  equivalence  margin  of  45.0  μm  ensures  that  there  are  no  clinically  relevant  diffe rences between FYB203 and Eylea in terms of changes in FCP thickness.

Considering that about 10% of patients might drop-out and/or would be non-evaluable, 400 patients in total were planned to be included in the study.

## Randomisation and blinding (masking)

## Randomisation

Subjects were randomised in a 1:1 ratio to receive either FYB203 or EU-approved Eylea at a dose of 2 mg  (0.05  mL  of  a  40  mg/mL  solution).  Randomisation  was  performed  stratified  by  country  and participation in the PK subgroup (yes/no).

All subjects were centrally assigned to randomised study treatment using the IWRS. Before the study was initiated, the login information and directions for the IWRS were provided to each study site.

## Treatment masking and unmasking

This was a double-masked study with limited access to the randomisation code.

At each study site there were at least 2 masked staff members (the PI and the VA examiner). There could  be  also  other  masked  study  site  staff  (e.g.,  study  coordinator,  study  nurse,  OCT  technician, photographer).

Due  to  differences  in  the  products  presentation,  the  IMPs  were  administered  by  an  unmasked  IVT administrator who was responsible for the study injections only. He/she could also perform the post-

<div style=\"page-break-after: always\"></div>

dose safety check or tonometry, according to the clinical practice of the study site. The treatment each patient received was only disclosed to the unmasked IVT administrator but not to other study site staff, patient, Sponsor, or study vendors. The treatment codes were held by the IWRS vendor. The unmasked IVT administrator could also have a back-up person.

The PI (or his/her masked study team to whom tasks had been delegated) did all pre- and post-injection assessments (Ophthalmologic examination, SD-OCT, FA and CFP, blood samples collection, and NEI VFQ25  administration),  except  measurements  of  refraction  and  VA.  The  masked  Investigator(s)  also assessed the relationship of all AEs to IMP, including those noted by the unmasked IVT administrator. The PI or the unmasked IVT administrator conducted tonometry to measure the IOP pre and post IVT injection.

Only the masked VA examiners measured refraction and BCVA. They were not permitted to have any further roles in obtaining data from a patient; however, they were allowed to perform additional study support tasks such as read-out of the temperature logger.

Except for the unmasked IVT administrator, unmasking was considered only when knowledge of the treatment assignment was deemed essential for the patient's medical care by the PI (or his/her delegate) or a regulatory body. PIs or their delegates were strongly discouraged from requesting the mask be broken for an individual patient, unless there was a patient safety issue that required unmasking and would change patient management. The process for breaking the mask was handled through the IWRS.

## Statistical methods

## Planned analyses

## Analysis sets

The safety analysis set (SAF) included all patients who received at least1 injection of study medication in the study eye. Patients were analysed according to the treatment they actually received in the study eye irrespective of their randomised treatment.

The full analysis set (FAS) included all patients who received at least 1 injection of study medication in the study eye. Patients were analysed according to the treatment they were randomised to.

The per protocol set (PPS) included all patients that were in the FAS and

· Had no major protocol deviations until Week 8 (defined as protocol deviations that would interfere with the interpretation of the BCVA efficacy data at Baseline or at Week 8)

- Had received treatment from the randomised treatment group only before Week 8
- Had a valid measurement of the BCVA at Baseline and at Week 8 available
- Had no positive total aflibercept concentration at Baseline.

The plasma concentration analysis set (PKS) included patients that were in the SAF and had at least 1 valid post-dose plasma concentration measurement. Patients who received treatment from different treatment groups at Visit 1 or Visit 3 or who had a positive total aflibercept concentration at Baseline were excluded from this analysis set.

## Primary endpoint analysis

The primary estimand was assessed through a mixed model repeated measurements (MMRM) including the BCVA at Baseline as covariate and region (Japan vs. ROW), visit, randomised treatment group, the Baseline-by-visit  interaction  and  the  treatment-by-visit  interaction  as  fixed  effects.  Within  patients'

<div style=\"page-break-after: always\"></div>

correlations were modelled using an unstructured variance-covariance matrix. Kenward-Roger degrees of freedom approximation were used. The MMRM used all available data collected until Week 24 (Visit 5) for the study eye for all patients in the FAS for model estimation.

The hypothesis that both treatments FYB203 and Eylea are therapeutically equivalent with respect to the primary efficacy endpoint was tested in terms of a 2-sided equivalence test. The equivalence margin of  3  ETDRS  letters  (as  rounded  to  the  nearest  integer)  was  tested  by  the  following  hypotheses corresponding to the primary estimand:

H0: |µBCVA,FYB203 - µBCVA,Eylea | ≥ 3.5

H1: |µBCVA,FYB203 - µBCVA,Eylea | &lt; 3.5

where µBCVA,FYB203 and µBCVA,Eylea denote the mean changes of ETDRS letters from Baseline to Week 8 in the respective treatment groups.

The difference between the least squares (LS) means of the treatment groups and the corresponding 2sided 90.4% and 95.2% CI were estimated from the MMRM to address different regulatory requirements regarding the confidence level. The significance level alpha was reduced from 0.5 to 0.48 and from 0.025 to 0.024, respectively, to control the overall type 1 error in the light of the masked sample size review.

In order not to inflate the overall study-wise significance level, a hierarchical test strategy was applied: the EU-specific analysis was only to be performed in a confirmatory way if the US-specific analysis had already shown equivalence between FYB203 and Eylea.

If  the  respective  CI  was  completely  contained  in  the  interval]-3.5;3.5[  ETDRS  letters,  H0  could  be rejected and equivalence of FYB203 and Eylea could be concluded (rounded to the next integer, this corresponded to an equivalence margin of 3 ETDRS letters).

The MMRM assumption of normal distribution of the residuals was assessed via respective residual plots.

## Handling of missing data

It was assumed that there would be no missing data for Baseline because the Baseline BCVA needed to be available to confirm the inclusion criteria. A patient without any post-Baseline BCVA measurement until Week 24 could not be included in the primary efficacy analysis.

The number of patients in the FAS without any post-Baseline BCVA value was assessed during the DRM, and it was seen that all treated patients had at least 1 post-Baseline BCVA assessment and therefore, no further imputation method would be needed.

Missing data were not explicitly imputed, however if a patient had a missing data point at a specific postBaseline visit, the model assumes that the patient's missing value at that visit is comparable to the observed values of another patient having identical Baseline characteristics and a comparable course of change from Baseline until Week 24.

## Supportive analyses

For the primary estimand, sensitivity analyses as described below were planned. The relevance of the sensitivity analyses was evaluated during the DRM considering the number of patients that fell into the respective category.

For the primary statistical analysis using the MMRM, it was assumed that post-treatment assessments are missing at random (MAR) and that missing assessments were thus not related to any efficacy or safety difference between the 2 treatments. To investigate this assumption, the MMRM was repeated including additional covariates:

<div style=\"page-break-after: always\"></div>

- -Patient discontinued study prior to Week 24 (Yes/No)
- -Patient discontinued treatment prior to Week 24 (Yes/No)
- -Patient had any major protocol deviation (Yes/No)

For the primary MMRM, it was assumed that the use of an ancillary chart did not influence the BCVA results. To investigate this assumption, the MMRM was repeated including the use of an ancillary chart (yes/no) at each visit as additional covariate.

For the primary MMRM, it was assumed that patients with similar post-treatment values until Week 24 behave similarly. The MMRM was repeated including only data until analysis visit Week 8 or all data until Week 56 to investigate a possible influence of this definition on the estimation of treatment differences.

For the primary analysis, it was assumed that there is a correlation between the different visits within a patient. To investigate this further, the change from Baseline to Week 8 in BCVA by ETDRS letters was analysed with an analysis of covariance (ANCOVA) model instead of an MMRM. The model included the change from Baseline to Week 8 in BCVA as the dependent variable, the Baseline BCVA value as covariate and region (Japan vs. ROW) and treatment group as fixed effects. This analysis was performed based on observed cases, i.e., only patients with a BCVA at Week 8 analysis visit were included.

A further sensitivity analysis to the MMRM was performed where missing BCVA assessments at Week 8 were imputed using multiple imputation (MI); and an ANCOVA model was used on the imputed datasets to  analyse  the  primary  efficacy  endpoint.  MI  used  the  Baseline  BCVA  value  as  well  as  region  and treatment group as covariates for imputation. A monotone imputation approach was used since it was expected that the covariates Baseline BCVA, region and treatment group would not be missing for any patient. The predictive mean matching method was used to impute missing values of the BCVA change from Baseline to ensure that imputed values would be in the range of observed values. Instead of the default of 25 imputations, 100 imputations and a seed of 2143 was used. The ANCOVA model was the same as specified above for the previous sensitivity analysis and was conducted separately for each of the 100 imputed datasets. The results were then combined to the final result.

To further investigate the assumption of MAR, tipping point analyses assuming 'missing not at random' were performed. A sensitivity  parameter  (θ)  was  introduced  for  each  treatment  ( -θ  for  the  FYB203 treatment group and +θ for Eylea, +θ for the FYB203 and -θ for Eylea, 0 for FYB203 and +θ or -θ for Eylea, +θ or -θ for FYB203 and 0 for Eylea). The MAR assumption with θ = 0 for both treatments was the starting point and was changed in fixed steps of ETDRS letters in both directions or only in 1 direction to increase the difference between the treatment groups. Missing values were imputed within the same treatment group using a monotone regression imputation model, 100 imputations, and Baseline BCVA and region as covariates. An ANCOVA was used to analyse the imputed datasets, also including Baseline BCVA and region as covariates.

## Supplemental estimands for the primary efficacy endpoint

The following supplemental estimands (referring to the primary efficacy endpoint) were assessed:

- -The  mean  difference  between  the  randomised  treatment  groups,  FYB203  and  Eylea,  in  the primary efficacy endpoint for the study eye, excluding patients from the FAS with major protocol deviations which directly impact the BCVA assessments until Week 8 (Visit 3).
- -The  mean  difference  between  the  randomised  treatment  groups,  FYB203  and  Eylea,  in  the primary efficacy endpoint for the study eye, excluding patients from the FAS who discontinued treatment before Week 8 or do not have a Week 8 BCVA assessment.

<div style=\"page-break-after: always\"></div>

- -The  mean  difference  between  the  randomised  treatment  groups,  FYB203  and  Eylea,  in  the primary efficacy endpoint for the study eye, based on the PPS (this secondary estimand is a combination of the previous ones stated above).

The supplemental estimands described above were assessed using the same statistical method as for the primary efficacy analysis.

Additionally, the following supplemental estimand was assessed:

- -The  mean  difference  between  the  randomised  treatment  groups,  FYB203  and  Eylea,  in  the primary efficacy endpoint for the study eye, based on the FAS with all patients excluded from the PPS analysed with an imputed (hypothetical) BCVA value. The BCVA values at Week 8 were imputed for all patients excluded from the PPS using a MI approach, regardless of whether a BCVA value at Week 8 was collected. This estimand was assessed with the same ANCOVA model as specified above as sensitivity analysis.

The following supplemental estimands were investigated to further investigate the assumptions for the primary estimand:

- -For the primary analysis, it was assumed that discontinuation of treatment would have the same impact  on  the  following  measurements  in  both  treatment  groups  and  could  therefore  be neglected. To investigate this assumption, the primary MMRM was repeated on data where all assessments following discontinuation of treatment are set to missing. This strategy follows the 'While on treatment strategy' as described in the ICH E9 addendum on estimands.
- -For  the  primary  analysis,  it  was  assumed  that  single  missed  injections  would  not  have  an influence on the following assessments. To investigate this assumption, the primary MMRM was repeated  based  on  data,  where  all  assessments  following  missed  injection  visits  are  set  to missing.  Missed  injection  visits  were  defined  as  analysis  visits  where  no  injection  could  be mapped to the defined visit window. Only the BCVA assessment following this missed injection visit  was  set  to  missing  and  assessments  collected  thereafter  could  still  be  included  in  the analysis.
- -For the primary analysis, it was assumed that major protocol deviations would have the same impact on the following measurements in both treatment groups and can therefore be neglected. To  investigate  this  assumption,  the  primary  MMRM  was  repeated  based  on  data,  where  all assessments following major protocol deviations were set to missing.
- -Certain  protocol  deviations  would  only  have  an  impact  on  single  BCVA  measurements,  e.g., prohibited  medications  that  where  taken  only  for  a  certain  time  period  and  are  washed  out thereafter.  These  deviations  were  identified  during  the  DRM  and  all  corresponding  BCVA assessments would have been set to missing and the primary MMRM would have been repeated based on this data. However, since only very few of these protocol deviations occurred, this analysis was not performed.

## Planned subgroup analyses

The primary efficacy analysis was repeated within pre-defined subgroups and results were displayed in a forest plot. The following subgroups were used:

- Gender (female and male)
- Use of an ancillary chart up to Week 56 (yes/no, Patients who only used the ancillary chart for single assessments will be excluded from this analysis)
- ADA status (any positive treatment-emergent ADA as defined in Section 7.13 of the SAP during study versus no positive treatment-emergent ADA during study up to Week 56)

<div style=\"page-break-after: always\"></div>

- Total lesion area at Baseline (&lt; 9mm2 versus ≥ 9mm2, cut -off confirmed during DRM)
- Lesion type at Baseline (types as reported by GRADE, calculations not to be done in subgroups where the sample size is too small leading to non-calculable estimates)
- Injection  syringe  use  (medical  devices  for  IMP  preparation  and  administration  procedure  as provided by the Sponsor versus other syringes used (at any time during study))
- Region (Japan versus ROW)

## Error probabilities, adjustment for multiplicity and interim analyses

The fixed  sample size  was  based  on  the  fixed  assumed  SD  of  9.0  letters.  As  there  had  been  some uncertainty about this parameter at the time of initial sample size calculation, a masked sample size review was performed after the first 200 treated patients had completed Week 8 (in November 2021). It revealed that the observed overall variability did not require an increase in sample size to maintain the intended statistical power.

However, a simulation study had been conducted prior to the initiation of the study to assess the impact of a possible sample size increase on the overall study-wise type 1 error rate alpha. The simulations using the US criteria (i.e., using a significance level of 5% for both one-sided tests) suggested that an adjustment of alpha to 4.8% would be needed to control the possible inflation of the type 1 error rate for the originally planned 'US analysis' of the first 320 patients. This corresponded to a 2-sided 90.4% confidence interval (CI) for the assessment of equivalence. Similarly, simulations using the EU criteria suggested a necessary adjustment of alpha to 2.4% for all EU-specific statistical analyses.

## Changes from protocol-specified analyses

The following change, concerning the scope of reporting, occurred after regulatory feedback from the FDA in February 2023:

Originally,  it  was  planned  to  perform  a  US-specific  analysis  based  on  40-week  data  of  the  first  320 treated patients. Further, the planned analysis on 24-week data based on all patients was planned to be submitted in the EU only. Due to regulatory feedback from the FDA in February 2023, the planned 24week analysis on all patients was performed for the US criteria using a 5% overall significance level and for the EU/Japan criteria using a 2.5% significance level overall.

## Results

## Participant flow

Study initiation date: Jul 21, 2020 (first patient, first visit), Study completion date: May 18, 2023 (last patient, last visit), Patients were treated between 12-Aug-2020 and 30-Mar-2023

Originally 400 patients were planned to be randomised, including 52 patients in Japan. However, actual number of patients randomised are 434 including 33 patients in Japan.

Up to Week 56, 19 (8.8%) patients in the FYB203 group and 12 (5.5%) patients in the Eylea group discontinued the study prematurely, for the following reasons:

In the FYB203 group, 5 patients experienced AEs (PTs: Oesophageal carcinoma stage 0, Cerebrovascular accident,  COVID-19,  Rhegmatogenous  retinal  detachment  and  Subretinal  fluid),  4  patients  died  (1 patient experienced PTs Pulmonary fibrosis and Cardiac failure, 1 patient experienced PTs COVID-19, COVID-19 pneumonia and Cardiac failure, 1 patient experienced PTs Aspiration, Toxic shock syndrome and Ileus, 1 patient experienced PT Acute myeloid leukaemia), 3 patients withdrew consent, 1 patient

<div style=\"page-break-after: always\"></div>

was lost  to  follow-up,  1  patient  had  a  protocol  violation  (related  to  the  geopolitical  situation  in  the Ukraine) and 5 patients discontinued due to other reasons (in 4 cases related to the geopolitical situation in the Ukraine, 1 patient refused to participate in the continuation of the study due to the improvement of vision).

In the Eylea group, 7 patients withdrew consent, 2 patients discontinued following physician decision, 1 patient died (PT: Cardiac failure), 1 patient was lost to follow-up and 1 patient discontinued due to other reasons (related to the geopolitical situation in the Ukraine.

A total  of  196  (91.2%)  patients  in  the  FYB203  group  and  206  (94.1%)  patients  in  the  Eylea  group completed the study until Week 56.

<div style=\"page-break-after: always\"></div>

<!-- image -->

ICF =informed consent form

Figure 3: Patient disposition diagram

## Conduct of the study

## Protocol amendments

Protocol Version 1.0 was not implemented and the first patients were enrolled under Protocol Version 2.0.

The  CSP  was  amended  once;  The  most  important  changes  introduced  in  Protocol  Version  3.0 (Amendment 1.0) were as follows:

- -The planned statistical analyses were updated: the originally planned main US analysis (after completion of 24 weeks of treatment) was removed. The final 'US analysis' (after 40 weeks of treatment, US sample size), the main 'EU analysis' (after 24 weeks, all patients), and the final

<div style=\"page-break-after: always\"></div>

'EU/Japan analysis' (after 56 weeks, all patients) were to be performed sequentially instead, with 3 separate database locks.

- -Potential increase in the sample size estimation for 'US analysis'.
- -The number of patients were updated to reflect the final numbers of randomised patients (1) overall and (2) in Japan, including:
- o study sites updates (i.e., from 80 to 85 study sites and inclusion of additional countries enrolling participants).
- o interim masked review of sample size performed in November 2021 confirming that the original assumptions for the sample size calculation were correct.
- -Details of MMRM model were adapted: removed patient as random effect and added Baselineby-visit interaction as fixed effect.

The changes were not considered to have affected the interpretation of study results as they were minor and occurred prior to study unmasking.

## Protocol deviations

In total, there were 27 (6.2%, Table 6) patients with major protocol deviations, which led to the exclusion from the PPS. Overall, the number of patients with major protocol deviations was well balanced between the treatment groups (14 patients in the FYB203 group and 13 patients in the Eylea group).

Please note that programmed protocol deviations and clinical research associate (CRA) reported protocol deviations might overlap for some protocol deviations and patients.

Table 7, 8, 9, and 10, report respectively: demographics, baseline diagnosis characteristics, baseline ophthalmological parameters, number of patients in each analysis set/reasons for exclusion from each analysis set.

<div style=\"page-break-after: always\"></div>

Table 6: Number and percentage of patients with any major protocol deviation or major intercurrent event (FAS, N=433)

|                                                                                   | FYB203 N=215 (%)   | Eylea N=218 n (%)   | Total N=433 (%)   |
|-----------------------------------------------------------------------------------|--------------------|---------------------|-------------------|
| Any major protocol deviation or intercurent event.2                               | 14 (6.5)           | 13 (6.0)            | 27 (6.2)          |
| BCVAschedule deviation                                                            | 6 (2.8)            | 7 (3.2)             | 13 (3.0)          |
| BCVA schedule deviation at V3 (programmed protocol deviation)                     | 6 (2.8)            | 7 (3.2)             | 13 (3.0)          |
| IPschedule deviation                                                              | 2 (0.9)            | 3 (1.4)             | 5 (71)            |
| IMP schedule deviation at V2 (programmed protocol deviation)                      | 2 (0.9)            | 3 (1.4)             | 5 (1.2)           |
| IP incompliance                                                                   | 2 (0.9)            | 2 (0.9)             | 4 (0.9)           |
| Temperature excursion of IMP at Visit 2 (CRA reported protocol deviation)         | 2 (0.9)            | 0 (0.0)             | 2 (0.5)           |
| Time window of IMP at Visit 2 (CRA reported protocol deviation)                   | 0 (0.0)            | 2 (0.9)             | 2 (0.5)           |
| Studytreatmentincompliance                                                        | 2 (0.9)            | 2 (0.9)             | 4 (0.9)           |
| Study treatment incompliance (programmed protocol deviation)                      | (0.9)              | 2 (0.9)             | 4 (0.9)           |
| Visit schedule deviation                                                          | 2 (0.9)            | 2 (0.9)             | 4 (0.9)           |
| Visit schedule deviation, V3 (CRA reported protocol deviation)                    | 1 (0.5)            | 2 (0.9)             | 3 (0.7)           |
| Visit schedule deviation, V3, COVIDi9 related (CRA reported protocol deviation)   | 1 (0.5)            | 0 (0.0)             | 1 (0.2)           |
| Inclusion criteria                                                                | 1 (0.5)            | 2 (0.9)             | 3 (0.7)           |
| Inclusion criterion 05 (CRA reported protocol deviation)                          | 1 (0.5)            | 2 (0.9)             | 3 (0.7)           |
| PositiveBaseline total aflibercept concentration                                  | 1 (0.5)            | 2 (0.9)             | 3 (0.7)           |
| Positive Baseline total aflibercept concentration (programmed protocol deviation) | 1 (0.5)            | 2 (0.9)             | 3 (0.7)           |
| Violation ofinclusioncriterion                                                    | 1 (0.5)            | 2 (0.9)             | 3 (0.7)           |
| Violation of inclusion criterion 05 (programmed protocol deviation)               | 1 (0.5)            | 2 (0.9)             | 3 (0.7)           |
| Violation of inclusion criterion 08 (programmed protocol deviation)               | (0.5)              | 2 (0.9)             | 3 (0.7)           |
| BCVA: wrong sequence of assessments                                               | 1 (0.5)            | 1 (0.5)             | 2 (0.5)           |
| BCVA at Baseline (CRA reported protocol deviation)                                | 1 (0.5)            | 1 (0.5)             | 2 (0.5)           |
| Randomization                                                                     | 1 (0.5)            | 1 (0.5)             | 2 (0.5)           |
| Randomization (CRA reported protocol deviation)                                   | 1 (0.5)            | 1 (0.5)             | 2 (0.5)           |
| Blinding                                                                          | 0 (0.0)            | 1 (0.5)             | 1 (0.2)           |
| Possible unblinding of PI (CRA reported protocol deviation)                       | 0 (0.0)            | 1 (0.5)             | 1 (0.2)           |
| Exclusion criterion                                                               | 1 (0.5)            | 0 (0.0)             | 1 (0.2)           |
| Exclusion criterion 03(CRAreportedprotocol deviation)                             | 1 (0.5)            | 0 (0.0)             | 1 (0.2)           |
| Violationofexclusioncriterion                                                     | 1 (0.5)            | 0 (0.0)             | 1 (0.2)           |
| Violation of exclusion criterion 03 (programmed protocol deviation)               | 1 (0.5)            | 0 (0.0)             | 1 (0.2)           |

BCVA = best corrected visual acuity, CRA = clinical research associate, FAS = fiull analysis set,

IMP=investigational medicinal product,N=total number ofpatientsin analysis set,n =number ofpatients in corresponding class,PI=principal investigator,V=Visit

2 A patient can have several major protocol deviations / intercurrent events in different categories. Visit schedule deviations reported by clinical research associates can include the same patients as programmed BCVA schedule deviations.

1 All protocol deviations except *Violation of inclusion criterion O8: Foveal center point retinal thickness is not taken atScreening\"interferedwith the interpretationof theBCVA efficacy data at BaselineorWeek 8

Source: Table 14.1.3.1.2,Table 14.1.3.2.2

<div style=\"page-break-after: always\"></div>

## Table 7: Demographics (FAS, N=433)

## Baseline data

| Parameter Category                    | FYB203 N=215   | Eylea N=218   | Total N=433   |
|---------------------------------------|----------------|---------------|---------------|
| Gender [n (%)]                        |                |               |               |
| Male                                  | 94 (43.7%)     | 91 (41.7%)    | 185 (42.7%)   |
| Female                                | 121 (56.3%)    | 127 (58.3%)   | 248 (57.3%)   |
| Of childbearing potential             | 0 (0.0%)       | 1 (0.5%)      | 1 (0.2%)      |
| Not of childbearing potential         | 121 (56.3%)    | 126 (57.8%)   | 247 (57.0%)   |
| Country [n (%)]                       |                |               |               |
| Bulgaria                              | 10 (4.7%)      | 11 (5.0%)     | 21 (4.8%)     |
| Czech Republic                        | 34 (15.8%)     | 35 (16.1%)    | 69 (15.9%)    |
| Hungary                               | 34 (15.8%)     | 34 (15.6%)    | 68 (15.7%)    |
| Israel                                | 6 (2.8%)       | 6 (2.8%)      | 12 (2.8%)     |
| Italy                                 | 9 (4.2%)       | 9 (4.1%)      | 18 (4.2%)     |
| Japan                                 | 17 (7.9%)      | 16 (7.3%)     | 33 (7.6%)     |
| Poland                                | 37 (17.2%)     | 40 (18.3%)    | 77 (17.8%)    |
| Russian Federation                    | 35 (16.3%)     | 36 (16.5%)    | 71 (16.4%)    |
| Ukraine                               | 33 (15.3%)     | 31 (14.2%)    | 64 (14.8%)    |
| Race [n (%)]                          |                |               |               |
| White                                 | 197 (91.6%)    | 201 (92.2%)   | 398 (91.9%)   |
| Asian                                 | 17 (7.9%)      | 16 (7.3%)     | 33 (7.6%)     |
| Other                                 | 1 (0.5%)       | 1 (0.5%)      | 2 (0.5%)      |
| Ethnicity [n (%)]                     |                |               |               |
| Hispanic or Latino                    | 3 (1.4%)       | 5 (2.3%)      | 8 (1.8%)      |
| Not Hispanic or Latino                | 212 (98.6%)    | 213 (97.7%)   | 425 (98.2%)   |
| Age at Screening[years]               |                |               |               |
| 11                                    | 215            | 218           | 433           |
| Missing values                        | 0              | 0             | 0             |
| Mean (SD)                             | 73.7 (7.72)    | 73.3 (7.70)   | 73.5 (7.71)   |
| Median                                | 74.0           | 74.0          | 74.0          |
| Min-Max                               | 51-93          | 51-92         | 51-93         |
| Q1-Q3                                 | 68.079.0       | 68.0-79.0     | 68.0-79.0     |
| Age categories 1 at Screening [n (%)] |                |               |               |
| 50-64 years                           | 17 (7.9%)      | 25 (11.5%)    | 42 (9.7%)     |
| 65-75 years                           | 105 (48.8%)    | 111 (50.9%)   | 216 (49.9%)   |
| > 75 years                            | 93 (43.3%)     | 82 (37.6%)    | 175 (40.4%)   |

<div style=\"page-break-after: always\"></div>

Table 8: Baseline diagnosis characteristics (FAS, N=433)

| Parameter Category                                         | FYB203        | Eylea N=218   | Total         |
|------------------------------------------------------------|---------------|---------------|---------------|
|                                                            | N=215         |               | N=433         |
| Study eye [n (%)]                                          |               |               |               |
| OD (right eye)                                             | 112 (52.1%)   | 99 (45.4%)    | 211 (48.7%)   |
| OS (left eye)                                              | 103 (47.9%)   | 119 (54.6%)   | 222 (51.3%)   |
| Iris color [n (%)]                                         |               |               |               |
| Light                                                      | 76 (35.3%)    | 84 (38.5%)    | 160 (37.0%)   |
| Medium                                                     | 96 (44.7%)    | 86 (39.4%)    | 182 (42.0%)   |
| Dark                                                       | 43 (20.0%)    | 48 (22.0%)    | 91 (21.0%)    |
| Baseline BCVA Snellen equivalent in study eye [m(%)]       |               |               |               |
| 20/40                                                      | 39 (18.1%)    | 40 (18.3%)    | 79 (18.2%)    |
| 20/50                                                      | 50 (23.3%)    | 46 (21.1%)    | 96 (22.2%)    |
| 20/63                                                      | 32 (14.9%)    | 33 (15.1%)    | 65 (15.0%)    |
| 20/80                                                      | 32 (14.9%)    | 35 (16.1%)    | 67 (15.5%)    |
| 20/100                                                     | 23 (10.7%)    | 17 (7.8%)     | 40 (9.2%)     |
| 20/125                                                     | 5 (2.3%)      | 15 (6.9%)     | 20 (4.6%)     |
| 20/160                                                     | 13 (6.0%)     | 13 (6.0%)     | 26 (6.0%)     |
| 20/200                                                     | 21 (9.8%)     | 19 (8.7%)     | 40 (9.2%)     |
| Lesion type at Baseline in the study eye [n (%)]           |               |               |               |
| Type 1 MNV                                                 | 71 (33.0%)    | 72 (33.0%)    | 143 (33.0%)   |
| Type 2 MNV                                                 | 49 (22.8%)    | 51 (23.4%)    | 100 (23.1%)   |
| Mixed type 1 and type 2 MNV                                | 74 (34.4%)    | 76 (34.9%)    | 150 (34.6%)   |
| Type 3 MNV                                                 | 19 (8.8%)     | 19 (8.7%)     | 38 (8.8%)     |
| Missing                                                    | 2 (0.9%)      | 0 (0.0%)      | 2 (0.5%)      |
| Time since first diagnosis of nAMID to randomization[days] |               |               |               |
| 11                                                         | 182           | 191           | 373           |
| Missing values                                             | 33            | 27            | 60            |
| Mean (SD)                                                  | 55.0 (101.64) | 53.1 (108.75) | 54.1 (105.20) |
| Median                                                     | 32.0          | 29.0          | 30.0          |
| Min-Max                                                    | 7-975         | 6-1226        | 6-1226        |
| Q1-Q3                                                      | 20.053.0      | 19.0-54.0     | 20.0-53.0     |

<div style=\"page-break-after: always\"></div>

Table 9: Baseline ophthalmological parameters (FAS, N=433)

|                                           | FYB203 N=215   | Eylea N=218    | Total N=433    |
|-------------------------------------------|----------------|----------------|----------------|
| Baseline (Vl)BCVA [ETDRS letters]         |                |                |                |
| 11                                        | 215            | 218            | 433            |
| Missing values                            | 0              | 0              | 0              |
| Mean (SD)                                 | 58.0 (11.35)   | 57.8 (11.22)   | 57.9 (11.27)   |
| Median                                    | 60.0           | 60.0           | 60.0           |
| Min-Max                                   | 34-73          | 34-73          | 34-73          |
| Q1-Q3                                     | 51.067.0       | 50.0-67.0      | 51.0-67.0      |
| Baseline (Vl) FCP retinal thickness [μum] |                |                |                |
| 1n                                        | 208            | 216            | 424            |
| Missing values                            | 7              | 2              | 9              |
| Mean (SD)                                 | 465.9 (157.06) | 487.0 (151.73) | 476.6 (154.55) |
| Median                                    | 432.5          | 448.5          | 439.0          |
| Min-Max                                   | 188-1161       | 269-930        | 188-1161       |
| Q1-Q3                                     | 347.0-550.5    | 364.0-598.5    | 353.0-573.5    |
| Baseline (Vl) FCS retinal thickness [μum] |                |                |                |
| 11                                        | 213            | 218            | 431            |
| Missing values                            | 2              | 0              | 2              |
| Mean (SD)                                 | 493.5 (140.50) | 514.5 (137.68) | 504.1 (139.31) |
| Median                                    | 463.0          | 484.0          | 472.0          |
| Min-Max                                   | 226-1152       | 292-911        | 226-1152       |
| Q1-Q3                                     | 393.0-558.0    | 402.0-611.0    | 397.0-585.0    |
| Screening' total lesion area [mm²]        |                |                |                |
| n                                         | 215            | 218            | 433            |
| Missing values                            | 0              | 0              | 0              |
| Mean (SD)                                 | 9.5 (5.74)     | 9.6 (5.95)     | 9.6 (5.84)     |
| Median                                    | 8.4            | 8.9            | 8.6            |
| Min-Max                                   | 0-23           | 1-34           | 0-34           |
| Q1-Q3                                     | 4.9-13.4       | 4.8-13.0       | 4.8-13.2       |
| Baseline (Vl) I0P [mmHg]                  |                |                |                |
| 11                                        | 215            | 218            | 433            |
| Missing values                            | 0              | 0              | 0              |
| Mean (SD)                                 | 15.0 (2.60)    | 15.6 (2.71)    | 15.3 (2.67)    |
| Median                                    | 15.0           | 16.0           | 15.0           |
| Min-Max                                   | 8-21           | 10-23          | 8-23           |
| Q1-Q3                                     | 13.017.0       | 14.0-17.0      | 13.0-17.0      |

<div style=\"page-break-after: always\"></div>

## Table 10: Number of patients in each analysis set and reasons for exclusion from each analysis set (all randomised patients, N=434)

## Numbers analysed

|                                                                  | FYB203   | FYB203   | Eylea   | Eylea   | Total   | Total   |
|------------------------------------------------------------------|----------|----------|---------|---------|---------|---------|
| Analysis set                                                     | N=215    | N=215    | N=219   | N=219   | N=434   | N=434   |
| Reason for exclusion                                             |          | (%)      | 11      | (%)     | n       | (%)     |
| Patients in SAF                                                  | 215      | (100.0)  | 218     | (99.5)  | 433     | (99.8)  |
| Reason for exclusion from SAF:                                   |          |          |         |         |         |         |
| No injection of study medication                                 | 0        | (0.0)    | 1       | (0.5)   | 1       | (0.2)   |
| Patientsin FAS                                                   | 215      | (100.0)  | 218     | (99.5)  | 433     | (99.8)  |
| Reason for exclusion from FAS:                                   |          |          |         |         |         |         |
| No injection of study medication                                 | 0        | (0.0)    | 1       | (0.5)   | 1       | (0.2)   |
| Patients in PPS                                                  | 201      | (93.5)   | 205     | (94.0)  | 406     | (93.8)  |
| PatientsinSAF/FAS                                                | 215      | (100.0)  | 218     | (100.0) | 433     | (100.0) |
| Reasons for exclusionfrom PPS:                                   |          |          |         |         |         |         |
| No BCVA measurement at Week 8                                    | 6        | (2.8)    | 5       | (2.3)   | 11      | (2.5)   |
| Major IMP schedule or administration deviation                   | 3        | (1.4)    | 4       | (1.8)   | 7       | (1.6)   |
| Violation ofinclusion/exclusion criteria                         | 2        | (0.9)    | 2       | (0.9)   | 4       | (0.9)   |
| Positive Baseline total aflibercept concentration                | 1        | (0.5)    | 2       | (0.9)   | 3       | (0.7)   |
| Measured BCVA values invalid/affected dueto protocoldeviation    | 1        | (0.5)    | 1       | (0.5)   | 2       | (0.5)   |
| Injections from different treatment than randomized until Week 8 | 1        | (0.5)    | 1       | (0.5)   | 2       | (0.5)   |
| Possible unmasking of study site staff or subject                | 0        | (0.0)    | 1       | (0.5)   | 1       | (0.2)   |
| NoBCVA measurement at Baseline                                   | 0        | (0.0)    | 0       | (0.0)   | 0       | (0.0)   |
| Patients in PKS*                                                 | 31       | (96.9)   | 26      | (92.9)  | 57      | (95.0)  |
| Patientsrecruitedintoplasma concentration sub-study              | 32       | (100.0)  | 28      | (100.0) | 60      | (100.0) |
| Reasons for exclusion from PKS:                                  |          |          |         |         |         |         |
| Positive Baseline total aflibercept concentration                | 1        | (3.1)    | 2       | (7.1)   | 3       | (5.0)   |

## Outcomes and estimation

For all data derivations and statistical analyses, SAS ®  Version 9.4 was used.

## Primary efficacy analysis

The primary efficacy endpoint, the change in BCVA by ETDRS letters from Baseline to Week 8 (Visit 3), was calculated to evaluate and compare functional changes in BCVA by ETDRS letters following treatment with FYB203 or Eylea at Week 8 compared to Baseline.

<div style=\"page-break-after: always\"></div>

Table 11: MMRM: Comparison of change in BCVA (ETDRS letters) from baseline to week 8, including data up to week 24 (US and EU analyses, FAS, N=433)

|                              |                           | MMRM LS estimation                              | MMRM LS estimation                              | MMRM LS estimation                              | MMRM LS estimation                              | MMRM LS estimation   | MMRM LS estimation   |
|------------------------------|---------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|----------------------|----------------------|
| Week (Visit) Treatment group | N                         | na                                              | mmissa                                          | LS meanb                                        | SEb                                             | 2-sided 90.4% CI     | 2-sided 95.2% CI     |
| Week 8 (V3)                  |                           |                                                 |                                                 |                                                 |                                                 |                      |                      |
| FYB203                       | 215                       | 215                                             | 0                                               | 6.6                                             | 0.73                                            | [5.4; 7.8]           | [5.2; 8.0]           |
| Eylea                        | 218                       | 218                                             | 0                                               | 5.6                                             | 0.73                                            | [4.4; 6.9]           | [4.2; 7.1]           |
| Difference: FYB203 -Eylea    | Difference: FYB203 -Eylea |                                                 |                                                 | 1.0                                             | 0.76                                            | [-0.3; 2.2]          | [-0.6; 2.5]          |
| US analysis                  | US analysis               | 2-sided 90.4% CI contained in ]-3.5; 3.5[ : yes | 2-sided 90.4% CI contained in ]-3.5; 3.5[ : yes | 2-sided 90.4% CI contained in ]-3.5; 3.5[ : yes | 2-sided 90.4% CI contained in ]-3.5; 3.5[ : yes |                      |                      |
| EU analysis                  | EU analysis               | 2-sided 95.2% CI contained in ]-3.5; 3.5[ : yes | 2-sided 95.2% CI contained in ]-3.5; 3.5[ : yes | 2-sided 95.2% CI contained in ]-3.5; 3.5[ : yes | 2-sided 95.2% CI contained in ]-3.5; 3.5[ : yes |                      |                      |

BCVA = best corrected visual acuity, CI = confidence interval, ETDRS = early treatment diabetic retinopathy study, FAS = full analysis set, LS = least squares, MMRM = Mixed Model Repeated Measures, N = total number of patients in the analysis set, n/nmiss = number of non-missing/missing assessments, SE = standard error of LS mean, V = Visit

- a For the calculation of LS means based on the MMRM, all patients with missing and non-missing Week 8
- assessments were considered ifthey have at least 1 post-Baseline BCVA value until Week 24.
- Estimates are adjusted for Baseline BCVA, region (Japan vs. Rest of world), treatment, visit, treatment-visitinteraction andBaseline-visit-interaction.
- ° If the CI for the difference in LS means was completely contained in the interval ]-3.5; 3.5 letters[, FYB203 and Eylea were considered equivalent.

Source: Table 14.1.4.1, Table 14.2.1.1 (\"US Analysis\"), Table 14.2.1.2 (\"EU Analysis\")

## Sensitivity analyses

The sensitivity analyses for the primary endpoint at Week 8 were performed using different MMRMs and ANCOVAs with and without MI.

All sensitivity analyses supported the result of the primary analysis, i.e., that the therapeutic equivalence of the 2 treatments with respect to the primary efficacy endpoint is given.

<div style=\"page-break-after: always\"></div>

Table 12: Summary of sensitivity analyses displaying least squares mean difference between FYB203 and Eylea in BCVA (ETDRS letters) change from baseline to week 8 (US and EU analyses, FAS, N=433)

| Method, set, data                                                                                                                 |   LS mean differencel |   SE | 2-sided 90.4% CI Source    | 2-sided 95.2%CI Source     | Within equivalence margin 1-3.5; 3.5[   |
|-----------------------------------------------------------------------------------------------------------------------------------|-----------------------|------|----------------------------|----------------------------|-----------------------------------------|
| MMRM, FAS Data up to Week 24, including patient discontinuation of study status prior to Week 24 (Yes/No) as additional covariate |                   1   | 0.76 | [-0.3; 2.2] Table 14.2.2.1 | [-0.6; 2.5] Table 14.2.3.1 | yes                                     |
| MMRM, FAS Data up to Week 24 including patient discontinuation of treatment prior to Week 24 (Yes/No) as additional covariate     |                   0.9 | 0.76 | [-0.3; 2.2] Table 14.2.2.2 | [-0.6; 2.5] Table 14.2.3.2 | yes                                     |
| MMRM, FAS Data up to Week 24, including patient any major protocol deviation status (Yes/No) as additional covariate              |                   0.9 | 0.76 | [-0.3; 2.2] Table 14.2.2.3 | [-0.6; 2.5] Table 14.2.3.3 | yes                                     |
| MMRM, FAS Data up to Week 24. including ancillary chart use (Yes/No) as additional covariate                                      |                   1   | 0.77 | [-0.3; 2.3] Table 14.2.2.4 | [-0.5; 2.5] Table 14.2.3.4 | yes                                     |
| MMRM, FAS Data up to Week 8                                                                                                       |                   0.9 | 0.77 | [-0.3; 2.2] Table 14.2.2.5 | [-0.6; 2.5] Table 14.2.3.5 | yes                                     |
| ANCOVA, FAS, observed cases                                                                                                       |                   1   | 0.77 | [-0.3; 2.3] Table 14.2.2.6 | [-0.5; 2.5] Table 14.2.3.6 | yes                                     |
| ANCOVA, FAS, multiple imputation                                                                                                  |                   1.1 | 0.77 | [-0.2; 2.4] Table 14.2.2.7 | [-0.4; 2.6] Table 14.2.3.7 | yes                                     |
| MMRM, FAS Data up to Week 56                                                                                                      |                   1   | 0.76 | [-0.3; 2.2] Table 14.2.2.8 | [-0.6; 2.5] Table 14.2.3.8 | yes                                     |

ANCOVA = Analysis of covariance, BCVA = best corrected visual acuity, CI = confidence interval.

ETDRS = early treatment diabetic retinopathy study, FAS = full analysis set, LS = least squares.

MMRM = Mixed Model Repeated Measures, N = total number of patients in the analysis set, SE = standard error of LS mean

1 Difference calculated as FYB203 -Eylea

## Tipping point analyses

Additionally, tipping point analyses for the primary efficacy endpoint to assess possible deviations from the MAR assumption underlying the MMRM analyses were performed. The analyses used MI under a missing not at random assumption and added various consta nt shifts of θ in various directions to the imputed values in each treatment group. The imputed datasets were then analysed with an ANCOVA model to calculate the LS means and CIs. The shift was broadened with each analysis performed until the equivalence criterion was no longer achieved.

<div style=\"page-break-after: always\"></div>

The smallest tipping point that would lead to a conclusion of lower efficacy of FYB203 compared to Eylea was a shift of 0 in the Eylea group and a shift of -88 or -79 letters in the FYB203 group for the US analysis and the EU analysis, respectively (last row in Table 13). Considering the observed data in the FYB203 group with a range of -16 to 31 letters for the change in BCVA from Baseline to Week 8 (Table 13) and the fact that imputed values would also be in this range, this would mean that changes for patients with missing data would have to be between -95 and -48 letters. The likelihood that all these patients would have much worse changes than the observed minimum changes is regarded as very low.

The tipping point analysis thus confirms the robustness of the therapeutic equivalence conclusion.

Table 13: Summary of Tipping Point Analyses Displaying Least Squares Mean Difference Between FYB203 and Eylea in BCVA (ETDRS Letters) Change From Baseline to Week 8, derived from ANCOVA after Multiple Imputation (US and EU Analyses, FAS, N=433)

| Tipping points,         | 2-sided 90.4% CI   | 2-sided 90.4% CI   | 2-sided 95.2% CI   | 2-sided 95.2% CI   |
|-------------------------|--------------------|--------------------|--------------------|--------------------|
| △(FYB203-Eylea)         | Eylea              | FYB203             | Eylea              | FYB203             |
| Shift inimputation (o)  | +53                | -53                | +48                | -48                |
| (FYB203-Eylea)          | -1.7 [-3.54; 0.17] | -1.7 [-3.54; 0.17] | -1.4 [-3.53; 0.67] | -1.4 [-3.53; 0.67] |
| Shift in imputation (0) | -22                | +22                | -18                | +18                |
| A (FYB203-Eylea)        | 2.1 [0.71; 3.53]   | 2.1 [0.71; 3.53]   | 1.9 [0.29; 3.54]   | 1.9 [0.29; 3.54]   |
| Shiftinimputation(o)    | +103               | 0                  | +92                | 0                  |
| △ (FYB203-Eylea)        | -1.3 [-3.52; 0.83] | -1.3 [-3.52; 0.83] | -1.1 [-3.50; 1.31] | -1.1 [-3.50; 1.31] |
| Shift in imputation (0) | -44                | 0                  | -36                | 0                  |
| △ (FYB203-Eylea)        | 2.0 [0.51; 3.50]   | 2.0 [0.51; 3.50]   | 1.8[0.13; 3.53]    | 1.8[0.13; 3.53]    |
| Shift in imputation (0) | 0                  | +38                | 0                  | +30                |
| △ (FYB203-Eylea)        | 2.1 [0.59; 3.54]   | 2.1 [0.59; 3.54]   | 1.8 [0.17; 3.51]   | 1.8 [0.17; 3.51]   |
| Shift in imputation (0) | 0                  | 88-                | 0                  | -79                |
| △(FYB203-Eylea)         | -1.4[-3.53; 0.63]  | -1.4[-3.53; 0.63]  | -1.2 [3.52; 1.12]  | -1.2 [3.52; 1.12]  |

ANCOVA = analysis of covariance, BCVA = best corrected visual acuity, CI = confidence interval,

ETDRS = early treatment diabetic retinopathy study, FAS = full analysis set, N = total number of patients in the analysis set, △ (FYB203-Eylea) = LS mean difference between FYB203 and Eylea

The 2-sided 90.4% and 95.2% confidence intervals were based on normal approximation.

Multiple imputation using Baseline BCVA, region (Japan vs. Rest of world) and treatment as covariates was used for imputation of missing assessments.

(FYB203-Eylea) LS mean estimates were adjusted for region (Japan vs. Rest of world) and Baseline BCVA [letters].

If CIs for difference in LS means were completely contained in the interval ]-3.5; 3.5[ letters, FYB203 and Eylea were considered equivalent. This table presents the tipping points, i.e., the smallest imputation shifts where the CIs for difference in LS means were not contained in the interval of ]-3.5; 3.5[ letters.

Source: Table 14.2.2.9 (\"US analysis\"), Table 14.2.3.9 (\"EU analysis\")

## Supplemental analyses

Supplemental analyses (Table 14) were performed using MMRM models restricted to the PPS population, to modified FAS populations, or using different approaches for handling of intercurrent events. As such, these analyses represent different (supplemental) estimands that differ in some properties from the primary estimand.

All supplemental analyses showed a similar difference between FYB203 and Eylea for the change in BCVA from Baseline to Week 8.

<div style=\"page-break-after: always\"></div>

Table 14: Summary of supplemental analyses displaying least squares mean difference between FYB203 and Eylea in BCVA (ETDRS letters) change from baseline to week 8 (US and EU analyses)

| Method, set, data                                                                                                       | LS mean difference                                                                                                                                                            | SE                                                                                                                                                                            | 2-sided ID %F'06 Source                                                                                                                                                       | 2-sided 95.2% CI Source                                                                                                                                                       | Within equivalence margin ]-3.5; 3.5[                                                                                                                                         |
|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MMRM, FAS Data up Week 24, excluding patients with major protocol deviations influencing BCVA umtil Week 8              | 0.8                                                                                                                                                                           | 0.79                                                                                                                                                                          | [-0.5; 2.1] Table 14.2.4.1                                                                                                                                                    | [-0.8; 2.4] Table 14.2.5.1                                                                                                                                                    | yes                                                                                                                                                                           |
| MMRM, FAS Data up to Week 24, excluding patients who discontinued treatment before Week 8 or did not have a Week 8 BCVA | 1.0                                                                                                                                                                           | 0.77                                                                                                                                                                          | [-0.3; 2.3] Table 14.2.4.2                                                                                                                                                    | [-0.5; 2.5] Table 14.2.5.2                                                                                                                                                    | yes                                                                                                                                                                           |
| MMRM, PPS Data up to Week 24                                                                                            | 0.8                                                                                                                                                                           | 0.79                                                                                                                                                                          | [-0.5; 2.1] Table 14.2.4.3                                                                                                                                                    | [-0.8; 2.4] Table 14.2.5.3                                                                                                                                                    | yes                                                                                                                                                                           |
| ANCOVA, FAS Multiple imputation for all patients excluded from the PPS                                                  | 0.8                                                                                                                                                                           | 0.79                                                                                                                                                                          | [-0.5; 2.2] Table 14.2.4.4                                                                                                                                                    | [-0.7; 2.4] Table 14.2.5.4                                                                                                                                                    | yes                                                                                                                                                                           |
| MMRM, FAS Data up to Week 24 while on treatment                                                                         | This analysis was not performed. Less than 10 patients had BCVA values until Week 24 that were assessed after discontinuation of treatment. Table 14.2.4.5 and Table 14.2.5.5 | This analysis was not performed. Less than 10 patients had BCVA values until Week 24 that were assessed after discontinuation of treatment. Table 14.2.4.5 and Table 14.2.5.5 | This analysis was not performed. Less than 10 patients had BCVA values until Week 24 that were assessed after discontinuation of treatment. Table 14.2.4.5 and Table 14.2.5.5 | This analysis was not performed. Less than 10 patients had BCVA values until Week 24 that were assessed after discontinuation of treatment. Table 14.2.4.5 and Table 14.2.5.5 | This analysis was not performed. Less than 10 patients had BCVA values until Week 24 that were assessed after discontinuation of treatment. Table 14.2.4.5 and Table 14.2.5.5 |
| Method, set,                                                                                                            | LS mean difference                                                                                                                                                            | SE                                                                                                                                                                            | 2-sided 90.4% CI Source                                                                                                                                                       | 2-sided 95.2% CI Source                                                                                                                                                       | Within equivalence margin ]-3.5; 3.5[                                                                                                                                         |
| MMRM, FAS Data up to Week 24 excluding assessments after missed injections                                              | 0.9                                                                                                                                                                           | 0.77                                                                                                                                                                          | [-0.4; 2.2] Table 14.2.4.6                                                                                                                                                    | [-0.6; 2.4] Table 14.2.5.6                                                                                                                                                    | yes                                                                                                                                                                           |
| MMRM, FAS Data up to Week 24 excluding assessments after major protocol deviations                                      | 0.8                                                                                                                                                                           | 0.78                                                                                                                                                                          | [-0.5; 2.1] Table 14.2.4.7                                                                                                                                                    | [-0.8; 2.3] Table 14.2.5.7                                                                                                                                                    | yes                                                                                                                                                                           |
| MMRM, FAS Data up to Week 24 excluding assessments directly after specific protocol deviations with impact on BCVA      | Analysis not performed chue to low number of relevant protocol deviations. Table 14.2.4.8 and Table 14.2.5.8                                                                  | Analysis not performed chue to low number of relevant protocol deviations. Table 14.2.4.8 and Table 14.2.5.8                                                                  | Analysis not performed chue to low number of relevant protocol deviations. Table 14.2.4.8 and Table 14.2.5.8                                                                  | Analysis not performed chue to low number of relevant protocol deviations. Table 14.2.4.8 and Table 14.2.5.8                                                                  | Analysis not performed chue to low number of relevant protocol deviations. Table 14.2.4.8 and Table 14.2.5.8                                                                  |

ANCOVA = analysis of covariance, BCVA = best corrected visual acuity, CI = confidence interval (based on normal approximation), ETDRS = early treatment diabetic retinopathy study, FAS = full analysis set.

LS = least squares, MMRM = Mixed Model Repeated Measures, PPS = per protocol set, SE = standard error ofLS mean

1 Difference calculated as FYB203 -Eylea

Source: directly in the table

## Secondary endpoints

Change in Foveal Centre Point Retinal Thickness From Baseline to Week 4

This endpoint (Table 15) was tested in a confirmatory way as key secondary endpoint for the EUspecific analysis only, for the US analysis all secondary endpoints were weighted equally and analysed without formal hypothesis testing.

<div style=\"page-break-after: always\"></div>

Table 15: Comparison of change in foveal centre retinal thickness (μm) from baseline to week 4 including data up to week 24 (EU analysis, FAS, N=433)

|                                         |                         | MMRMLS estimation   | MMRMLS estimation   | MMRMLS estimation   | MMRMLS estimation   | MMRMLS estimation   |
|-----------------------------------------|-------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Week (Visit) Treatment group Difference | N                       | n                   | nmissa              | LS meanb            | SEb                 | 2-sided 95.2% CI    |
| Week 4 (V2)                             |                         |                     |                     |                     |                     |                     |
| FYB203                                  | 215                     | 206                 | 9                   | -171.4              | 10.32               | [-191.9; -150.9]    |
| Eylea                                   | 218                     | 210                 | 8                   | -166.9              | 10.39               | [-187.5; -146.3]    |
| Difference:FYB203-Eylea                 | Difference:FYB203-Eylea |                     |                     | -4.5                | 10.03               | [-24.4; 15.4]       |

CI = confidence interval, FAS = full analysis set, FCP = foveal center point, LS = least squares, N = total number of patients in the treatment group and analysis set, n/nmiss = number of non-missing/missing assessments, MMRM =Mlixed Model Repeated Measues, SE = standard error of the LS mean, V =Visit

The 2-sided 95.2% CI was based on normal approximation.

For the calculation of LS means based on the MMRM, all patients with missing and non-missing Week 4 assessments were considered ifthey have at least 1 post-Baseline FCP value umtil Week 24.

b Estimates are adjusted for Baseline FCP, region (Japan vs. Rest of world), treatment, visit, treatment-visitinteraction and Baseline-visit-interaction.

Source: Table 14.1.4.1,Table 14.2.6.1.1.1

To account for missing values in a different way, MI followed by an ANCOVA was performed on the FAS and the PPS and served as a sensitivity analysis.

In the PPS, the estimated LS mean difference of 7.5 μm (95.2% CI: [ -28.2 μm; 13.1 μm]) between the treatments was similar to the FAS.

In the FAS, the ANCOVA including MI showed a similar estimated LS mean difference between the 2 treatments of 7.1 μm (95.0% CI: [ -27.3 μm; 13.1 μm]).

Change in Foveal Central Subfield Retinal Thickness From Baseline to Week 4

Table 16: Comparison of change in fcs retinal thickness (μm) from baseline to week 4 including data up to week 24 (FAS, N=433)

|                            |                          | MMRMLS estimation   | MMRMLS estimation   | MMRMLS estimation   | MMRMLS estimation   | MMRMLS estimation   |
|----------------------------|--------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Week (Visit)               | N                        | n                   | mmissa              | LS meanb            | SEb                 | 2-sided             |
| Treatment group Difference |                          |                     |                     |                     |                     | 95.0% CI            |
| Week 4 (V2)                |                          |                     |                     |                     |                     |                     |
| FYB203                     | 215                      | 212                 | 3                   | -163.5              | 9.55                | [-182.3; -144.7]    |
| Eylea                      | 218                      | 215                 | 3                   | -157.4              | 9.63                | [-176.3; -138.4]    |
| Difference:FYB203 -Eylea   | Difference:FYB203 -Eylea |                     |                     | -6.2                | 9.22                | [-24.3; 12.0]       |

CI = confidence interval, FAS = fuill analysis set, FCS = foveal central subfields, LS = least squares,

MMRM = Mixed Model Repeated Measures, N = total number of patients in the treatment group and analysis set, n/nmiss = mumber of non-missing/missing assessments, SE = standard error of the LS mean, V = Visit The 2-sided 95.2% CI was based on normal approximation.

For the calculation of LS means based on the MMRM, all patients with missing and non-missing Week 4 assessments were considered if they have at least 1 post-Baseline FCS value umtil Week 24.

b Estimates are adjusted for Baseline FCS, region (Japan vs. Rest of world), treatment, visit, treatment-visitinteraction and Baseline-visit-interaction.

Source: Table 14.1.4.1, Table 14.2.6.4.1.1

In the PPS, the estimated LS mean difference of 6.2 μm (95.0% CI: [ -24.9 μm; 12.4 μm]) between the treatments was similar to the FAS.

In the FAS, the ANCOVA including MI showed a similar estimated LS mean difference between the 2 treatments of 5.9 μm (95.0% CI: [ -24.1 μm; 12.4 μm]).

<div style=\"page-break-after: always\"></div>

## Changes in Foveal Centre Point and Foveal Central Subfield Retinal Thickness From Baseline to Week 24, Week 40 and Week 56

## Foveal Centre Point Retinal Thickness

Figure 11-3 shows the absolute FCP retinal thickness by treatment group until Week 56 in the FAS. The 2 treatment groups showed similar FCP retinal thickness measurements at Baseline and at each postBaseline visit. In the FAS, the overall Baseline median (IQR) FCP retinal thickness was 440.0 (354.0 574.0) μm. At Week 24, the median (IQR) reduced to 274.0 (208.0 -358.0) μm. The reduction sustained throughout the study, resulting in an overall median (IQR) of 261.5 (200.5 346.0) μm at Week 40 and a median (IQR) of 248.0 (191.0 328.0) μm at Week 56.

<!-- image -->

Legendbelownextfigure.

Source:Figure14.2.6.3.4.1

Figure 4: Absolute FCP retinal thickness (μm) from baseline to week 56 (FAS, N=433)

<div style=\"page-break-after: always\"></div>

Table 17: Comparison of change in FCP retinal thickness (μm) from baseline to week 24, week 40 and week 56 (FAS, N=433)

|                                            |                         | MMRMLS estimation   | MMRMLS estimation   | MMRMLS estimation   | MMRMLS estimation   | MMRMLS estimation   |
|--------------------------------------------|-------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Week (Visit) Treatment group Difference    | N                       | n                   | nmissa              | LS meanb            | SEb                 | 2-sided 95.0% CI    |
| Week 24 (V5), including data up to Week 24 |                         |                     |                     |                     |                     |                     |
| FYB203                                     | 215                     | 206                 | 9                   | -172.1              | 11.87               | [-195.4; -148.7]    |
| Eylea                                      | 218                     | 210                 | 8                   | -163.8              | 11.91               | [-187.2; -140.4]    |
| Difference:FYB203-Eylea                    | Difference:FYB203-Eylea |                     |                     | -8.2                | 12.98               | [-33.7; 17.3]       |
| Week 40 (V7), including data up to Week 56 |                         |                     |                     |                     |                     |                     |
| FYB203                                     | 215                     | 206                 | 9                   | -193.6              | 11.35               | [-215.9; -171.3]    |
| Eylea                                      | 218                     | 213                 | 5                   | -185.7              | 11.32               | [-208.0; -163.5]    |
| Difference:FYB203-Eylea                    | Difference:FYB203-Eylea |                     |                     | -7.9                | 12.37               | [32.2; 16.4]        |
| Week 56 (V9), including data up to Week 56 |                         |                     |                     |                     |                     |                     |
| FYB203                                     | 215                     | 206                 | 9                   | -207.9              | 10.84               | [-229.2; -186.7]    |
| Eylea                                      | 218                     | 213                 | 5                   | -202.7              | 10.81               | [-224.0; -181.5]    |
| Difference:FYB203-Eylea                    | Difference:FYB203-Eylea |                     |                     | -5.2                | 11.41               | [-27.7; 17.2]       |

CI = confidence interval, FAS = full analysis set, FCP = foveal center point, LS = least squares,

MMRM = Mixed Model Repeated Measures, N = total number of patients in the treatment group and analysis set, n/nmiss = number of non-missing/missing assessments, SE = standard error of the LS mean, V = Visit

The 2-sided 95.0% CI was based on normal approximation.

a For the calculation of LS means based on the MMRM, all patients with missing and non-missing

Week 24/Week 40/Week 56 assessments were considered if they had at least 1 post-Baseline FCP value until Week 24/Week 56/Week 56.

b Estimates are adjusted for Baseline FCP, region (Japan vs. Rest of world), treatment, visit, treatment-visitinteraction and Baseline-visit-interaction.

Source: Table 14.1.4.1, Table 14.2.6.3.8.1 (Week 24), Table 14.2.6.3.9.1 (Week 40). Table 14.2.6.3.10.1 (Week 56)

In the PPS, the estimated LS mean differences between the 2 treatment groups of 12.5 μm (95.0% CI: [-39.1 μm; 14.0 μm]) at Week 24, -11.4 μm (95.0% CI: [ -36.2 μm; 13.4 μm]) at Week 40 and -9.1 μm (95.0% CI: [32.3 μm; 14.0 μm]) at Week 56 were similar to the FAS.

## Foveal Central Subfield Retinal Thickness

Figure 11-5 shows the absolute FCS retinal thickness by treatment group until Week 56 in the FAS. The 2 treatment groups showed similar FCS retinal thickness measurements at Baseline and at each postBaseline visit. In the FAS, the overall Baseline median (IQR) FCS retinal thickness was 472.0 (398.0 585.0) μm. At Week 24, the median (IQR) reduced to 323.0 (266.0 -409.0) μm. The reduction was sustained throughout the study, resulting in an overall median (IQR) of 316.0 (262.0 399.0) μm at Week 40 and a median (IQR) of 303.0 (250.0 373.0) μm at Week 56.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Sonrce. Fimre142644 1

Figure 5: Absolute FCS retinal thickness (μm) from baseline to week 56 (FAS, N=433)

Table 18: Comparison of change in FCS retinal thickness (μm) from baseline to week 24, week 40 and week 56 (FAS, N=433)

|                                            |                            | MMRMLS estimation   | MMRMLS estimation   | MMRMLS estimation   | MMRMLS estimation   | MMRMLS estimation   |
|--------------------------------------------|----------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Week (Visit) Treatment group Difference    | N                          | n                   | mmissa              | LS meanb            | SEb                 | 2-sided 95.0% CI    |
| Week 24 (V5), including data up to Week 24 |                            |                     |                     |                     |                     |                     |
| FYB203                                     | 215                        | 212                 | 3                   | -159.3              | 10.73               | [-180.3; -138.2]    |
| Eylea                                      | 218                        | 215                 | 3                   | -153.0              | 10.77               | [-174.1; -131.8]    |
| Difference: FYB203 - Eylea                 | Difference: FYB203 - Eylea |                     |                     | -6.3                | 11.49               | [28.9; 16.3]        |
| Week 40 (V7), including data up to Week 56 |                            |                     |                     |                     |                     |                     |
| FYB203                                     | 215                        | 212                 | 3                   | -180.7              | 10.23               | [-200.8; -160.6]    |
| Eylea                                      | 218                        | 215                 | 3                   | -176.9              | 10.24               | [-197.0; -156.7]    |
| Difference: FYB203 - Eylea                 | Difference: FYB203 - Eylea |                     |                     | 8'5-                | 10.99               | [-25.4; 17.8]       |
| Week 24 (V5), including data up to Week 56 |                            |                     |                     |                     |                     |                     |
| FYB203                                     | 215                        | 212                 | m                   | -192.9              | 9.80                | [-212.2; -173.7]    |
| Eylea                                      | 218                        | 215                 | 3                   | -192.3              | 9.80                | [-211.6; -173.1]    |
| Difference: FYB203 -Eylea                  | Difference: FYB203 -Eylea  |                     |                     | -0.6                | 10.16               | [-20.6; 19.4]       |

CI = confidence interval, FAS = full analysis set, FCS = foveal central subfield, LS = least squares, MMRM = Mixed Model Repeated Measures, N = total mumber of patients in the treatment group and analysis set, n/nmiss = number of non-missing/missing assessments, SE = standard error of the LS mean, V = Visit

The 2-sided 95.0% CI was based on normal approximation.

a For the calculation of LS means based on the MMRM, all patients with missing and non-missing Week 24/Week40/Week 56 assessments were considered if they had at least 1 post-Baseline FCS value umtil

Week24/Week56/Week56

b Estimates are adjusted for Baseline FCS, region (Japan vs. Rest of world), treatment, visit, treatment-visitinteraction and Baseline-visit-interaction.

Source: Table 14.1.4.1, Table 14.2.6.4.8.1 (Week 24), Table 14.2.6.4.9.1 (Week 40). Table 14.2.6.4.10.1 (Week 50)

<div style=\"page-break-after: always\"></div>

In the PPS, the estimated LS mean differences between the 2 treatment groups of 8.3 μm (95.0% CI: [-31.7 μm; 15.2 μm]) at Week 24, -5.4 μm (95.0% CI: [ -27.4 μm; 16.6 μm]) at Week 40 and -2.8 μm (95.0% CI: [23.4 μm; 17.7 μm]) at Week 56 were similar to the FAS.

Change in BCVA From Baseline to Week 24, Week 40 and Week 56

Table 19: Comparison of change in BCVA (ETDRS Letters) from baseline to week 24, week 40 and week 56 (FAS, N=433)

|                                              |                          | MMRMLS estimation   | MMRMLS estimation   | MMRMLS estimation   | MMRMLS estimation   | MMRMLS estimation   |
|----------------------------------------------|--------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| Week (Visit) Treatment group Difference      | N                        | n                   | nmissa              | LS meanb            | SEb                 | 2-sided 95.0% CI    |
| Week 24 (V5), , including data up to Week 24 |                          |                     |                     |                     |                     |                     |
| FYB203                                       | 215                      | 215                 | 0                   | 6.5                 | 0.82                | [4.9; 8.1]          |
| Eylea                                        | 218                      | 218                 | 0                   | 6.2                 | 0.82                | [4.6; 7.8]          |
| Difference:FYB203 -Eylea                     | Difference:FYB203 -Eylea |                     |                     | 0.3                 | 0.93                | [-1.5; 2.2]         |
| Week 40 (V7), including data up to Week 56   |                          |                     |                     |                     |                     |                     |
| FYB203                                       | 215                      | 215                 | 0                   | 7.7                 | 0.87                | [5.9; 9.4]          |
| Eylea                                        | 218                      | 218                 | 0                   | 6.3                 | 0.87                | [4.6; 8.0]          |
| Difference:FYB203 -Eylea                     | Difference:FYB203 -Eylea |                     |                     | 1.4                 | 1.02                | [0.6; 3.4]          |
| Week 56 (V9), including data up to Week 56   |                          |                     |                     |                     |                     |                     |
| FYB203                                       | 215                      | 215                 | 0                   | 7.5                 | 0.92                | [5.7; 9.3]          |
| Eylea                                        | 218                      | 218                 | 0                   | 6.2                 | 0.91                | [4.4; 8.0]          |
| Difference: FYB203-Eylea                     | Difference: FYB203-Eylea |                     |                     | 1.3                 | 1.09                | [0.9; 3.5]          |

BCVA = best corrected visual acuity, CI = confidence interval, ETDRS = early treatment diabetic retinopathy study, FAS = full analysis set, LS = least squares, MMRM = Mixed Model Repeated Measures, N = total number of patients in the treatment group and analysis set, n/nmiss = number of non-missing/missing assessments, SE = standard error, V =Visit

The 2-sided 95.0% CI was based on normal approximation

For the calculation of LS means based on the MMRM, all patients with missing and non-missing

Week 24/Week 40/Week 56 assessments were considered if they have at least 1 post-Baseline BCVA value until Week 24/Week 56/Week 56.

imteraction and Baseline-visit-interaction.

Source: Table 14.1.4.1, Table 14.2.6.2.12.1 (Week 24), Table 14.2.6.2.13.1 (Week 40),Table 14.2.6.2.14.1 (Week 56)

In the PPS, the estimated LS mean differences between the 2 treatment groups of 0.1 ETDRS letter (95.0% CI: [-1.8; 2.0]) at Week 24, 1.0 ETDRS letter (95.0% CI: [-1.0; 3.0]) at Week 40 and 0.9 ETDRS letter (95.0% CI: [-1.3; 3.1]) at Week 56 were similar to the FAS.

## Gain or Loss of Best Corrected Visual Acuity by ≥ 5, 10 an d 15 ETDRS Letters From Baseline to Week 24, Week 40 and Week 56

Table 20 summarises the proportion of patients with specific categories of gains or losses in BCVA from Baseline to Week 24, Week 40 and Week 56.

At Week 24, the proportion of patients who gained or lost 5 to 9, 10 to 14, or more than 15 ETDRS letters  compared  to  Baseline  were  comparable  between  the  FYB203  and  Eylea  groups.  Overall, approximately 20% of patients gained 15 or more ETDRS letters, 10 to 14 ETDRS letters or 5 to 9 ETDRS letters, each. No relevant change in BCVA, i.e. gain or loss up to 4 ETDRS letters, was experienced by 27.2% of patients. A total of 10.7% of patients lost at least 5 letters.

At Week 40, 23.3%, 21.2% and 19.7% of the patients overall gained 15 or more, 10 to 14, or 5 to 9 ETDRS letters, respectively. No relevant change in BCVA, i.e. gain or loss up to 4 ETDRS letters, was

<div style=\"page-break-after: always\"></div>

experienced by 20.4% of patients treated with FYB203 and 26.0% of patients treated with Eylea. A total of 12.6% of patients lost at least 5 letters.

At Week 56, 27.7% of patients in the FYB203 group and 24.4% of patients in the Eylea group gained BCVA by 15 or more ETDRS letters. Furthermore, 22.9% of patients in the FYB203 group and 17.9% of patients in the Eylea group gained BCVA by 10 to 14 ETDRS letters. 18.1% of patients in the FYB203 group and 19.4% of patients in the Eylea group gained 5 to 9 ETDRS letters. No relevant change in BCVA, i.e. gain or loss up to 4 ETDRS letters, was experienced by 22.4% of patients. A total of 12.5% of patients lost at least 5 letters. Similar percentages were observed between the 2 treatment groups.

Table 20: Proportion of patients gaining or losing &lt; 5, 5 to 9, 10 to 14, or ≥15 ETDRS letters from baseline to week 24, week 40 and week 56 (FAS, N=433)

|                           |                           | FYB203 (N=215)   | FYB203 (N=215)   | Eylea (N=218)   | Eylea (N=218)   | Total (N=433)   | Total (N=433)   |
|---------------------------|---------------------------|------------------|------------------|-----------------|-----------------|-----------------|-----------------|
| BCVA change from Baseline | BCVA change from Baseline | 11               | (%)              | N               | (%)             |                 | (%)             |
| Week 24                   |                           |                  |                  |                 |                 |                 |                 |
| ≥ 15 letters              | (gain 15 or more)         | 45               | (22.4)           | 38              | (18.7)          | 83              | (20.5)          |
| ≥10 and< 15 letters       | (gain 10-14)              | 41               | (20.4)           | 39              | (19.2)          | 80              | (19.8)          |
| ≥ 5 and < 10 letters      | (gain 5-9)                | 41               | (20.4)           | 47              | (23.2)          | 88              | (21.8)          |
| >-5 and<51etters          | (gain or loss up to 4)    | 52               | (25.9)           | 58              | (28.6)          | 110             | (27.2)          |
| >-10 and ≤-5 letters      | (loss 59)                 | 12               | (6.0)            | 13              | (6.4)           | 25              | (6.2)           |
| >-15 and≤-10 letters      | (loss 10-14)              | 6                | (3.0)            | 2               | (1.0)           | 8               | (2.0)           |
| ≤-15 letters              | (loss 15 or more)         | 4                | (2.0)            | 6               | (3.0)           | 10              | (2.5)           |
| Missing                   |                           | 14               |                  | 15              |                 | 29              |                 |
| Week 40                   |                           |                  |                  |                 |                 |                 |                 |
| ≥15 letters               | (gain 15 or more)         | 48               | (25.1)           | 43              | (21.5)          | 91              | (23.3)          |
| ≥10 and<15 letters        | (gain 10-14)              | 44               | (23.0)           | 39              | (19.5)          | 83              | (21.2)          |
| ≥ 5 and< 10 letters       | (gain 5-9)                | 39               | (20.4)           | 38              | (19.0)          | 77              | (19.7)          |
| >-5 and<5letters          | (gain or loss up to 4)    | 39               | (20.4)           | 52              | (26.0)          | 91              | (23.3)          |
| >-10 and ≤-5 letters      | (loss 59)                 | 14               | (7.3)            | 21              | (10.5)          | 35              | (9.0)           |
| > -15 and≤-10 letters     | (loss 10-14)              | 3                | (1.6)            | 2               | (1.0)           | 5               | (1.3)           |
| ≤-15 letters              | (loss 15 or more)         | 4                | (2.1)            | 5               | (2.5)           | 9               | (2.3)           |
| Missing                   |                           | 24               |                  | 18              |                 | 42              |                 |
| Week 56                   |                           |                  |                  |                 |                 |                 |                 |
| ≥ 15 letters              | (gain 15 or more)         | 52               | (27.7)           | 49              | (24.4)          | 101             | (26.0)          |
| ≥ 10 and < 15 letters     | (gain 10-14)              | 43               | (22.9)           | 36              | (17.9)          | 79              | (20.3)          |
| ≥ 5 and < 10 letters      | (gain 5-9)                | 34               | (18.1)           | 39              | (19.4)          | 73              | (18.8)          |
| >-5 and<51etters          | (gain or 1oss up to 4)    | 39               | (20.7)           | 48              | (23.9)          | 87              | (22.4)          |
| > -10 and ≤-5 letters     | (1oss 59)                 | 12               | (6.4)            | 13              | (6.5)           | 25              | (6.4)           |
| > -15 and ≤-10 letters    | (loss 10-14)              | 6                | (3.2)            | 7               | (3.5)           | 13              | (3.3)           |
| <-15 letters              | (loss 15 or more)         | 2                | (1.1)            | 9               | (4.5)           | 11              | (2.8)           |
| Missing                   |                           | 27               |                  | 17              |                 | 44              |                 |

BCVA = best corrected visual acuity, ETDRS = early treatment diabetic retinopathy study, FAS = fuill analysis set, N = total number of patients in the treatment group and analysis set, n = number of non-missing assessments

bar plots Figuue 14.2.6.2.7.1 for Week 24 FAS, Figuue 14.2.6.2.7.2 for Week 24 PPS, Figuwe 14.2.6.2.9.1 for Week 40 FAS, Figure 14.2.6.2.9.2 for Week 40 PPS, Figure 14.2.6.2.11.1 for Week 56 FAS and Figure 14.2.6.2.11.2 for Week 56 PPS

## Fluid-Free Macula at Each Visit

Table 21summarises the number and proportion of patients who had absence of disease activity (fluidfree macula) by analysis visit. At Baseline, no patient had a fluid-free macula. The highest proportion of patients with fluid-free macula was observed at Week 8, with 56.7% in the FYB203 group and 54.3% in the Eylea group. Afterwards, with the extension of the dosing intervals from 4 to 8 weeks, it reduced to 34.5% in the FYB203 group and 35.8% in the Eylea group at Week 16. Until Week 56, it increased again to 42.2% in the FYB203 group and 50.5% in the Eylea group.

<div style=\"page-break-after: always\"></div>

Table 21: Summary of patients with fluid-free macula by analysis visit (FAS, N=433)

|          | Fluid- free   | FYB203 (N=215)   | FYB203 (N=215)   | Eylea (N=218)   | Eylea (N=218)   | Total (N=433)   | Total (N=433)   | Difference FYB203 -Eylea   | Difference FYB203 -Eylea   |
|----------|---------------|------------------|------------------|-----------------|-----------------|-----------------|-----------------|----------------------------|----------------------------|
| Week     | macul a       | N                | (%)              |                 | (%)             | n               | (%)             | % diff.                    | 95.0% CI                   |
| Baseline | Yes           | 0/214            | (0.0)            | 0/ 217          | (0.0)           | 0/ 431          | (0.0)           | n1.c.                      | n.c.                       |
| Week 4   | Yes           | 85/215           | (39.5)           | 87/ 214         | (40.7)          | 172/ 429        | (40.1)          | -1.12%                     | [-10.36%;8.14%]            |
| Week 8   | Yes           | 118/208          | (56.7)           | 114/ 210        | (54.3)          | 232/ 418        | (55.5)          | 2.45%                      | [-7.07%;11.92%]            |
| Week 16  | Yes           | 70/203           | (34.5)           | 73/ 204         | (35.8)          | 143/ 407        | (35.1)          | -1.30%                     | [-10.55%;7.97%]            |
| Week 24  | Yes           | 71/198           | (35.9)           | 65/ 200         | (32.5)          | 136/ 398        | (34.2)          | 3.36%                      | [-5.96%;12.64%]            |
| Week32   | Yes           | 69/199           | (34.7)           | 81/ 202         | (40.1)          | 150/ 401        | (37.4)          | -5.43%                     | [-14.81%;4.06%]            |
| Week 40  | Yes           | 73/188           | (38.8)           | 86/ 197         | (43.7)          | 159/ 385        | (41.3)          | -4.83%                     | [-14.57%;5.02%]            |
| Week 48  | Yes           | 76/191           | (39.8)           | 86/ 193         | (44.6)          | 162/ 384        | (42.2)          | -4.77%                     | [-14.56%;5.11%]            |
| Week 56  | Yes           | 79/187           | (42.2)           | 100/ 198        | (50.5)          | 179/ 385        | (46.5)          | -8.26%                     | [-18.07%;1.72%]            |

CI = confidence interval, FAS = full analysis set, N = total number of patients in the treatment group and analysis set, n = number of non-missing assessments, n.c. = not calculable

Source: Table 14.2.6.6.1.1. See also bar plots Figure 14.2.6.6.3.1 for FAS and Figure 14.2.6.6.3.2 for PPS

## Changes in Total Lesion Area to Week 24, Week 40 and Week 56

The  2  treatment  groups  showed  similar  total  lesion  area  measurements  at  Baseline  (assessed  at Screening) and at each following visit. In the FAS, the overall Baseline median (IQR) lesion area was 8.6 (4.8 - 13.2) mm 2 . At Week 24, it decreased to 6.8 (3.9 - 11.0) mm 2 . The reduction was sustained throughout the study, resulting in an overall lesion area of 6.5 (3.7 - 11.0) mm 2  at Week 40 and 6.1 (3.3 - 11.0) mm 2  at Week 56.

Figure 6 shows the changes from Baseline total lesion area (assessed at Screening) by treatment group until Week 56. Overall in the FAS, a similar reduction from Baseline was observed throughout the study, with a median (IQR) change of -1.1 (-3.8 - 0.7) mm 2  at Week 24, -1.1 (-3.9 - 0.9) mm 2  at Week 40 and -1.5 (-4.3 - 1.0) mm 2  at Week 56.

<div style=\"page-break-after: always\"></div>

<!-- image -->

FAS =full analysis set, IQR = inter quartile range: 1 quartile-3rd quartile, V = visit

Boxplot markers: x = arithmetic mean, line = median, lower box boundary = 1s quartile, upper box boundary = 3rd quartile, 0 = outlier (below 1.5*IQR), upper whisker=maximumvaluebelowupperfence,lowerwhisker=minimumvalue abovelowerfence,upperfence=1.5times theIQR above the3*quartile, lowerfence=1.5timestheIQRbelowthe1squartile

Source:Figure14.2.6.5.6.1

Figure 6: Changes from screening in total lesion (mm 2 ) at week 24, week 40 and week 56 (FAS, N=433)

Table 22: Comparison of change in total lesion area (mm 2 ) from screening to week 24, week 40 and week 56 (FAS, N=433)

|                                            |                           | ANCOVA/MMRMLS estimation   | ANCOVA/MMRMLS estimation   | ANCOVA/MMRMLS estimation   | ANCOVA/MMRMLS estimation   | ANCOVA/MMRMLS estimation   |
|--------------------------------------------|---------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| Week (Visit) Treatment group Difference    | N                         | n                          | nmissa                     | LS meanb                   | SEb                        | 2-sided 95.0% CI           |
| Week 24 (V5)                               |                           |                            |                            |                            |                            |                            |
| FYB203                                     | 215                       | 191                        | 24                         | -1.1                       | 0.44                       | [-2.0; -0.2]               |
| Eylea                                      | 218                       | 195                        | 23                         | -1.4                       | 0.44                       | [-2.3; -0.6]               |
| Difference:FYB203-Eylea                    | Difference:FYB203-Eylea   |                            |                            | 0.3                        | 0.42                       | [-0.5; 1.2]                |
| Week 40 (V7), including data up to Week 56 |                           |                            |                            |                            |                            |                            |
| FYB203                                     | 215                       | 204                        | 11                         | -0.9                       | 0.45                       | [-1.8; 0.0]                |
| Eylea                                      | 218                       | 206                        | 12                         | -1.2                       | 0.45                       | [-2.0; -0.3]               |
| Difference: FYB203 -Eylea                  | Difference: FYB203 -Eylea |                            |                            | 0.2                        | 0.47                       | [-0.7; 1.1]                |
| Week 56 (V9), including data up to Week 56 |                           |                            |                            |                            |                            |                            |
| FYB203                                     | 215                       | 204                        | 11                         | -1.4                       | 0.47                       | [-2.3; -0.4]               |
| Eylea                                      | 218                       | 206                        | 12                         | -1.5                       | 0.46                       | [-2.4; -0.6]               |
| Difference:FYB203-Eylea                    | Difference:FYB203-Eylea   |                            |                            | 0.1                        | 0.49                       | [-0.8; 1.1]                |

ANCOVA = analysis of covariance, CI = confidence interval, FAS = fuill analysis set, LS = least squares, MMRM = Mixed Model Repeated Measures, N = total number of patients in the treatment group and analysis set, n/nmiss = number of non-missing/missing assessments, SE = standard error of the LS mean, V = Visit The 2-sided 95.0% CI was based on normal approximation.

Note: There were no values for the change in total lesion area before Week 24, therefore the MMRM results are identical to an ANCOVA.

For the calculation of LS means based on the MMRM, all patients with missing and non-missing Week 40/Week 56 assessments were considered if they have at least 1 post-Baseline total lesion area value until Week 56/Week 56

b Estimates are adjusted for Baseline total lesion area, region (Japan vs. Rest of world), treatment, visit, treatment-visit-interaction and Baseline-visit-interaction.

(Week 56)

<div style=\"page-break-after: always\"></div>

In the PPS, the estimated LS mean differences between the 2 treatments of +0.2 mm² ([95.0% CI: 0.6; 1.1]) at Week 24, +0.1 mm² ([95.0% CI: -0.9; 1.0]) at Week 40 and +0.1 mm² ([95.0% CI: -0.9; 1.1]) at Week 56 were similar to the FAS.

The ANCOVA including MI using the FAS showed a similar LS mean difference between the 2 treatments at Week 24: +0.4 (95.0% CI: -0.4; 1.2) mm².

## Change in Vision-Related Functioning and Well-Being (NEI VFQ-25) From Baseline to Week 24, Week 40 and Week 56

The absolute values and changes from Baseline in the NEI VFQ-25 subscales are presented for the FAS and PPS in section below and summarised in Table 26. As for the composite score, the subscales scores also showed a stable general health and functioning in the context of visual disability. There were no relevant differences between the 2 treatment groups. Single patients showed changes in both directions in the 2 treatment groups in composite as well as in subscale scores.

Table 23: Mean and median NEI VFQ-25 vision-targeted composite and subscale scores at baseline and change from baseline at week 24, week 40 and week 56 (FAS, N=433)

| NEIVFQ-25 vision-targeted composite and subscale scores   | NEIVFQ-25 vision-targeted composite and subscale scores   | FYB203 (N=215) Mean (SD); Median   | Eylea (N=218) Mean (SD); Median   | Total (N=433) Mean (SD); Median   |
|-----------------------------------------------------------|-----------------------------------------------------------|------------------------------------|-----------------------------------|-----------------------------------|
| Composite score                                           | Baseline                                                  | 74.8 (16.91); 79.0                 | 77.4 (15.84); 83.0                | 76.1 (16.41); 80.0                |
|                                                           | △V5/W24                                                   | 3.8 (11.06); 3.0                   | 1.8 (10.97); 1.0                  | 2.8 (11.05); 2.0                  |
|                                                           | △V7/W40                                                   | 4.0 (11.25); 3.0                   | 2.4 (13.00); 2.0                  | 3.1 (12.19); 2.0                  |
|                                                           | △V9/W56                                                   | 3.8 (12.22); 4.0                   | 1.7 (12.46); 2.0                  | 2.8 (12.37); 3.0                  |
| Subscale scores                                           |                                                           |                                    |                                   |                                   |
| General health                                            | Baseline                                                  | 42.7 (19.53); 50.0                 | 42.8 (18.65); 50.0                | 42.7 (19.07); 50.0                |
| General health                                            | △V5/W24                                                   | 0.3 (18.63); 0.0                   | -1.2 (16.50); 0.0                 | -0.5 (17.58); 0.0                 |
| General health                                            | AV7/W40                                                   | 1.2 (19.69); 0.0                   | -1.0 (18.56); 0.0                 | 0.1 (19.12); 0.0                  |
| General health                                            | △V9/W56                                                   | 2.5 (21.14); 0.0                   | -1.5 (19.47); 0.0                 | 0.4 (20.37); 0.0                  |
| General vision                                            | Baseline                                                  | 58.0 (15.76); 60.0                 | 59.6 (15.59); 60.0                | 58.8 (15.68); 60.0                |
| General vision                                            | △V5/W24                                                   | 4.3 (16.92); 0.0                   | 4.6 (17.02); 0.0                  | 4.4 (16.95); 0.0                  |
| General vision                                            | △V7/W40                                                   | 5.1 (16.62); 0.0                   | 5.3 (17.19); 0.0                  | 5.2 (16.89); 0.0                  |
| General vision                                            | △V9/W56                                                   | 5.6 (16.98); 0.0                   | 4.3 (16.36); 0.0                  | 4.9 (16.65); 0.0                  |
| Ocular pain                                               | Baseline                                                  | 80.2 (21.61); 88.0                 | 82.2 (20.41); 88.0                | 81.2 (21.02); 88.0                |
| Ocular pain                                               | AV5/W24                                                   | 2.7 (18.02); 0.0                   | 1.0 (19.84); 0.0                  | 1.8 (18.96); 0.0                  |
| Ocular pain                                               | AV7/W40                                                   | 5.1 (19.58); 0.0                   | 0.3 (21.19); 0.0                  | 2.6 (20.54); 0.0                  |
| Ocular pain                                               | △V9/W56                                                   | 3.9 (20.92); 0.0                   | 1.9 (20.66); 0.0                  | 2.8 (20.78); 0.0                  |
| Near activities                                           | Baseline                                                  | 66.6 (20.92); 67.0                 | 70.2 (21.10); 75.0                | 68.4 (21.06); 67.0                |
| Near activities                                           | △V5/W24                                                   | 5.4 (19.79); 0.0                   | 3.7 (18.26); 0.0                  | 4.5 (19.03); 0.0                  |
| Near activities                                           | AV7/W40                                                   | 6.5 (17.65); 0.0                   | 3.9 (19.72); 4.0                  | 5.2 (18.77); 0.0                  |
| Near activities                                           | V9/W56                                                    | 6.1 (19.81); 8.0                   | 3.4 (19.88); 0.0                  | 4.7 (19.87); 8.0                  |
| Distance activities                                       | Baseline                                                  | 76.4 (21.50); 83.0                 | 79.1 (20.03); 83.0                | 77.7 (20.79); 83.0                |
| Distance activities                                       | △V5/W24                                                   | 2.5 (18.46); 0.0                   | 1.0 (15.93); 0.0                  | 1.8 (17.23); 0.0                  |
| Distance activities                                       | △V7/W40                                                   | 3.7 (15.64); 0.0                   | 0.8 (17.24); 0.0                  | 2.2 (16.52); 0.0                  |
| Distance activities                                       | AV9/W56                                                   | 2.9 (16.50); 0.0                   | 0.3 (16.13); 0.0                  | 1.6 (16.34); 0.0                  |
| Social functioning                                        | Baseline                                                  | 88.4 (18.15); 100.0                | 89.0 (17.27); 100.0               | 88.7(17.69); 100.0                |
| Social functioning                                        | V5/W24                                                    | 2.3 (16.01); 0.0                   | 1.2 (13.93); 0.0                  | 1.7 (14.99); 0.0                  |
| Social functioning                                        | AV7/W40                                                   | 0.6 (15.49); 0.0                   | 0.6 (17.40); 0.0                  | 0.6 (16.48); 0.0                  |
| Social functioning                                        | △V9/W56                                                   | 0.9 (15.20); 0.0                   | 0.4 (14.68); 0.0                  | 0.7 (14.92); 0.0                  |

<div style=\"page-break-after: always\"></div>

| Mental health     | Baseline   | 64.0 (24.13); 69.0   | 68.5 (22.77); 75.0   | 66.2 (23.54); 75.0   |
|-------------------|------------|----------------------|----------------------|----------------------|
|                   | △V5/W24    | 7.7 (20.46); 6.0     | 3.2 (19.71);6.0      | 5.4 (20.19);6.0      |
|                   | AV7/W40    | 6.7 (20.83); 6.0     | 6.4 (19.46); 6.0     | 6.5 (20.11); 6.0     |
|                   | AV9/W56    | 7.1 (20.92); 6.0     | 4.9 (20.51); 6.0     | 6.0 (20.71); 6.0     |
| Role difficulties | Baseline   | 64.1 (29.15); 63.0   | 70.4 (27.54); 75.0   | 67.3(28.49); 75.0    |
|                   | AV5/W24    | 5.4 (27.26); 0.0     | 1.1 (22.92); 0.0     | 3.2 (25.21); 0.0     |
|                   | AV7/W40    | 5.2 (26.31); 0.0     | 1.5 (24.64); 0.0     | 3.3 (25.48); 0.0     |
|                   | △V9/W56    | 5.6 (27.08); 0.0     | 0.7 (25.64); 0.0     | 3.0 (26.42); 0.0     |
| Dependency        | Baseline   | 81.8 (24.80); 92.0   | 85.6 (22.95); 100.0  | 83.8 (23.92); 100.0  |
|                   | △V5/W24    | 3.3 (20.68); 0.0     | 0.7 (16.72); 0.0     | 2.0 (18.80); 0.0     |
|                   | △V7/W40    | 2.8 (17.40); 0.0     | 2.8 (19.68); 0.0     | 2.8 (18.60); 0.0     |
|                   | AV9/W56    | 2.4 (19.05); 0.0     | 1.1 (19.58); 0.0     | 1.7 (19.31); 0.0     |
| Driving           | Baseline   | 68.6 (31.96); 75.0   | 72.2 (30.85); 83.0   | 70.4 (31.36); 83.0   |
|                   | △V5/W24    | 2.2 (15.94); 0.0     | 1.0 (18.55); 0.0     | 1.6 (17.29); 0.0     |
|                   | AV7/W40    | 1.8 (22.26); 0.0     | 1.4 (21.84); 0.0     | 1.6 (21.98); 0.0     |
|                   | △V9/W56    | 4.0 (25.05); 0.0     | -0.0 (21.87); 0.0    | 2.0 (23.49); 0.0     |
| Color vision      | Baseline   | 91.5 (17.85); 100.0  | 92.3 (14.47); 100.0  | 91.9 (16.22); 100.0  |
|                   | △V5/W24    | 0.8 (15.87); 0.0     | 0.1 (15.18); 0.0     | 0.4 (15.51); 0.0     |
|                   | AV7/W40    | 0.0 (14.97); 0.0     | 0.5 (14.97); 0.0     | 0.3 (14.95); 0.0     |
|                   | △V9/W56    | 1.1 (17.36); 0.0     | -0.4 (14.93); 0.0    | 0.3 (16.14); 0.0     |
| Peripheral vision | Baseline   | 80.8 (21.91); 75.0   | 82.0 (20.50); 75.0   | 81.4 (21.20); 75.0   |
|                   | △V5/W24    | 3.8 (19.74); 0.0     | 0.9 (19.70); 0.0     | 2.3 (19.75); 0.0     |
|                   | AV7/W40    | 4.8 (21.04); 0.0     | 0.0 (21.56); 0.0     | 2.3 (21.41); 0.0     |
|                   | △V9/W56    | 3.4 (20.01);0.0      | -0.6 (19.48); 0.0    | 1.3 (19.82); 0.0     |

△=difference,FAS =full analysis set,N=total number ofpatients in the treatment group and analysis set, NEI VFQ-25 =National Eye Institute Visual Fumction Questionnaire 25, SD = standard deviation, V = visit, W = week

Source:Table 14.2.6.7.1.1,Table section14.2.6.7.4

Figure 7 shows the absolute values of the composite score by treatment group at Baseline, Week 24, Week 40 and Week 56. The NEI VFQ-25 composite scores were similar at each visit for the 2 treatment groups. In the FAS, the overall Baseline median (IQR) composite score was 80.0 (67.0 - 89.0) score points, 84.0 (70.0 - 92.0) score points at Week 24, 83.0 (71.0 - 91.0) score points at Week 40 and 83.0 (70.0 - 92.0) score points at Week 56.

Figure 7: Absolute values of the composite NEI VFQ-25 score at baseline, week 24, week 40 and week 56 (FAS, N=433)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Pre-defined subgroup analyses

Table 24: Subgroup analyses of the primary efficacy endpoints (US and EU Analyses, FAS, N=433)

| Comparison of tr'eatments atWeek8 MMRlIestimated LSmean△(FYB203-Eylea)   | Comparison of tr'eatments atWeek8 MMRlIestimated LSmean△(FYB203-Eylea)   | Comparison of tr'eatments atWeek8 MMRlIestimated LSmean△(FYB203-Eylea)   | Comparison of tr'eatments atWeek8 MMRlIestimated LSmean△(FYB203-Eylea)          | Comparison of tr'eatments atWeek8 MMRlIestimated LSmean△(FYB203-Eylea)   | Comparison of tr'eatments atWeek8 MMRlIestimated LSmean△(FYB203-Eylea)   | Comparison of tr'eatments atWeek8 MMRlIestimated LSmean△(FYB203-Eylea)          |
|--------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|---------------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Subgroup by Category (N)                                                 | Subgroup by Category (N)                                                 | △                                                                        | 2-sided CIs, Source                                                             |                                                                          | △                                                                        | 2-sided CIs, Source                                                             |
| Gender                                                                   | Female (N=248)                                                           | 0.2                                                                      | 90.4% CI: [-1.5; 1.9] Table 14.2.7.1.1 95.2% CI: [-1.8; 2.2] Table 14.2.7.2.1   | Male (N=185)                                                             | 1.7                                                                      | 90.4% CI: [-0.2; 3.7] Table 14.2.7.1.2 95.2% CI: [-0.5; 4.0] Table 14.2.7.2.2   |
| Ancillary chart use                                                      | Yes (N=20)                                                               | -1.7                                                                     | 90.4% CI: [-5.5; 2.1] Table 14.2.8.1.1 95.2% CI: [-6.3; 2.9] Table 14.2.8.2.1   | No (N=411)                                                               | 1.2                                                                      | 90.4% CI: [-0.1; 2.5] Table 14.2.8.1.2 95.2% CI: [-0.4; 2.8] Table 14.2.8.2.2   |
| ADA status                                                               | Positive (N=6)                                                           | n.c.                                                                     | Table 14.2.9.1.1 Table 14.2.9.2.1                                               | Negative (N=404)                                                         | 0.9                                                                      | 90.4% CI [-0.4; 2.2] Table 14.2.9.1.2 95.2% CI: [-0.7; 2.5] Table 14.2.9.2.2    |
| Total lesion area                                                        | <9 mm² (N=228)                                                           | 0.6                                                                      | 90.4% CI: [-1.2; 2.3] Table 14.2.10.1.1 95.2% CI: [-1.5; 2.6] Table 14.2.10.2.1 | ≥9mm² (N=205)                                                            | 1.1                                                                      | 90.4% CI: [-0.7; 3.0] Table 14.2.10.1.2 95.2%CI: [-1.0; 3.3] Table 14.2.10.2.2  |
| Lesion type                                                              | Type 1 MNV (N=143)                                                       | 1.0                                                                      | 90.4% CI: [-1.0; 3.0] Table 14.2.11.1.1 95.2% CI: [-1.4; 3.4] Table 14.2.11.2.1 | Type 2 MNV (N=100)                                                       | 2.3                                                                      | 90.4% CI: [-0.8; 5.4] Table 14.2.11.1.2 95.2% CI: [-1.4; 6.0] Table 14.2.11.2.2 |
| Lesion type                                                              | Mixed Type 1 and Type 2 MNV (N=150)                                      | 1.1                                                                      | 90.4% CI: [-1.0; 3.2] Table 14.2.11.1.3 95.2% CI: [-1.4; 3.6] Table 14.2.11.2.3 | Type 3 MNV (N=38)                                                        | -1.5                                                                     | 90.4% CI: [-5.7; 2.8] Table 14.2.11.1.4 95.2% CI: [-6.6; 3.7] Table 14.2.11.2.4 |
| Injection syringe use                                                    | Original syringe by Sponsor (N=418)                                      | 0.9                                                                      | 90.4% CI: [-0.4; 2.2] Table 14.2.12.1.1 95.2% CI: [-0.7; 2.4] Table 14.2.12.2.1 | Other syringes (N=15)                                                    | 3.3                                                                      | 90.4%CI: [-3.2; 9.8] Table 14.2.12.1.2 95.2% CI [-4.6; 11.2] Table 14.2.12.2.2  |
| Region                                                                   | Japan (N=33)                                                             | -0.5                                                                     | 90.4% CI: [-5.2; 4.1] Table 14.2.13.1.1 95.2% CI: [-6.1; 5.0] Table 14.2.13.2.1 | ROW (N=400)                                                              | 1.1                                                                      | 90.4% CI: [-0.2; 2.4] Table 14.2.13.1.2 95.2%CI: [-0.5; 2.7] Table 14.2.13.2.2  |

△ = difference, ADA = anti-drug antibody, CI= confidence interval, FAS =full analysis set, LS =least squares MMRM = Mixed Mode1 Repeated Measures, MNV = macular neovascularization, N = total number of Source: directly in the table

## Summary of main efficacy results

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the biosimilarity assessment (see later sections).

<div style=\"page-break-after: always\"></div>

## Table 25: Summary of efficacy for trial FYB203-03-01

| Title: A Phase 3 Randomized, Double-masked, Multicenter Study to Compare the Efficacy and Safety of the Proposed Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients with Neovascular Age- Related Macular Degeneration (MAGELLAN-AMD)   | Title: A Phase 3 Randomized, Double-masked, Multicenter Study to Compare the Efficacy and Safety of the Proposed Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients with Neovascular Age- Related Macular Degeneration (MAGELLAN-AMD)                                                                                                                                                                                                                                                                                                                               | Title: A Phase 3 Randomized, Double-masked, Multicenter Study to Compare the Efficacy and Safety of the Proposed Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients with Neovascular Age- Related Macular Degeneration (MAGELLAN-AMD)                                                                                                                                                                                                                                                                                                                               | Title: A Phase 3 Randomized, Double-masked, Multicenter Study to Compare the Efficacy and Safety of the Proposed Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients with Neovascular Age- Related Macular Degeneration (MAGELLAN-AMD)                                                                                                                                                                                                                                                                                                                               | Title: A Phase 3 Randomized, Double-masked, Multicenter Study to Compare the Efficacy and Safety of the Proposed Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients with Neovascular Age- Related Macular Degeneration (MAGELLAN-AMD)                                                                                                                                                                                                                                                                                                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Design                                                                                                                                                                                                                                                 | FYB203-03-01 (protocol number), 2019-003923-39 (EudraCT number) Parallel, randomised, active-controlled, double-masked, multi-centre study. Subjects were randomised in a 1:1 ratio to receive either FYB203 or EU- approved Eylea at a dose of 2 mg (0.05 mL of a 40 mg/mL solution). The treatment consisted of 1 IVT injection every 4 weeks for 3 consecutive doses starting at Baseline (Visit 1) through Week 8 (Visit 3) followed by 1 IVT injection every 8 weeks over a period of approximately 48 weeks (Visit 8), resulting in a total of 8 IVT injections per subject. | FYB203-03-01 (protocol number), 2019-003923-39 (EudraCT number) Parallel, randomised, active-controlled, double-masked, multi-centre study. Subjects were randomised in a 1:1 ratio to receive either FYB203 or EU- approved Eylea at a dose of 2 mg (0.05 mL of a 40 mg/mL solution). The treatment consisted of 1 IVT injection every 4 weeks for 3 consecutive doses starting at Baseline (Visit 1) through Week 8 (Visit 3) followed by 1 IVT injection every 8 weeks over a period of approximately 48 weeks (Visit 8), resulting in a total of 8 IVT injections per subject. | FYB203-03-01 (protocol number), 2019-003923-39 (EudraCT number) Parallel, randomised, active-controlled, double-masked, multi-centre study. Subjects were randomised in a 1:1 ratio to receive either FYB203 or EU- approved Eylea at a dose of 2 mg (0.05 mL of a 40 mg/mL solution). The treatment consisted of 1 IVT injection every 4 weeks for 3 consecutive doses starting at Baseline (Visit 1) through Week 8 (Visit 3) followed by 1 IVT injection every 8 weeks over a period of approximately 48 weeks (Visit 8), resulting in a total of 8 IVT injections per subject. | FYB203-03-01 (protocol number), 2019-003923-39 (EudraCT number) Parallel, randomised, active-controlled, double-masked, multi-centre study. Subjects were randomised in a 1:1 ratio to receive either FYB203 or EU- approved Eylea at a dose of 2 mg (0.05 mL of a 40 mg/mL solution). The treatment consisted of 1 IVT injection every 4 weeks for 3 consecutive doses starting at Baseline (Visit 1) through Week 8 (Visit 3) followed by 1 IVT injection every 8 weeks over a period of approximately 48 weeks (Visit 8), resulting in a total of 8 IVT injections per subject. |
| Design                                                                                                                                                                                                                                                 | Duration of treatment:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Duration of treatment:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 56 weeks (duration of treatment) Last investigational product (IP; FYB203 or Eylea) injection was at Week 48 and last assessment was done at Week 56.                                                                                                                                                                                                                                                                                                                                                                                                                              | 56 weeks (duration of treatment) Last investigational product (IP; FYB203 or Eylea) injection was at Week 48 and last assessment was done at Week 56.                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Hypothesis                                                                                                                                                                                                                                             | Equivalence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Equivalence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Equivalence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Equivalence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Treatments groups                                                                                                                                                                                                                                      | FYB203 (215)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | FYB203 (215)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 215 subjects started treatment with FYB203, a total of 196 subjects in the FYB203 group completed the study until Week 56                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 215 subjects started treatment with FYB203, a total of 196 subjects in the FYB203 group completed the study until Week 56                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Treatments groups                                                                                                                                                                                                                                      | Eylea (218)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Eylea (218)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 218 subjects started treatment with Eylea, a total of 206 subjects in the Eylea group completed the study until Week 56                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 218 subjects started treatment with Eylea, a total of 206 subjects in the Eylea group completed the study until Week 56                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                                                              | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Change from baseline in Best Corrected Visual Acuity (BCVA) by ETDRS letters at Week 8.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Change from baseline in Best Corrected Visual Acuity (BCVA) by ETDRS letters at Week 8.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Change from baseline in Best Corrected Visual Acuity (BCVA) by ETDRS letters at Week 8.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Database lock                                                                                                                                                                                                                                          | 10-Aug-2023                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 10-Aug-2023                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 10-Aug-2023                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 10-Aug-2023                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Results and Analysis                                                                                                                                                                                                                                   | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Analysis description                                                                                                                                                                                                                                   | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Analysis population and time point description                                                                                                                                                                                                         | Patients with nAMD who were randomised to receive either FYB203 or Eylea and who received at least 1 dose of investigational medicinal product, i.e., the FAS. Absolute change from Baseline to Week 8 in BCVA by ETDRS letters: CHG BCVA , Week 8 = BCVA Week 8 - BCVA Base , using analysis visits.                                                                                                                                                                                                                                                                              | Patients with nAMD who were randomised to receive either FYB203 or Eylea and who received at least 1 dose of investigational medicinal product, i.e., the FAS. Absolute change from Baseline to Week 8 in BCVA by ETDRS letters: CHG BCVA , Week 8 = BCVA Week 8 - BCVA Base , using analysis visits.                                                                                                                                                                                                                                                                              | Patients with nAMD who were randomised to receive either FYB203 or Eylea and who received at least 1 dose of investigational medicinal product, i.e., the FAS. Absolute change from Baseline to Week 8 in BCVA by ETDRS letters: CHG BCVA , Week 8 = BCVA Week 8 - BCVA Base , using analysis visits.                                                                                                                                                                                                                                                                              | Patients with nAMD who were randomised to receive either FYB203 or Eylea and who received at least 1 dose of investigational medicinal product, i.e., the FAS. Absolute change from Baseline to Week 8 in BCVA by ETDRS letters: CHG BCVA , Week 8 = BCVA Week 8 - BCVA Base , using analysis visits.                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability                                                                                                                                                                                                        | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | FYB203                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | FYB203                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Eylea                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability                                                                                                                                                                                                        | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 215                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 215                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 218                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability                                                                                                                                                                                                        | Mixed model repeated measurements (MMRM) LSMeans (Standard Error [SE]) of percent change from baseline in BCVA at Week 8                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 6.6 (0.73)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 6.6 (0.73)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 5. 6 (0.73)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability                                                                                                                                                                                                        | LSMean difference (FYB203 - Eylea) [95.2% CI]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 2.5]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

## 2.5.6. Discussion on clinical efficacy

## Design and conduct of clinical study

The applicant conducted a single pivotal phase III study in patients with neovascular age-related macular degeneration (nAMD). The study was not aimed at establishing efficacy per se since efficacy in the respective therapeutic indications has already been established for the reference product Eylea. Instead, the study aimed at demonstrating similarity with respect to efficacy between the biosimilar candidate and  the  reference  product.  Study  FYB203-03-01  was  a  randomised,  double-masked,  parallel  group, multicentre study to evaluate the clinical efficacy, safety, and immunogenicity of FYB203 compared to EU-approved Eylea. The Applicant conducted a single pivotal phase III study in patients with neovascular age-related macular degeneration (nAMD) (FYB203-03-01).

The  applicant  claims  the  same  indications  as  those  approved  for  the  respective  presentation  of  the reference  product  Eylea  (nAMD,  branch  RVO  or  central  RVO,  DME,  myopic  CNV).  The  receptor  and mechanism of action of aflibercept are the same across different ophthalmological indications approved for the reference product and aflibercept is directly delivered at its site of action. Since nAMD patients are generally considered a sensitive population for assessing similarity in clinical efficacy (see section 3) of  aflibercept,  it  is  agreed  that,  if  similarity  is  demonstrated  in  nAMD  patients,  the  findings  can  be extrapolated to other indications approved for Eylea (CRVO/BRVO, DME and myopic CNV).

The  study  was  conducted  in  subjects  with  neovascular  age-related  macular  degeneration  (nAMD). Studies with the originator showed that the treatment effect of aflibercept was largest in patients with nAMD. There are no data that evaluates the treatment effect of Eylea vs. sham in patients with nAMD. However, in MARINA (and ANCHOR) where Lucentis (ranibizumab) was evaluated, it was shown that, on average, sham-treated patients lost around 10 letters of BCVA over 12 months whereas the treated arm gained 7 letters. In the VIEW studies where Eylea was evaluated compared to ranibizumab in a very similar  nAMD  population,  subjects  gained  on  average  around  7  letters.  By  imputing  natural  disease history data from sham-treated subjects in MARINA, the overall treatment effect would thus translate into close to 20 letters in BCVA.

In addition, if left untreated, neovascular AMD shows homogeneous disease progressions with only few confounding factors, resulting in severe visual impairment. The selected patient population is considered relevant and sufficiently sensitive for the detection of potential differences between FYB203 and the reference  product.  Furthermore,  the  mechanism  of  action  of  Eylea  is  the  same  across  all  approved indications and the safety profile is similar among populations. The administered dose is in line with the posology approved for Eylea. The duration of treatment was 48 weeks, last assessments were made at Week 56. This is considered acceptable for the assessment of biosimilarity.

The inclusion and exclusion criteria are acceptable. Only treatment-naïve patients were included in the study. The recruitment of patients with a BCVA between 20/40 and 20/200 is endorsed, as it allows for quantification of changes in BCVA regarding improvement as well as potential worsening. Furthermore, the CHMP recommended lowering the cutoff of total area of whole lesion to ≤ 9 disc areas, which was acknowledged. In addition, patients with fibrosis &gt; 50% of the total lesion in the study eye and patients with spherical equivalent of the refractive error in the study eye demonstrating more than 6 dioptres of myopia were excluded. Therefore, the criteria are in line with the scientific advice.

Subjects were randomised in a ratio of 1:1 to either FYB203 or Eylea (administered via intravitreal injection 2 mg every 4 weeks for the first 3 months, followed by 2 mg once every 8 weeks). The EUlicenced Eylea was used as the comparator in the Phase 3 Study which is endorsed. Randomisation was stratified by country (Japan, rest of world) and participation in PK sub-study (yes, no). Patients were

<div style=\"page-break-after: always\"></div>

centrally assigned to study treatment by interactive web response system. Randomisation method is acceptable.

Due to differences in the products presentation, the FYB203 and Eylea EU were administered by an unmasked IVT administrator who was responsible for the study injections only. The unmasked study site personnel could also perform the post-dose safety check or tonometry, according to the clinical practice of  the  study  site.  The  treatment  each  subject  received  was  only  disclosed  to  the  unmasked  IVT administrator but not to other study site staff, patient, sponsor, or study vendors. This is acceptable.

The methods used for the primary (Best Corrected Visual Acuity) and secondary efficacy assessments (Ophthalmological  Examination,  Colour  Fundus  Photography  and  Fluorescein  Angiography,  Spectral Domain  Optical  Coherence  Tomography  and  NEI  VFQ-25)  represent  standard  used  for  respective assessments and are considered adequate.

Overall, the study design of Phase III study FYB203-03-01 is considered adequate to establish similarity between FYB203 and the reference product Eylea.

## Objectives, endpoints and estimands

The primary objective of the study was to demonstrate similar efficacy of FYB203 and Eylea EU in terms of BCVA. The primary endpoint was mean change from baseline in BCVA score using ETDRS testing charts at Week 8. Given that the maximum improvement of BCVA appeared to be reached starting at 12 weeks in VIEW 1 and VIEW 2 pivotal aflibercept studies, 8 weeks is considered a sensitive time-point to detect any differences between FYB203 and Eylea in terms of BCVA change from baseline. Therefore, the primary endpoint 'change in BCVA by ETDRS letters between Week 8 and baseline' is considered an appropriate primary endpoint for the assessment of biosimilarity. Treatment policy strategy to handle intercurrent events in the analysis of primary endpoint is acceptable as well.

The  proposed  equivalence  range  for  the  mean  difference  in  the  primary  endpoint  for  the  wet  AMD population  of  ±  3.5  letters  is  considered  conservative  enough  to  establish  the  clinical  equivalence between FYB203 and Eylea and is therefore endorsed.

The  applicant  performed  the  main  analysis  of  primary  efficacy  endpoint  for  assessing  equivalence between a biosimilar and an innovator product based on the full analysis set, i.e., those patients who received at least 1 injection of study medication in the study eye. The corresponding analysis of the primary efficacy endpoint, the change in BCVA by ETDRS letters from baseline to Week 8 on per protocol set was also performed.

Secondary endpoints evaluated the change in BCVA by ETDRS letters; foveal (centre point and central subfield) thickness at different time points and over time; the proportion of subjects who gained or lost ≥5, 10, or 15 ETDRS letters compared to baseline; percentage of subjects with fluid -free macula; change in lesion size compared to baseline; PK, ADAs analyses; and quality of life assessment. The secondary endpoints are adequately defined to further support biosimilarity assessment and the maintenance of efficacy over time and are supported.

## Statistical methods for estimation and sensitivity analysis

Main analysis model for primary efficacy endpoint, i.e., linear mixed-effects model (MMRM) with fixed effects of BCVA at baseline, region, visit, treatment, baseline by visit interaction and treatment by visit interaction is acceptable. Covariance structure within patient is modelled by unstructured covariance matrix and Kenward-Roger approximation of degrees of freedom for testing of fixed effects in MMRM. Such MMRM can be considered as acceptable.

Basic sample size calculation of 400 patients for 'EU analysis' is acceptable. Actual number of patients considered for study was 434 randomised patients.

<div style=\"page-break-after: always\"></div>

Masked sample size review (MSSR) was performed after first 200 treated patients who completed study Week 8 (Visit 3) as there was some uncertainty about assumed value of standard deviation (SD) for primary efficacy endpoint, i.e., 9 letters, which was used for sample size calculation. Based on estimated common SD after first 200 treated patients, final sample size could be increased up to 800 patients from original number of 400 patients. However, as estimate of common SD for primary efficacy endpoint was 8.14 letters which was less than 9 letters, original number of 400 patients was retained.

According to section 7.4.3. Recommendations based on the masked sample size review in document 16.1.9. Documentation of Statistical Methods, common SD estimated after first 200 treated patients for key secondary efficacy endpoint for 'EU analysis' could also influence value of final sample size which could be up to 800 patients. Assumed value of SD for sample size calculation was 135 µm. However, as estimate of  common SD for key secondary efficacy endpoint for 'EU analysis' was 110.11 µm (see Sample size re-assessment in Statistical Methods), original number of 400 patients was retained.

As MSSR was planned to be performed after 200 patients, the applicant performed a simulations prior to study initiation to assess impact of MSSR on potential inflation of overall type 1 error probability (OT1EP). Results of simulations indicated inflation of OT1EP and 95.2% confidence interval (CI) had to be used for assessment of equivalence in 'EU analysis' instead of nominal 95% CI.

The applicant provided missing Appendix I to the SAP which described the methodology applied as well as the results of the simulations for both the EMA and the FDA specific analyses.

It was pointed out by the assessor that simulations may not exhaust all possible scenarios and analytical calculation of OT1EP should be performed to verify that 95.2% CI is reasonable. The applicant stated that MSSR after 200 subjects did not inflate OT1EP as original sample size of 400 patients was retained. Moreover, the applicant stated that although OT1EP can be calculated analytically (see Friede and Kieser (2003): Blinded sample size reassessment in non-inferiority and equivalence) such calculation needed numerical method and result could be imprecise. Instead, tipping point analysis was performed by the applicant with respect to both primary endpoint and key secondary endpoint for full analysis set and for per  protocol  set,  respectively,  in  'EU  analysis'.  This  calculation  searched  for  maximum  value  of confidence level (CL) which led to equivalence across both endpoints and in both analysis sets considered for  these  endpoints.  Such  maximum  value  of  CL  was  99.90%.  Consequently,  99.90%  CI  can  be considered as sufficient CL to cover possible OT1EP inflation due to MSSR. Hence, issue with MSSR is resolved.

Two protocol amendments were made. Amendment 1 was issued before screening of subjects started. The second amendment was issued after study initiation. The changes were clearly described and no influence on study results is expected since occurred prior to study unmasking. There was also change in the planned subgroup analysis relevant for this application - only the regions Japan versus ROW were used, since the differences between study population in Japan versus the other countries was regarded as  more  important  than  possible  differences  between  countries.  Numerically,  the  originally  planned analysis by country was not recommended due to the very small number of patients in 1 country. This is acceptable.

Study conduct: The study completion rate was high (more than 91%), with slightly more subjects in Elyea arm in comparison with FYB203 arm. Up to Week 8, which was when the primary analysis was evaluated, 3 patients from FYB203 group and 2 patients from Eylea treatment group discontinued the IP. The primary reason for the subject's discontinuation before week 8 is not clear but given the low number of patients who discontinued before Week 8, the impact is considered negligible and the issue will not be further pursued.

Classification of the protocol deviation as a major or minor was not prespecified in the study protocol. All protocol deviations for all treated patients were reviewed during the Blind Data Review Meeting before

<div style=\"page-break-after: always\"></div>

database lock and unmasking for the originally planned US analysis with data up to Week 24 in order to allocate all patients into the different analysis sets. Major Protocol deviations were defined as a deviation, which should impact the BCVA assessment until Week 8.

A total of 367 (84.8%) patients had at least 1 minor protocol deviation and 27 patients (6.2%) had at least 1 major protocol deviation, which led to the exclusion from the PPS. The percentage of patients with any protocol deviation was comparable between treatment arms. The most common major protocol deviations that led to exclusion from PPS were BCVA schedule deviations with comparable occurrence between treatment groups.

The proportion of patients with major protocol deviation due to study treatment incompliance was low and well comparable between the groups [2 subjects in both groups].  Visit schedule deviation at week 8 (V3 - when assessment of the primary endpoint was performed) occurred in 1 subject (0.5%) in FYB203 group and 2 subjects (0.9%) in Eylea group. Covid19 related V3 visit schedule deviation occurred only in 1 subject from FYB203 group. Deviations from the protocol were clearly described and do not raise any concerns.

Since the classification of the protocol deviation was not prespecified in the study protocol, demonstration of the robustness of the primary analysis of both FAS and PPS is of particular importance.

Of  the  434  subjects  randomised,  433  (99.8%)  subjects  were  included  in  the  FAS  (primary  analysis population)  and  406  (93.8%)  subjects  were  included  in  the  PPS  (analysis  set  used  in  a  sensitivity analysis). One subject randomised to the Eylea group in FAS did not receive the IP. In addition, there were two subjects (1 in each study groups) who received wrong IMPs. Therefore, SAF and FAS are not identical. In the FAS, patients were analysed according to their randomisation, while in the SAF they were analysed according to the treatment currently received. Number of patients excluded from the PPS was comparable between treatment groups.

Overall, the mean age of the patients included in the study was 73.5 years (range: 68-79 years). The majority of subjects were white (91.9%). There was a higher proportion of females (57.3%) compared to males (42.7%) participated in the study. The baseline demographic characteristics were comparable across the treatment groups.

Most of the patients were diagnosed 30 days before randomisation (median value), however, for 60 patients this information is missing. The median time since first diagnosis of nAMD was 32.0 days in the FYB203 group and 29.0 days in the Eylea group. The mean BCVA score [ETDRS letters] at baseline was 57.9 letters (median 60 letters) and well balanced across treatment groups.

The lesion type (in most subjects Type 1 MNV, type 2 NV or mixed type 1 and type 2 MNV), total lesion area (mean value at screening 9.6 mm 2  (5.84)) and IOP (mean 15.3 mmHg) was comparable across treatment arms. Baseline (V1) FCP and FCS retinal thickness were slightly thicker in the Eylea group (mean 448.5 µm and 484.0 µm, respectively) vs FYB203 group (465.9 µm and 493.5 µm, respectively).

Both treatment arms were similar regarding medical history, prior medications and treatments, as well as concomitant medications. Almost half of patients (49.9%) had cataract in the study eye at baseline (48.4% and 51.4 % in FYB203 and Eylea treatment groups, respectively). In the fellow eye, dry agerelated  macular  degeneration  occurred  overall,  in  267  (62.7%)  patients  and  cataract  in  50.8  %. Neovascular age-related macular degeneration was diagnosed in 33 patients (7.6%) (17 (7.9%) and 16 (7.3%) in FYB203 and Eylea treatment groups, respectively) at baseline. Fellow eye treatment with Eylea was not permitted during the first eight weeks of the study to exclude any potential impact on the efficacy evaluation at Week 8 and no injections were performed prior to the Week 8 assessments. Overall, the number of patients who needed fellow eye treatment was low and similar between groups (FYB203: 19

<div style=\"page-break-after: always\"></div>

(8.8%); Eylea: 20 (9.2%)). Fellow eye treatment was to be separated by at least 14 days from study eye treatment such that treatments could not have been mixed up.

A tabulated summary of intercurrent events until week 8 was provided. No other pre-defined intercurrent event was observed during this time period, except for treatment discontinuation prior to week 8. The number of subjects discontinuing treatment prior to week 8 was comparable between treatment arms thus does not represent a risk for biosimilarity assessment. During the first 24 weeks, vitrectomy was performed on the study eye in one subject from FYB203 group and laser therapy was performed in one subject in the Eylea group. These therapies may have affected the primary efficacy endpoint and were prohibited during the study period but were not classified as a major deviation. The reason why this was not classified as a major protocol deviation is unclear. However, as only 2 patients were affected by this (1 in each arm) the impact on study results is considered negligible. Therefore, the issue is not further pursued.

## Efficacy data and additional analyses

## Primary efficacy analysis

The least squares (LS) mean observed for change from baseline in BCVA at Week 8 was similar in both treatment groups, i.e., 6.6 letters and 5.6 letters in FYB203 and Eylea group, respectively, based on patients  from  full  analysis  set  (FAS).  The  LS  mean  difference  in  BCVA  of  the  change  from  baseline between FYB203 and Eylea at Week 8 was 1.0 letter with 95.2% confidence interval (CI) of [-0.6 letter; 2.5 letters] and was completely contained within the predefined equivalence range (ER) of [-3.5 letters, 3.5 letters].

The  sensitivity  analyses  for  the  primary  endpoint  were  performed  using  linear  mixed  effects  model (MMRM) and analysis of covariance (ANCOVA) model. Impact of missing data in FAS on study results was  investigated  by  ANCOVA  model.  Impact  of  different  structure  of  FAS  on  study  results  was investigated  by  MMRM.  The  results  of  these  sensitivity  analyses  for  the  primary  efficacy  endpoint supported the robustness of the equivalence between FYB203 and Eylea based on FAS.

Further, tipping point analysis for the primary efficacy endpoint was performed to investigate whether missing at random (MAR) assumption underlying the use of MMRM was reasonable for missing data in the FAS. Missing data were imputed by missing not at random mechanism and shifted by certain range of  values.  Due  to  high  value  of  shift  either  for  FYB203  or  Eylea  or  both  the  MAR  assumption  was reasonable and MMRM could be used.

The number of patients with missing assessments was overall low and comparable between treatment groups (6 and 5 in the FYB203 and Eylea group, respectively), indicating that the performed tipping analyses will likely not be much different from the primary analysis. The smallest tipping point that would lead to a conclusion of lower efficacy of FYB203 compared to Eylea was a shift of 0 in the Eylea group and a shift of -79 letters in the FYB203 group. The likelihood that all these patients would have much worse changes than the observed minimum changes is regarded as very low.

Finally, supplemental analyses for primary endpoint using MMRM restricted to the PPS, to modified FAS, or using different approaches for handling of intercurrent events were performed. These supplemental analyses  led  to  equivalence  as  95.2%  CIs  were  fully within  ER  [-3.5  letters,  3.5  letters]  for  each considered supplemental analysis.

The analysis of the primary efficacy endpoint, the change in BCVA by ETDRS letters from baseline to Week 8 on per protocol set (PPS) was performed. For PPS, 95.2% confidence interval (CI) for difference between FYB203 and Eylea is (-0.8 letter, 2.4 letters) and this CI fully lies within equivalence range (ER)

<div style=\"page-break-after: always\"></div>

which is (-3.5 letters, 3.5 letters). Thus, results based both on PPS and FAS are consistent and support the similarity of the products.

## Secondary efficacy endpoints

## Change in foveal centre point retinal thickness and foveal central subfield retinal thickness

Change in foveal centre point retinal thickness in the study eye from baseline to Week 4 based on the FAS and PPS was considered as a key secondary endpoint. The estimated LS mean change in FCP retinal thickness from baseline to Week 4 was -171.4 μ m in patients treated with FYB203 and -166.9 μ m in patients treated with Eylea. The estimated LS mean difference between the treatment groups was -4.5 μ m (95.2% CI: [-24.4 μ m; 15.4 μ m]) and completely contained in the pre-defined equivalence range of [-45.0 μ m; 45.0 μ m]. In the PPS, the estimated LS mean difference of -7.5 μ m (95.2% CI: [-28.2 μ m; 13.1 μ m]) between the treatments was similar to the FAS.

The difference between treatments increased at later time points as compared to the difference observed at Week 4, as follows: (-8.2 μ m (95.0% CI: [-33.7 μ m; 17.3 μ m]) at Week 24; -7.9 μ m (95.0% CI: [32.2 μ m; 16.4 μ m]) at Week 40 and -5.2 μ m (95.0% CI: [-27.7 μ m; 17.2 μ m]) at Week 56); however, it was still contained within the acceptance range.

The estimated LS mean change in FCS retinal thickness from baseline to Week 4 was -163.5 μ m in patients treated with FYB203 and -157.4 μ m in patients treated with Eylea. The estimated LS mean difference between the treatments was -6.2 μ m (95.0% CI: [-24.3 μ m; 12.0 μ m]). In the PPS, the estimated LS mean difference of -6.2 μ m (95.0% CI: [-24.9 μ m; 12.4 μ m]) between the treatments was similar to the FAS.

The difference between treatments at later time points was similar or smaller to the one observed at Week 4. The estimated LS mean differences between the two treatment groups were -6.3 μ m (95.0% CI: [-28.9 μ m; 16.3 μ m]) at Week 24, -3.8 μ m (95.0% CI: [-25.4 μ m; 17.8 μ m]) at Week 40 and -0.6 μ m (95.0% CI: [-20.6 μ m; 19.4 μ m]) at Week 56. Similar to change in FCP retinal thickness, change FCS retinal thickness slightly worse performance of FYB203 compared to Eylea, however still within the pre-specified margins.

In summary, a decrease from baseline in foveal centre point and foveal central subfield retinal thickness was observed in both treatment groups at all time points. No significant differences between treatments were noted.

## Change in BCVA From Baseline to Week 24, Week 40 and Week 56

In the FAS, increase in ETDRS letters from Baseline was observed throughout the study, with a median (IQR) increase of 8.0 (0.0 - 13.0) ETDRS letters at Week 24, 8.0 (1.0 - 14.0) ETDRS letters at Week 40 and 8.0 (0.0 15.0) ETDRS letters at Week 56.

The estimated LS mean differences in BCVA between the 2 treatment groups were 0.3 ETDRS letter (95.0% CI: [-1.5; 2.2]) at Week 24, 1.4 ETDRS letters (95.0% CI: [-0.6; 3.4]) at Week 40 and 1.3 ETDRS letters (95.0% CI: [-0.9; 3.5]) at Week 56.

## The proportion of patients who gained or lost ≥ 5, 10 and 15 ETDRS letters

The proportion of patients who gained or lost ≥ 5, 10 and 15 ETDRS letters was comparable between the 2 treatment groups at all time points. The number of patients who gained more than 15 letters was slightly higher in FYB203 group (22.4%, 25.1% and 27.7% of at week 24, 40 and 56, respectively) compared to Eylea group (18.7%, 21.5% and 24.4% of at week 24, 40 and 56, respectively).

The proportion of subjects who lost 15 or more letters in BCVA compared to baseline at Week 56 was slightly lower in the FYB203 (FYB203:  1.1% [2 subjects] vs Eylea: 4.5% [9 subjects].

<div style=\"page-break-after: always\"></div>

## Fluid-Free Macula at Each Visit

No patient had a fluid-free macula at baseline. The highest proportion of patients with fluid-free macula was observed at Week 8 (56.7% in the FYB203 group and 54.3% in the Eylea group). A reduction in the proportion of subjects with a fluid-free macula occurred after week 8, according to the applicant, as a result of the extension in dosing intervals. After that, the proportion of patients increased again to 42.2% in the FYB203 group and 50.5% in the Eylea group. No statistically difference between treatment groups was observed.

## Change in total lesion area

The ANCOVA/MMRM was used to analyse the change in total lesion area from Baseline to Week 24, Week 40 and Week 56 on the FAS. The estimated LS mean changes of total lesion area from Screening until Week 56 were similar between the 2 treatment groups. At Week 24, the estimated LS mean change in total lesion area was -1.1 mm² in patients treated with FYB203 and -1.4 mm² in patients treated with Eylea. At Week 40, it was -0.9 mm² in patients treated with FYB203 and -1.2 mm² in patients treated with Eylea. At Week 56, it was -1.4 mm² in patients treated with FYB203 and -1.5 mm² letters in patients treated with Eylea. The estimated LS mean differences between the 2 treatment groups were +0.3 mm² (95.0% CI: [-0.5; 1.2]) at Week 24, +0.2 mm² (95.0% CI: [-0.7; 1.1]) at Week 40 and +0.1 mm² (95.0% CI: [-0.8; 1.1]) at Week 56.

Change from Baseline in vision-related functioning and well-being measured by NEI VFQ-25 in patients treated with FYB203 or Eylea was highly variable. No statistical comparison between groups was made.

No substantial difference between treatment groups were observed.

The subgroup analysis revealed in some cases inequivalence for difference between treatments with respect to primary efficacy endpoint if corresponding 95.2% confidence interval (CI) was compared to equivalence range [-3.5 letters, 3.5 letters].

This was revealed in case of the males (the LS mean difference was 1.7 letters with 95.2% CI of [-0.5 letter, 4.0 letters]) where upper limit of 95.2% CI was higher than 3.5 letters. Further, this was revealed in case of certain lesion types. More specifically, Type 2 MNV (the LS mean difference was 2.3 letters with 95.2% CI of [-1.4 letter, 6.0 letters]) where upper limit of 95.2% CI was higher than 3.5 letters, Mixed Type 1 and Type 2 MNV (the LS mean difference was 1.1 letters with 95.2% CI of [-1.4 lett er, 3.6 letters]) where upper limit of 95.2% CI was higher than 3.5 letters and Type 3 MNV (the LS mean difference was 1.5 letters with 95.2% CI of [-6.6 letters, 3.7 letters]) where lower limit of 95.2% CI was less than -3.5 letters.

However, number of subjects in individual subgroups may not lead to sufficient statistical power (at least 80%) to conclude equivalence with respect to range [-3.5 letters, 3.5 letters] as study was not planned for subgroup analyses. In this case it was sufficient that point estimates for treatment difference for individual subgroups were fully within equivalence range [-3.5 letters, 3.5 letters].

The results of the subgroup analysis by ADA result up to Week 8 were not assessed due to extremely small numbers of ADA positive patients up to Week 8 (6 patients only).

The  subgroup  analysis  by  ancillary  chart  use,  injection  syringe  use  and  region  also  revealed  some differences. However, due to the unequal size of the groups, no firm conclusion could be drawn from the results.

<div style=\"page-break-after: always\"></div>

## 2.5.7. Conclusions on the clinical efficacy

The clinical data indicate similarity between the proposed biosimilar Ahzantive and the reference product Eylea EU.

## 2.5.8. Clinical safety

The  clinical  safety  assessment  of  FYB203-03-01  (further  referred  as  FYB203  -  proposed  aflibercept biosimilar)  is  based  on  one  phase  III  parallel-group,  1:1  randomised,  double-masked,  multicentre completed study (MAGELLAN-AMD). The study compares the efficacy and safety of the FYB203 biosimilar with EU Eylea in patients with neovascular Age-Related Macular Degeneration (AMD).

Table 26: Evaluation and visit schedule

<!-- image -->

<div style=\"page-break-after: always\"></div>

5Tonometry had to be measured prior to the injection and within 30 to 60 minutes after the injection.

6 A complete ophthalmic examination had to be performed prior to the IVT injection.

$Evaluationof systemic aflibercept concentrationonly.

9In case ofconfirmedADAs,the ADA titerandNAbs were evaluated.Additional ADA sampling and evaluationwere performedinpatients experiencingsignals ofunexpectedocularinflammation.

collected.

12 No significant anatomical change in the studyeye compared to Screening and visual acuity in the studyeye within the defined inclusion criteria range (Snellen equivalent20/40[0.5]to20/200[0.1])andwithin51ettersoftheScreeningBCVA.

11 A safety check (light perception, ophthalmoscopy, and tonometry) was performed within 60 minutes post IVT.

13 See Appendix 3 of the CSP (Appendix 16.1.1.3) for the list of clinical laboratory tests to be performed.

CSP[Appendix16.1.1.3]).Urine samples had tobe collectedbefore performing FA(when applicable)toavoid false elevations in urine proteinvalues.

All assessmentsofaparticularvisithadtobeperformedduring1day,exceptforScreening

Source:Section 1.3of theCSP(Appendix16.1.1.3)

## 2.5.8.1. Patient exposure

Table 27: Patient exposure (cut off)

|                                      | Patients enrolled a                        | Patients exposed b                         | Patients exposed to the proposed dose range c   | Patients with long term d safety data     |
|--------------------------------------|--------------------------------------------|--------------------------------------------|-------------------------------------------------|-------------------------------------------|
| Blinded studies (placebo-controlled) | N/A                                        | N/A                                        | N/A                                             | N/A                                       |
| Blinded studies (active -controlled) | Total: N= 434 FYB203: N= 215 Eylea: N= 219 | Total: N= 433 FYB203: N= 215 Eylea: N= 218 | Total: N= 382 FYB203: N= 183 Eylea: N= 199      | Total: N= 402 FYB203: N= 196 Eylea: N=206 |
| Open studies                         | N/A                                        | N/A                                        | N/A                                             | N/A                                       |
| Post marketing                       | N/A                                        | N/A                                        | N/A                                             | N/A                                       |
| Compassionate use                    | N/A                                        | N/A                                        | N/A                                             | N/A                                       |

a  Patients randomised at Week 0.

b  Received at least 1 dose of active treatment.

c  Patients who received all 8 scheduled injections until Week 56.

d  In general this refers to 6 months and 12 months continuous exposure data, or intermittent exposure. In this case, patients completed study until Week 56.

Patients  with  newly  diagnosed  neovascular  age-related  macular  degeneration  (AMD)  were  randomly allocated to two treatment groups in a 1:1 ratio - one arm received test product FYB203 and one arm received reference product Eylea (Table 7).

Overall, 712 patients were screened and enrolled (including 7 re-screened patients) in 77 in 9 countries. In  total,  434  patients  were  randomised  to  receive  the  FYB203  treatment  (215  patients)  or  Eylea treatment (219 patients). After consent withdrawal by 1 patient, 433 patients started the treatment (FYB203 - 215 patients; Eylea - 218 patients). These patients formed the FAS (full analysis set) and the SAF (safety analysis set).

The treatment consisted of 1 IVT injection every 4 weeks for 3 consecutive doses starting at Baseline (Visit  1)  through  Week  8  (Visit  3)  followed  by  1  IVT  injection  every  8  weeks  over  a  period  of approximately 48 weeks (Visit 8), resulting in a total of 8 IVT injections per patient. The study was completed at Week 56.

A total  of  196  (91.2%)  patients  in  the  FYB203  group  and  206  (94.1%)  patients  in  the  Eylea  group completed the study until Week 56, which is acceptable. The provided safety database is considered sufficient to assess the comparability of common and very common adverse events. However, it is too small to inform on less frequently occurring adverse events.

<div style=\"page-break-after: always\"></div>

Until Week 56, 183 patients (85.1%) in the FYB203 group and 199 patients (91.3%) in the Eylea group received all 8 scheduled injections (88.2% in total).

Up to Week 56, 19 (8.8%) patients in the FYB203 group and 12 (5.5%) patients in the Eylea group discontinued the study prematurely. In the FYB203 group , 5 patients experienced AEs, 4 patients died, 3 patients withdrew consent, 1 patient was lost to follow-up, 1 patient had a protocol violation and 5 patients discontinued due to other reasons. In the Eylea group , 7 patients withdrew consent, 2 patients discontinued following physician decision, 1 patient died, 1 patient was lost to follow-up and 1 patient discontinued due to other reasons.

There were 27 (6.2%) patients with major protocol deviations leading to the exclusion from the PPS (per protocol set), resulting in a PPS of 201 patients treated with FYB203 and 205 patients treated with Eylea.

The  PKS  (plasma  concentration  analysis  set)  consisted  of  31  patients  treated  with  FYB203  and  26 patients treated with Eylea. Three patients were excluded from the 60 recruited patients due to positive total aflibercept concentration at Baseline.

The mean (SD) treatment duration was 323.1 (58.97) days and the mean (SD) study duration was 398.7 (53.03) days. In general, the treatment and study duration were well balanced between both treatment groups and no relevant differences were observed.

## 2.5.8.2. Adverse events

## Overview of TEAEs

An  overview  of  all  TEAE  sub-categories  occurring  during  the  course  of  the  study  until  Week  56  is presented  in  Table  28depicting  the  number  of  events  and  the  number  and  percentage  of  patients corresponding to each sub-category.

Overall, there were no clinically relevant differences in TEAEs between the 2 treatment groups until Week 56: 498 events were reported in 165 (76.7%) patients treated with FYB203 versus 536 events in 158 (72.5%) patients treated with Eylea.

Overall, the SAE occurrences until Week 56 were comparable in the 2 treatment groups: 38 events in 19 (8.8%) patients treated with FYB203 and 40 events in 28 (12.8%) patients treated with Eylea. The SAEs were mostly systemic and rarely local.

<div style=\"page-break-after: always\"></div>

Table 28: Overview of treatment-emergency adverse events (SAF, N=433)

| TEAE category                                 | FYB203 N=215   | FYB203 N=215   | FYB203 N=215   | Eylea N=218   | Eylea N=218   | Eylea N=218   | Total N=433   | Total N=433   | Total N=433   |
|-----------------------------------------------|----------------|----------------|----------------|---------------|---------------|---------------|---------------|---------------|---------------|
|                                               | n              | (%)            | Ev             | n             | (%)           | Ev            | n             | (%)           | Ev            |
| TEAEs                                         | 165            | (76.7)         | 498            | 158           | (72.5)        | 536           | 323           | (74.6)        | 1034          |
| Local (study eye)                             | 67             | (31.2)         | 125            | 75            | (34.4)        | 157           | 142           | (32.8)        | 282           |
| Local (fellow eye)                            | 45             | (20.9)         | 53             | 48            | (22.0)        | 58            | 93            | (21.5)        | 111           |
| Systemic                                      | 124            | (57.7)         | 320            | 113           | (51.8)        | 321           | 237           | (54.7)        | 641           |
| Serious TEAEs (SAEs)                          | 19             | (8.8)          | 38             | 28            | (12.8)        | 40            | 47            | (10.9)        | 78            |
| Local (study eye)                             | 2              | (0.9)          | 3              | 2             | (0.9)         | 2             | 4             | (0.9)         | 5             |
| Local (fellow eye)                            | 0              | (0.0)          | 0              | 3             | (1.4)         | 3             | 3             | (0.7)         | 3             |
| Systemic                                      | 17             | (7.9)          | 35             | 23            | (10.6)        | 35            | 40            | (9.2)         | 70            |
| Fatal TEAEs                                   | 4              | (1.9)          | 8              | 1             | (0.5)         | 1             | 5             | (1.2)         | 9             |
| Nonfatal SAEs                                 | 18             | (8.4)          | 30             | 27            | (12.4)        | 39            | 45            | (10.4)        | 69            |
| Severe TEAEs                                  | 10             | (4.7)          | 23             | 15            | (6.9)         | 20            | 25            | (5.8)         | 43            |
| Local (study eye)                             | 2              | (0.9)          | 3              | 0             | (0.0)         | 0             | 2             | (0.5)         | 3             |
| Local (fellow eye)                            | 0              | (0.0)          | 0              | 4             | (1.8)         | 4             | 4             | (0.9)         | 4             |
| Systemic                                      | 8              | (3.7)          | 20             | 11            | (5.0)         | 16            | 19            | (4.4)         | 36            |
| Related TEAEs to study treatment              | 20             | (9.3)          | 34             | 16            | (7.3)         | 32            | 36            | (8.3)         | 66            |
| Related serious TEAEs                         | 2              | (0.9)          | 3              | 0             | (0.0)         | 0             | 2             | (0.5)         | 3             |
| RelatedsevereTEAEs                            | 3              | (1.4)          | 4              | 0             | (0.0)         | 0             | 3             | (0.7)         | 4             |
| Related TEAEs toIVT injectionprocedure        | 28             | (13.0)         | 55             | 37            | (17.0)        | 93            | 65            | (15.0)        | 148           |
| TEAEsleading to withdrawal of study treatment | 10             | (4.7)          | 18             | 2             | (0.9)         | 2             | 12            | (2.8)         | 20            |
| TEAE leading to discontinuationofstudy        | 9              | (4.2)          | 16             | 1             | (0.5)         | 1             | 10            | (2.3)         | 17            |
| AESIs                                         | 6              | (2.8)          | 10             | 7             | (3.2)         | 12            | 13            | (3.0)         | 22            |

Ev = number of TEAEs of specified adverse event type, IVT = intravitreal, N = total number of patients, n = number of patients with at least 1 adverse event of specified adverse event type, SAE = serious adverse event, SAF = safety analysis set, TEAE = treatment-emergent adverse event, AESI = Adverse event of special interest

Treatment-emergent adverse events (TEAEs) which were observed in at least 2% of the patients are displayed in Table 29 by System Organ Class (SOC) and Preferred Term (PT). The assessment includes all ocular and nonocular, local and systemic TEAEs in ≥2.0% of patients.

<div style=\"page-break-after: always\"></div>

Table 29: Frequency of treatment emergency adverse events in ≥ 2.0% of patients in either of the treatment groups (SAF, N=433)

| System Organ Class Preferred Term (MedDRA 23.0 Mixed)   | FYB203 N=215   | FYB203 N=215   | FYB203 N=215   | Eylea N=218   | Eylea N=218   | Eylea N=218   | Total N=433   | Total N=433   | Total N=433   |
|---------------------------------------------------------|----------------|----------------|----------------|---------------|---------------|---------------|---------------|---------------|---------------|
|                                                         |                | (%)            | Ev             | n             | (%)           | Ev            |               | (%)           | Ev            |
| Any TEAE                                                | 165            | (76.7)         | 498            | 158           | (72.5)        | 536           | 323           | (74.6)        | 1034          |
| Eye disorder's, overall                                 | 84             | (39.1)         | 149            | 95            | (43.6)        | 171           | 179           | (41.3)        | 320           |
| Neovascular age-related macular degeneration            | 28             | (13.0)         | 31             | 28            | (12.8)        | 35            | 56            | (12.9)        | 66            |
| Cataract                                                | 11             | (5.1)          | 16             | 10            | (4.6)         | 11            | 21            | (4.8)         | 27            |
| Conjunctival haemomhage                                 | 5              | (2.3)          | 5              | 14            | (6.4)         | 24            | 19            | (4.4)         | 29            |
| Visual acuity reduced                                   | 9              | (4.2)          | 9              | 6             | (2.8)         | 6             | 15            | (3.5)         | 15            |
| Eye pain                                                | 6              | (2.8)          | 6              | 6             | (2.8)         | 9             | 12            | (2.8)         | 15            |
| Vision blurred                                          | 6              | (2.8)          | 6              | 3             | (1.4)         | 4             | 9             | (2.1)         | 10            |
| Visual impairment                                       | 3              | (1.4)          | 3              | 5             | (2.3)         | 5             | 8             | (1.8)         | 8             |
| Infections andinfestations,overall                      | 58             | (27.0)         | 92             | 55            | (25.2)        | 76            | 113           | (26.1)        | 168           |
| COVID-19                                                | 19             | (8.8)          | 21             | 18            | (8.3)         | 18            | 37            | (8.5)         | 39            |
| Nasopharyngitis                                         | 10             | (4.7)          | 11             | 6             | (2.8)         | 6             | 16            | (3.7)         | 17            |
| Conjunctivitis                                          | 6              | (2.8)          | 11             | 6             | (2.8)         | 6             | 12            | (2.8)         | 17            |
| Coronavirus infection                                   | 6              | (2.8)          | 6              | 1             | (0.5)         | 1             | 7             | (1.6)         | 7             |
| Musculoskeletal andconnectivetissue                     | 22             | (10.2)         | 29             | 22            | (10.1)        | 33            | 44            | (10.2)        | 62            |
| disorder's,overall                                      |                |                |                |               |               |               |               |               |               |
| Back pain                                               | 5              | (2.3)          | 5              | 6             | (2.8)         | 6             | 11            | (2.5)         | 11            |
| Osteoarthritis                                          | 10             | (4.7)          | 11             | 1             | (0.5)         | 1             | 11            | (2.5)         | 12            |
| Investigations, overall                                 | 20             | (9.3)          | 37             | 23            | (10.6)        | 56            | 43            | (9.9)         | 93            |
| Intraocular pressure increased                          | 8              | (3.7)          | 11             | 9             | (4.1)         | 26            | 17            | (3.9)         | 37            |
| Vascular disorders, overall                             | 21             | (9.8)          | 28             | 17            | (7.8)         | 23            | 38            | (8.8)         | 51            |
| Hypertension                                            | 15             | (7.0)          | 16             | 9             | (4.1)         | 12            | 24            | (5.5)         | 28            |
| Gastrointestinal disorder's,overall                     | 22             | (10.2)         | 28             | 15            | (6.9)         | 30            | 37            | (8.5)         | 58            |
| Injury, poisoning and procedural complications, overall | 15             | (7.0)          | 19             | 15            | (6.9)         | 20            | 30            | (6.9)         | 39            |
| Nervous system disorder's, overall                      | 16             | (7.4)          | 20             | 13            | (6.0)         | 19            | 29            | (6.7)         | 39            |

| System Organ Class Preferred Term (MedDRA 23.0 Mixed)                       | FYB203 N=215   | FYB203 N=215   | FYB203 N=215   | Eylea N=218   | Eylea N=218   | Eylea N=218   | Total N=433   | Total N=433   | Total N=433   |
|-----------------------------------------------------------------------------|----------------|----------------|----------------|---------------|---------------|---------------|---------------|---------------|---------------|
|                                                                             | n              | (%)            | Ev             | n             | (%)           | Ev            | n             | (%)           | Ev            |
| Headache                                                                    | 4              | (1.9)          | 4              | 7             | (3.2)         | 12            | 11            | (2.5)         | 16            |
| Metabolismandnutritiondisorders,overall                                     | 12             | (5.6)          | 17             | 10            | (4.6)         | 14            | 22            | (5.1)         | 31            |
| Respiratory, thoracic and mediastinal disorder's,overall                    | 12             | (5.6)          | 14             | 10            | (4.6)         | 10            | 22            | (5.1)         | 24            |
| Generaldisordersandadministrationsite conditions, overall                   | 6              | (2.8)          | 9              | 11            | (5.0)         | 13            | 17            | (3.9)         | 22            |
| Neoplasms benign, malignant and uspecified (incl cysts and polyps), overall | 7              | (3.3)          | 10             | 9             | (4.1)         | 14            | 16            | (3.7)         | 24            |
| Renal and urinary disorders, overall                                        | 9              | (4.2)          | 10             | 6             | (2.8)         | 9             | 15            | (3.5)         | 19            |
| Cardiac disorder's, overall                                                 | 5              | (2.3)          | 8              | 9             | (4.1)         | 12            | 14            | (3.2)         | 20            |
| Ear and labyrinthdisorders,overall                                          | 4              | (6:1)          | 5              | 7             | (3.2)         | 7             | 11            | (2.5)         | 12            |
| Blood and lymphaticsystem disorders, overall                                | 5              | (2.3)          | 7              | 4             | (1.8)         | 6             | 9             | (2.1)         | 13            |
| Hepatobiliary disorders, overall                                            | 5              | (2.3)          | 6              | 4             | (1.8)         | 4             | 9             | (2.1)         | 10            |
| Skin and subcutaneous tissue disorders, overall                             | 2              | (0.9)          | 2              | 6             | (2.8)         | 7             | 8             | (1.8)         | 9             |

Ev = number of TEAEs of specified adverse event type, MedDRA = medical dictionary for regulatory activities,

N = total number of patients, n = number of patients with at least 1 AE of specified AE type, SAF = safety analysis set,TEAE =treatment-emergent adverse event

Source:Table14.3.2.2.2

Overall, there were no clinically relevant differences in TEAEs between the two treatment groups until Week 56: 498 events were reported in 165 (76.7%) patients treated with FYB203 versus 536 events in 158 (72.5%) patients treated with Eylea. The most commonly affected SOCs in both treatment groups in at least 2.0% of patients in the SAF were Eye disorders (see below for more details) and Infections and infestations (COVID-19). Slight imbalances in frequencies of TEAEs by SOC or PT have been reported (e.g., for PT conjunctival haemorrhage (FYB203 vs. Eylea: 5 (2.3%) subjects vs. 14 (6.4%) subjects). However, also considering relationship to study treatment and/or procedure, no safety concerns are

<div style=\"page-break-after: always\"></div>

raised based on these imbalances. There were no clinically relevant differences between both treatment groups. No new or unknown TEAEs for the class of drug were identified.

Table 30: Frequency of treatment-emergency adverse events by maximum intensity (SAF, N-433)

| Maximum Intensity   | FYB203 N=215   | FYB203 N=215   | Eylea N=218   | Eylea N=218   | Total N=433   | Total N=433   |
|---------------------|----------------|----------------|---------------|---------------|---------------|---------------|
|                     | n              | (%)            | N             | (%)           |               | (%)           |
| AnyTEAE             | 165            | (76.7)         | 158           | (72.5)        | 323           | (74.6)        |
| Mild                | 96             | (44.7)         | 85            | (39.0)        | 181           | (41.8)        |
| Moderate            | 59             | (27.4)         | 58            | (26.6)        | 117           | (27.0)        |
| Severe              | 10             | (4.7)          | 15            | (6.9)         | 25            | (5.8)         |

N = total number of patients in analysis set, n =number of patients with at least 1 adverse event in corresponding class, SAF = safety analysis set, TEAE = treatment-emergent adverse event,

Source:Table14.3.2.2.5

The SOC Eye disorders included total 7 events in 6 (1.4%) patients (Table 34 below). In the FYB203 group, PT Iridocyclitis was recorded in 1 (0.5%) patient, PT Retinal pigment epithelial tear was recorded in 1 (0.5%) patient and PT Uveitis was recorded in 1 (0.5%) patient. All 3 PTs were observed in the study eye and were probably related to study treatment. PT Iridocyclitis and PT Uveitis were listed as SAEs. Additionally, PT Cerebrovascular accident under SOC Nervous system disorders was reported as possibly  related  to  study  treatment.  In  the  Eylea  group,  PT  Neovascular  age-related  macular degeneration was reported for 2 (0.9%) patients, PT Glaucoma was reported for 1 (0.5%) patient and PT  Macular  degeneration  in  1  (0.5%)  patient.  All  3  PTs  were  observed  in  the  fellow  eye  and  were unrelated to study treatment. The PT Neovascular age-related macular degeneration in the fellow eye was listed as an SAE.

Other severe TEAEs until Week 56 were reported in the SOC Infections and infestations:4 (1.9%) patients treated with FYB203 and 1 (0.5%) patient treated with Eylea; SOC Neoplasms benign, malignant and unspecified:  3  (1.4%)  patients  treated  with  FYB203  and  2  (0.9%)  patients  treated  with  Eylea;  SOC Cardiac disorders: 1 (0.5%) patient treated with FYB203 and 2 (0.9%) patients treated with Eylea; SOC Nervous system disorders: 1 (0.5%) patient treated with FYB203 and 2 (0.9%) patients treated Eylea. PTs under other SOCs occurred mostly in single patients in either of the 2 treatment groups.

<div style=\"page-break-after: always\"></div>

Table 31: Frequency of severe treatment-emergent adverse events (SAF, N=433)

| SystemOrganClass Preferred Term (MedDRA 23.0Mixed)                           | FYB203 N=215   | FYB203 N=215   | FYB203 N=215   | Eylea N=218 Ev   | Eylea N=218 Ev   | Eylea N=218 Ev   | Total N=433   | Total N=433   |
|------------------------------------------------------------------------------|----------------|----------------|----------------|------------------|------------------|------------------|---------------|---------------|
|                                                                              |                | (%)            | Ev             |                  | (%)              | n                | (%)           | Ev            |
| Severe TEAEs                                                                 |                |                |                |                  |                  |                  |               |               |
| Any                                                                          | 10             | (4.7)          | 23             | 15               | (6.9) 20         | 25               | (5.8)         | 43            |
| Eye disorder's, overall                                                      | 2              | (0.9)          | 3              | 4 (1.8)          | 4                | 6                | (1.4)         | 7             |
| Neovascular age-related macular                                              | 0              | (0.0)          | 0              | 2                | (0.9) 2          | 2                | (0.5)         | 2             |
| degeneration                                                                 |                |                |                |                  |                  |                  |               |               |
| Glaucoma                                                                     | 0              | (0.0)          | 0              | 1                | (0.5) 1          | 1                | (0.2)         | 1             |
| Iridocyclitis                                                                | 1              | (0.5)          | 1              | 0                | (0.0) 0          | 1                | (0.2)         | 1             |
| Macular degeneration                                                         | 0              | (0.0)          | 0              | 1                | (0.5) 1          | 1                | (0.2)         | 1             |
| Retinal pigment epithelial tear                                              | 1              | (0.5)          | 1              | 0 0              | (0.0) 0          | 1                | (0.2)         | 1             |
| Uveitis                                                                      | 1              | (0.5)          | 1              | (0.0) (0.5)      | 0                | 1                | (0.2)         | 1             |
| Infections and infestations,overall                                          | 4              | (1.9)          | 7              | 1                | 1                | 5                | (1.2)         | 8             |
| COVID-19                                                                     |                | (0.9)          | 2              | 0                | (0.0) 0          | 2                | (0.5)         | 2             |
| Appendicitis                                                                 | 0              | (0.0)          | 0              | 1                | (0.5) 1          | 1                | (0.2)         | 1             |
| COVID-19 pneumonia                                                           | 1              | (0.5)          | 1              | 0                | (0.0) 0          | 1                | (0.2)         | 1             |
| Coronavirusinfection                                                         | 1              | (0.5)          | 1              | 0                | (0.0) 0          | 1                | (0.2)         | 1             |
| Gallbladder empyema                                                          | 1              | (0.5)          | 1              | 0                | (0.0) 0          | 1                | (0.2)         | 1             |
| Toxic shock syndrome                                                         | 1              | (0.5)          | 1              | 0                | (0.0) 0          |                  | 1 (0.2)       | 1             |
| Urosepsis                                                                    | 1              | (0.5)          | 1              | 0                | 0                | 1                | (0.2)         | 1             |
| Neoplasms benign, malignant and umspecified (incl cysts and polyps), overall | 3              | (1.4)          | 3              | (0.0) 2 (0.9)    | 3                | 5                | (1.2)         | 6             |
| Acutemyeloid1eukaemia                                                        | 1              | (0.5)          | 1              | 0                | (0.0) 0          | 1                | (0.2)         | 1             |
| Adenocarcinoma gastric                                                       | 0              | (0.0)          | 0              | 1 (0.5)          | 1                | 1                | (0.2)         |               |

<div style=\"page-break-after: always\"></div>

| SystemOrgan Class Preferred Term (MedDRA 23.0 Mixed)   | FYB203 N=215   | FYB203 N=215   | FYB203 N=215   | Eylea N=218   | Eylea N=218   | Total N=433   |    |
|--------------------------------------------------------|----------------|----------------|----------------|---------------|---------------|---------------|----|
|                                                        | (%)            | Ev             |                | (%)           | Ev            | (%)           | Ev |
| Adenocarcinoma of colon                                | 1 (0.5)        | 1              | 0              | (0.0)         | 0             | 1 (0.2)       | 1  |
| Gallbladder cancer                                     | 0 (0.0)        | 0              | 1              | (0.5)         | 2             | 1 (0.2)       | 2  |
| Oesophageal carcinoma stage 0                          | 1 (0.5)        | 1              | 0              | (0.0)         | 0             | 1 (0.2)       | 1  |
| Cardiac disorders, overall                             | 1 (0.5)        | 1              | 2              | (0.9)         | 2             | 3 (0.7)       | 3  |
| Cardiac failure                                        | 1 (0.5)        | 1              | 1              | (0.5)         | 1             | 2 (0.5)       | 2  |
| Angina pectoris                                        | 0 (0.0)        | 0              | 1              | (0.5)         | 1             | 1 (0.2)       | 1  |
| Nervous system disorders, overall                      | 1 (0.5)        | 1              | 2              | (0.9)         | 2             | 3 (0.7)       | 3  |
| Cerebrovascular accident                               | 1 (0.5)        | 1              | 0              | (0.0)         | 0             | 1 (0.2)       | 1  |
| Dementia                                               | 0 (0.0)        | 0              | 1              | (0.5)         | 1             | 1 (0.2)       | 1  |
| Transient ischaemic attack                             | 0 (0.0)        | 0              | 1              | (0.5)         | 1             | 1 (0.2)       | 1  |
| Musculoskeletal andconnectivetissue                    | 0 (0.0)        | 0              | 2              | (0.9)         | 2             | 2 (0.5)       | 2  |
| disorder's, overall                                    |                |                |                |               |               |               |    |
| Back pain                                              | 0 (0.0)        | 0              | 1              | (0.5)         | 1             | 1 (0.2)       | 1  |
| Rheumatoid arthritis                                   | 0 (0.0)        | 0              | 1              | (0.5)         | 1             | 1 (0.2)       | 1  |
| Respiratory, thoracic and mediastinal                  | 2 (0.9)        | 2              | 0              | (0.0)         | 0             | 2 (0.5)       | 2  |
| disorders, overall                                     |                |                |                |               |               |               |    |
| Aspiration                                             | 1 (0.5)        | 1              | 0              | (0.0)         | 0             | 1 (0.2)       | 1  |
| Pulmonary fibrosis                                     | 1 (0.5)        | 1              | 0              | (0.0)         | 0             | 1 (0.2)       | 1  |
| Blood and lymphatic system disorders,                  | 0 (0.0)        | 0              | 1              | (0.5)         | 2             | 1 (0.2)       | 2  |
| overall                                                |                |                |                |               |               |               |    |
| Anaemia                                                | 0 (0.0)        | 0              | 1              | (0.5)         | 1             | 1 (0.2)       | 1  |
| Iron deficiency anaemia                                | 0 (0.0)        | 0              | 1              | (0.5)         | 1             | 1 (0.2)       | 1  |
| Gastrointestinal disorders,overall                     | 1 (0.5)        | 2              | 0              | (0.0)         | 0             | 1 (0.2)       | 2  |
| Abdominal adhesions                                    | 1 (0.5)        | 1              | 0              | (0.0)         | 0             | 1 (0.2)       | 1  |
| Ileus                                                  | 1 (0.5)        | 1              | 0              | (0.0)         | 0             | 1 (0.2)       | 1  |
| Hepatobiliary disorders, overall                       | 1 (0.5)        | 2              | 0              | (0.0)         | 0             | 1 (0.2)       | 2  |
| Gallbladder disorder                                   | 1 (0.5)        | 2              | 0              | (0.0)         | 0             | 1 (0.2)       | 2  |
| Injury, poisoning and procedural                       | 0 (0.0)        | 0              | 1              | (0.5)         | 1             | 1 (0.2)       | 1  |
| complications, overall Radiusfracture                  | 0 (0.0)        | 0              | 1              | (0.5)         | 1             | 1 (0.2)       | 1  |
| Metabolism and nutrition disorders, overall            | 0 (0.0)        | 0              | 1              | (0.5)         | 1             | 1 (0.2)       | 1  |
| Diabetic metabolic decompensation                      | 0 (0.0)        | 0              | 1              | (0.5)         | 1             | 1 (0.2)       | 1  |
| Renal and urinary disorders, overall                   | 1 (0.5)        | 2              | 0              | (0.0)         | 0             | 1 (0.2)       | 2  |
| Calculus urinary                                       | 1 (0.5)        | 1              | 0              | (0.0)         | 0             | 1 (0.2)       | 1  |
| Renal failure                                          | 1 (0.5)        | 1              | 0              | (0.0)         | 0             | 1 (0.2)       | 1  |
| Surgical and medicalprocedures,overall                 | 0 (0.0)        | 0              | 1              | (0.5)         | 1             | 1 (0.2)       | 1  |
| Chemotherapy                                           | 0 (0.0)        | 0              |                | 1             | 1             | 1 (0.2) 1     | 1  |
| Vascular disorder's,overall                            | 0 (0.0)        | 0 0            | 1              | (0.5)         | 1             |               | 1  |
| Aortic aneurysm                                        | 0 (0.0)        |                | 1              | (0.5) (0.5)   | 1             | (0.2) 1 (0.2) |    |

Ev = number of adverse events of the specified preferred term or system organ class, MedDRA = medical dictionary for regulatory activities, N = total number of patients in analysis set, n = number of patients with at least 1 adverse event in corresponding class, SAF = safety analysis set, TEAE =treatment-emergent adverse event

Source:Table 14.3.2.2.11

<div style=\"page-break-after: always\"></div>

Table 32: Frequency of treatment-emergent adverse events related to study treatment (SAF, N=433)

| System Organ Class Preferred Term (MedDRA 23.0 Mixed)        | FYB203 N=215   | FYB203 N=215   | FYB203 N=215   | Eylea N=218   | Eylea N=218   | Eylea N=218   | Total N=433   | Total N=433   |
|--------------------------------------------------------------|----------------|----------------|----------------|---------------|---------------|---------------|---------------|---------------|
|                                                              |                | (%)            | Ev             |               | (%)           | Ev            | (%)           | Ev            |
| Related TEAEs 1                                              |                |                |                |               |               |               |               |               |
| Any                                                          | 20             | (9.3)          | 34             | 16            | (7.3) 32      | 36            | (8.3)         | 66            |
| Eye disorders,overall                                        | 15             | (7.0)          | 23             | 11            | (5.0) 15      | 26            | (6.0)         | 38            |
| Neovascular age-related macular degeneration                 | 6              | (2.8)          | 7              | 3             | (1.4) 4       | 9             | (2.1)         | 11            |
| Retinal pigment epithelial tear                              | 3              | (1.4)          | 3              | 1             | 1             | 4             | (0.9)         | 4             |
| Eye pain                                                     | 3              | (1.4)          | 3              | (0.5) 0 (0.0) | 0             | 3             | (0.7)         | 3             |
| Iritis                                                       | 1              | (0.5)          | 1              | 2 (0.9)       | 3             | 3             | (0.7)         | 4             |
| Vitritis                                                     | 1              | (0.5)          | 1              | 1 (0.5)       | 1             |               | (0.5)         | 7             |
| Conjunctival haemorrhage                                     | 0              | (0.0)          | 0              | 1 (0.5)       | 1             |               | (0.2)         | 1             |
| Iridocyclitis                                                | 1              | (0.5)          | 2              | 0 (0.0)       | 0             | 1             | (0.2)         | 乙             |
| Lacrimation increased                                        | 1              | (0.5)          | 1              | 0 (0.0)       | 0             | 1             | (0.2)         | 1             |
| Macular degeneration                                         | 0              | (0.0)          | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Retinal depigmentation                                       | 0              | (0.0)          | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Retinal disorder                                             | 0              | (0.0)          | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Retinal haemorrhage                                          | 0              | (0.0)          | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Scleralhaemorrhage                                           | 0              | (0.0)          | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Subretinal fibrosis                                          | 1              | (0.5)          | 1              | 0 (0.0)       | 0             | 1             | (0.2)         | 1             |
| Subretinal fluid                                             | 1              | (0.5)          | 1              | 0 (0.0)       | 0             | 1             | (0.2)         | 1             |
| Uveitis                                                      | 1              | (0.5)          | 2              | 0 (0.0)       | 0             | 1             | (0.2)         | 2             |
| Vitreous floaters                                            | 1              | (0.5)          | 1              | 0 (0.0)       | 0             | 1             | (0.2)         | 1             |
| Investigations, overall                                      | 1              | (0.5)          | 2              | 6 (2.8)       | 14            | 7             | (1.6)         | 16            |
| Intraocular pressure increased                               | 1              | (0.5)          | 2              | 5 (2.3)       | 12            | 6             | (1.4)         | 14            |
| Blood alkaline phosphatase increased                         | 0              | (0.0)          | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Gamma-glutamyltransferase increased                          | 0              | (0.0)          | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Nervous system disorders, overall                            | 3              | (1.4)          | 4              | 0 (0.0)       | 0             | 3             | (0.7)         | 4             |
| Headache                                                     | 2              | (0.9)          | 2              | 0 (0.0)       | 0             | 2             | (0.5)         | 7             |
| Cerebrovascular accident                                     | 1              | (0.5)          | 1              | 0 (0.0)       | 0             | 1             | (0.2)         | 1             |
| Somnolence                                                   | 1              | (0.5)          | 1              | 0 (0.0)       | 0             | 1             | (0.2)         | 1             |
| Vascular disorder's,overall                                  | 1              | (0.5)          | 1              | 1 (0.5)       | 1             | 2             | (0.5)         | 乙             |
| Hypertension                                                 | 1              | (0.5)          | 1              | 1 (0.5)       | 1             | 2             | (0.5)         | 乙             |
| Blood and lymphatic system disorders, overall                | 1              | (0.5)          | 1              | 0 (0.0)       | 0             | 1             | (0.2)         | 1             |
| Anaemia                                                      | 1              | (0.5)          | 1              | 0 (0.0)       | 0             | 1             | (0.2)         | 1             |
| Ear and labyrinth disorders, overall                         | 0              | (0.0)          | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Deafness neurosensory                                        | 0              | (0.0)          | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| General disorders and administrationsite conditions, overall | 1              | (0.5)          | 1              | 0 (0.0)       | 0             | 1             | (0.2)         | 1             |
| Asthenia                                                     | 1              | (0.5)          | 1              | 0 (0.0)       | 0             | 1             | (0.2)         | 1             |
| Infections and infestations, overall                         | 0              | (0.0)          | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Conjunctivitis                                               | 0              | (0.0)          | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Injury, poisoning and procedural complications, overall      | 1              | (0.5)          | 2              | 0 (0.0)       | 0             | 1             | (0.2)         | 2             |
|                                                              | 1              | (0.5)          | 2              | 0             | 0             | 1             |               | 2             |
| Intraocular injection complication                           |                |                |                | (0.0)         |               |               | (0.2)         |               |

A total of 36 (8.3%) patients experienced 66 TEAEs related to the study treatment. The occurrences of related  TEAEs were similar in both treatment groups: 34 events in 20 (9.3%) patients treated with FYB203 and 32 events in 16 (7.3%) patients treated with Eylea.

<div style=\"page-break-after: always\"></div>

Table 33: Frequency of treatment-emergent adverse events related to study procedure (IVT injection) (SAF, N=433)

| SystemOrganClass Preferred Term (MedDRA 23.0Mixed)   | FYB203 N=215   | FYB203 N=215   | FYB203 N=215   | Eylea N=218   | Eylea N=218   | Eylea N=218   | Total N=433   | Total N=433   | Total N=433   |
|------------------------------------------------------|----------------|----------------|----------------|---------------|---------------|---------------|---------------|---------------|---------------|
|                                                      | n              | (%)            | Ev             | N             | (%)           | Ev            | n             | (%)           | Ev            |
| AnyRelated TEAEs                                     | 28             | (13.0)         | 55             | 37            | (17.0)        | 93            | 65            | (15.0)        | 148           |
| Eye disorders, overall                               | 23             | (10.7)         | 38             | 31            | (14.2)        | 59            | 54            | (12.5)        | 97            |
| Conjunctival haemorrhage                             | 4              | (1.9)          | 4              | 14            | (6.4)         | 24            | 18            | (4.2)         | 28            |
| Eye pain                                             | 4              | (1.9)          | 4              | 5             | (2.3)         | 8             | 9             | (2.1)         | 12            |
| Visionblurred                                        | 5              | (2.3)          | 5              | 0             | (0.0)         | 0             | 5             | (1.2)         | 5             |
| Neovascular age-related macular                      | 2              | (0.9)          | 3              | 2             | (0.9)         | 3             | 4             | (0.9)         | 6             |
| degeneration Iritis                                  | 1              | (0.5)          | 1              | 2             | (0.9)         | 3             | 3             | (0.7)         | 4             |
| Punctatekeratitis                                    | 1              | (0.5)          | 1              | 2             | (0.9)         | 4             | 3             | (0.7)         | 5             |
| Swelling of eyelid                                   | 0              | (0.0)          | 0              | 3             | (1.4)         | 4             | 3             | (0.7)         | 4             |
| Vitreous floaters                                    | 2              | (0.9)          | 2              | 1             | (0.5)         | 1             | 3             | (0.7)         | 3             |
| Conjunctival hyperaemia                              | 1              | (0.5)          | 1              | 1             | (0.5)         | 1             | 2             | (0.5)         | 2             |
| Iridocyclitis                                        | 1              | (0.5)          | 2              | 1             | (0.5)         | 1             | 2             | (0.5)         | 3             |

| System Organ Class Preferred Term (MedDRA 23.0Mixed)   | FYB203 N=215   | FYB203 N=215   | Eylea N=218   | Eylea N=218   | Total N=433   | Total N=433   | Total N=433   |
|--------------------------------------------------------|----------------|----------------|---------------|---------------|---------------|---------------|---------------|
|                                                        | (%)            | Ev             | N (%)         | Ev            | n             | (%)           | Ev            |
| Lacrimation increased                                  | 1 (0.5)        | 1              | 1 (0.5)       | 1             | 2             | (0.5)         | 2             |
| Photophobia                                            | 1 (0.5)        | 1              | 1 (0.5)       | 3             | 2             | (0.5)         | 4             |
| Visual impairment                                      | 0 (0.0)        | 0              | 2 (0.9)       | 2             | 2             | (0.5)         | 2             |
| Vitritis                                               | 1 (0.5)        | 1              | 1 (0.5)       | 1             | 乙             | (0.5)         | 2             |
| Cataract subcapsular                                   | 1 (0.5)        | 1              | 0 (0.0)       | 0             | 1             | (0.2)         | 1             |
| Conjunctival suffusion                                 | 1 (0.5)        | 1              | 0 (0.0)       | 0             | 1             | (0.2)         | 1             |
| Eye irritation                                         | 0 (0.0)        | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Foreign body sensation in eyes                         | 0 (0.0)        | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Macularhole                                            | 1 (0.5)        | 1              | 0 (0.0)       | 0             |               | (0.2)         | 1             |
| Ocular hypertension                                    | 1 (0.5)        | 2              | 0 (0.0)       | 0             | 1             | (0.2)         | 2             |
| Photopsia                                              | 1 (0.5)        | 1              | 0 (0.0)       | 0             | 1             | (0.2)         | 1             |
| Rhegmatogenous retinal detachment                      | 1 (0.5)        | 3              | 0 (0.0)       | 0             | 1             | (0.2)         | 3             |
| Scleral haemorrhage                                    | 0 (0.0)        | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Uveitis                                                | 1 (0.5)        | 2              | 0 (0.0) 0     | 0             | 1             | (0.2)         | 2             |
| Vitreous detachment                                    | 1 (0.5)        | 1              | (0.0)         | 0             | 1             | (0.2)         | 1             |
| Investigations, overall                                | 6 (2.8)        | 8              | 8 (3.7)       | 22            | 14            | (3.2)         | 30            |
| Intraocular pressure increased                         | 6 (2.8)        | 8              | 8 (3.7)       | 22            | 14            | (3.2)         | 30            |
| Generaldisorder'sandadministration                     | 1 (0.5)        | 3              | 4 (1.8)       | 4             | 5             | (1.2)         | 7             |
| siteconditions,overall                                 |                |                |               |               |               |               |               |
| Sensationofforeignbody                                 | 0 (0.0)        | 0              | 3 (1.4)       | 3             | 3             | (0.7)         | 3             |
| Injection sitepain                                     | 1 (0.5)        | 3              | 1 (0.5)       | 1             | 2             | (0.5)         | 4             |
| Nervous system disorders, overall                      | 3 (1.4)        | 3              | 2 (0.9)       | 4             | 5             | (1.2)         | 7             |
| Headache                                               | 乙 (0.9)        | 2              | 2 (0.9)       | 4             | 4             | (0.9)         | 6             |
| Somnolence                                             | 1 (0.5)        | 1              | 0 (0.0)       | 0             | 1             | (0.2)         | 1             |
| Injury, poisoning and procedural                       | 1 (0.5)        | 2              | 2 (0.9)       | 2             | 3             | (0.7)         | 4             |
| complications, overall                                 |                |                |               |               |               |               |               |
| Intraocular injection complication                     | 1 (0.5)        | 2              | 2 (0.9)       | 2             | 3             | (0.7)         | 4             |
| Infectionsandinfestations,overall                      | 0 (0.0)        | 0              | 2 (0.9)       | 2             | 2             | (0.5)         | 2             |
| Conjunctivitis                                         | 0 (0.0)        | 0              | 2 (0.9)       | 2             | 2             | (0.5)         | 2             |
| Musculoskeletaland connective tissue                   | 1 (0.5)        | 1              | 0 (0.0)       | 0             | 1             | (0.2)         | 1             |
| disorders, overall                                     |                |                |               |               |               |               |               |
| Pain in extremity                                      | 1 (0.5)        | 1              | 0 (0.0)       | 0             | 1             | (0.2)         | 1             |

1 Related TEAEs are all TEAEs which are \"probably\" or \"possibly\" related to study procedure or relationship is unknown or missing

Ev = number of adverse events of specified preferred term or system organ class, MedDRA = medical dictionary forregulatory activities,N=totalnumber ofpatientsinanalysisset,n=number ofpatientswithatleast 1 adverse event in corresponding class, SAF = safety analysis set, TEAE = treatment-emergent adverse event

Source:Table 14.3.2.2.31

The number and percentage of patients with TEAEs related to the study procedure until Week 56 were similar in both treatment groups, with 55 events in 28 (13.0%) patients treated with FYB203 versus 93 events in 37 (17.0%) patients treated with Eylea.

Most frequently, the TEAEs with a relation to study procedure belonged to the SOC Eye disorders. The most frequently reported PT was Conjunctival haemorrhage: 4 events in 4 (1.9%) patients treated with FYB203 versus 24 events in 14 (6.4%) patients treated with Eylea. All cases of conjunctival haemorrhage in the study eye were considered probably related to study procedure. All events were of mild severity and recovered/resolved. Therefore, no issues are raised. The second most frequently reported PT was

<div style=\"page-break-after: always\"></div>

Eye pain: 4 events in 4 (1.9%) patients treated with FYB203 and 8 events in 5 (2.3%) patients treated with Eylea. Other PTs under the SOC Eye disorders occurred mostly in single patients.

A notable PT related to study procedure was IOP increased, which was recorded with 8 events in 6 (2.8%) FYB203 treated patients versus 22 events in 8 (3.7%) patients treated with Eylea.

Table 34: frequency of local (ocular, study eye) treatment-emergent adverse events in ≥ 1.0% of patients in either of the treatment groups (SAF, N=433)

| SystemOrganClass PreferredTerm(MedDRA23.0Mixed)                                                                                                                                                                    | FYB203 N=215                                                                                                                                                                                                       |                                                                                                                                                                                                                    | Eylea N=218                                                                                                                                                                                                        | Eylea N=218                                                                                                                                                                                                        | Eylea N=218                                                                                                                                                                                                        | Total N=433                                                                                                                                                                                                        | Total N=433                                                                                                                                                                                                        | Total N=433                                                                                                                                                                                                        |                                                                                                                                                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                    | (%)                                                                                                                                                                                                                | Ev                                                                                                                                                                                                                 | n                                                                                                                                                                                                                  | (%)                                                                                                                                                                                                                | Ev                                                                                                                                                                                                                 | n                                                                                                                                                                                                                  | (%)                                                                                                                                                                                                                | Ev                                                                                                                                                                                                                 |                                                                                                                                                                                                                    |
| Anylocal(ocular)TEAE instudyeye                                                                                                                                                                                    | 67 (31.2)                                                                                                                                                                                                          | 125                                                                                                                                                                                                                | 75                                                                                                                                                                                                                 | (34.4)                                                                                                                                                                                                             | 157                                                                                                                                                                                                                | 142                                                                                                                                                                                                                | (32.8)                                                                                                                                                                                                             | 282                                                                                                                                                                                                                |                                                                                                                                                                                                                    |
| Eye disorders,overall                                                                                                                                                                                              | 60 (27.9)                                                                                                                                                                                                          | 103                                                                                                                                                                                                                | 66                                                                                                                                                                                                                 | (30.3)                                                                                                                                                                                                             | 116                                                                                                                                                                                                                | 126                                                                                                                                                                                                                | (29.1)                                                                                                                                                                                                             | 219                                                                                                                                                                                                                |                                                                                                                                                                                                                    |
| Conjunctival haemorrhage                                                                                                                                                                                           | 4 (1.9)                                                                                                                                                                                                            | 4                                                                                                                                                                                                                  | 14                                                                                                                                                                                                                 | (6.4)                                                                                                                                                                                                              | 24                                                                                                                                                                                                                 | 18                                                                                                                                                                                                                 | (4.2)                                                                                                                                                                                                              | 28                                                                                                                                                                                                                 |                                                                                                                                                                                                                    |
| Cataract                                                                                                                                                                                                           | 8 (3.7)                                                                                                                                                                                                            | 9                                                                                                                                                                                                                  | 7                                                                                                                                                                                                                  | (3.2)                                                                                                                                                                                                              | 7                                                                                                                                                                                                                  | 15                                                                                                                                                                                                                 | (3.5)                                                                                                                                                                                                              | 16                                                                                                                                                                                                                 |                                                                                                                                                                                                                    |
| Neovascularage-relatedmaculardegeneration                                                                                                                                                                          | 7 (3.3)                                                                                                                                                                                                            | 9                                                                                                                                                                                                                  | 7                                                                                                                                                                                                                  | (3.2)                                                                                                                                                                                                              | 9                                                                                                                                                                                                                  | 14                                                                                                                                                                                                                 | (3.2)                                                                                                                                                                                                              | 18                                                                                                                                                                                                                 |                                                                                                                                                                                                                    |
| Eye pain                                                                                                                                                                                                           | 6 (2.8)                                                                                                                                                                                                            | 6                                                                                                                                                                                                                  | 6                                                                                                                                                                                                                  | (2.8)                                                                                                                                                                                                              | 9                                                                                                                                                                                                                  | 12                                                                                                                                                                                                                 | (2.8)                                                                                                                                                                                                              | 15                                                                                                                                                                                                                 |                                                                                                                                                                                                                    |
| Visual acuity reduced                                                                                                                                                                                              | 7 (3.3)                                                                                                                                                                                                            | 7                                                                                                                                                                                                                  | 4                                                                                                                                                                                                                  | (1.8)                                                                                                                                                                                                              | 4                                                                                                                                                                                                                  | 11                                                                                                                                                                                                                 | (2.5)                                                                                                                                                                                                              | 11                                                                                                                                                                                                                 |                                                                                                                                                                                                                    |
| Visionblurred                                                                                                                                                                                                      | 6 (2.8)                                                                                                                                                                                                            | 6                                                                                                                                                                                                                  | 3                                                                                                                                                                                                                  | (1.4)                                                                                                                                                                                                              | 3                                                                                                                                                                                                                  | 9                                                                                                                                                                                                                  | (2.1)                                                                                                                                                                                                              | 9                                                                                                                                                                                                                  |                                                                                                                                                                                                                    |
| Visualimpairment                                                                                                                                                                                                   | 3 (1.4)                                                                                                                                                                                                            | 3                                                                                                                                                                                                                  | 5                                                                                                                                                                                                                  | (2.3)                                                                                                                                                                                                              | 5                                                                                                                                                                                                                  | 8                                                                                                                                                                                                                  | (1.8)                                                                                                                                                                                                              | 8                                                                                                                                                                                                                  |                                                                                                                                                                                                                    |
| Retinal pigment epithelial tear                                                                                                                                                                                    | 4 (1.9)                                                                                                                                                                                                            | 4                                                                                                                                                                                                                  | 2                                                                                                                                                                                                                  | (0.9)                                                                                                                                                                                                              | 2                                                                                                                                                                                                                  | 6                                                                                                                                                                                                                  | (1.4)                                                                                                                                                                                                              | 6                                                                                                                                                                                                                  |                                                                                                                                                                                                                    |
| Retinal haemorrhage                                                                                                                                                                                                | 3 (1.4)                                                                                                                                                                                                            | 3                                                                                                                                                                                                                  | 2                                                                                                                                                                                                                  | (0.9)                                                                                                                                                                                                              | 2                                                                                                                                                                                                                  | 5                                                                                                                                                                                                                  | (1.2)                                                                                                                                                                                                              | 5                                                                                                                                                                                                                  |                                                                                                                                                                                                                    |
| Iritis                                                                                                                                                                                                             | 1 (0.5)                                                                                                                                                                                                            | 1                                                                                                                                                                                                                  | 3                                                                                                                                                                                                                  | (1.4)                                                                                                                                                                                                              | 4                                                                                                                                                                                                                  | 4                                                                                                                                                                                                                  | (0.9)                                                                                                                                                                                                              | 5                                                                                                                                                                                                                  |                                                                                                                                                                                                                    |
| Macular fibrosis                                                                                                                                                                                                   | 3 (1.4)                                                                                                                                                                                                            | 3                                                                                                                                                                                                                  | 1                                                                                                                                                                                                                  | (0.5)                                                                                                                                                                                                              | 1                                                                                                                                                                                                                  | 4                                                                                                                                                                                                                  | (0.9)                                                                                                                                                                                                              | 4                                                                                                                                                                                                                  |                                                                                                                                                                                                                    |
| Swelling of eyelid                                                                                                                                                                                                 | 0 (0.0)                                                                                                                                                                                                            | 0                                                                                                                                                                                                                  | 4                                                                                                                                                                                                                  | (1.8)                                                                                                                                                                                                              | 5                                                                                                                                                                                                                  | 4                                                                                                                                                                                                                  | (0.9)                                                                                                                                                                                                              | 5                                                                                                                                                                                                                  |                                                                                                                                                                                                                    |
| Vitreous detachment                                                                                                                                                                                                | 3 (1.4)                                                                                                                                                                                                            | 3                                                                                                                                                                                                                  | 1                                                                                                                                                                                                                  | (0.5)                                                                                                                                                                                                              | 1                                                                                                                                                                                                                  | 4                                                                                                                                                                                                                  | (0.9)                                                                                                                                                                                                              | 4                                                                                                                                                                                                                  |                                                                                                                                                                                                                    |
| Vitreous floaters                                                                                                                                                                                                  | 3 (1.4)                                                                                                                                                                                                            | 3                                                                                                                                                                                                                  | 1                                                                                                                                                                                                                  | (0.5)                                                                                                                                                                                                              | 1                                                                                                                                                                                                                  | 4                                                                                                                                                                                                                  | (0.9)                                                                                                                                                                                                              | 4                                                                                                                                                                                                                  |                                                                                                                                                                                                                    |
| Photopsia                                                                                                                                                                                                          | 3 (1.4)                                                                                                                                                                                                            | 3                                                                                                                                                                                                                  | 0                                                                                                                                                                                                                  | (0.0)                                                                                                                                                                                                              | 0                                                                                                                                                                                                                  | 3                                                                                                                                                                                                                  | (0.7)                                                                                                                                                                                                              | 3                                                                                                                                                                                                                  |                                                                                                                                                                                                                    |
| Subretinal fluid                                                                                                                                                                                                   | 3 (1.4)                                                                                                                                                                                                            | 3                                                                                                                                                                                                                  | 0                                                                                                                                                                                                                  | (0.0)                                                                                                                                                                                                              | 0                                                                                                                                                                                                                  | 3                                                                                                                                                                                                                  | (0.7)                                                                                                                                                                                                              | 3                                                                                                                                                                                                                  |                                                                                                                                                                                                                    |
| Vitreoretinal traction syndrome                                                                                                                                                                                    | 3 (1.4)                                                                                                                                                                                                            | 3                                                                                                                                                                                                                  | 0                                                                                                                                                                                                                  | (0.0)                                                                                                                                                                                                              | 0                                                                                                                                                                                                                  | 3                                                                                                                                                                                                                  | (0.7)                                                                                                                                                                                                              | 3                                                                                                                                                                                                                  |                                                                                                                                                                                                                    |
| Investigations, overall                                                                                                                                                                                            | 7 (3.3)                                                                                                                                                                                                            | 9                                                                                                                                                                                                                  | 9                                                                                                                                                                                                                  | (4.1)                                                                                                                                                                                                              | 25                                                                                                                                                                                                                 | 16                                                                                                                                                                                                                 | (3.7)                                                                                                                                                                                                              | 34                                                                                                                                                                                                                 |                                                                                                                                                                                                                    |
| Intraocular pressure increased                                                                                                                                                                                     | 7 (3.3)                                                                                                                                                                                                            | 9                                                                                                                                                                                                                  | 9                                                                                                                                                                                                                  | (4.1)                                                                                                                                                                                                              | 25                                                                                                                                                                                                                 | 16                                                                                                                                                                                                                 | (3.7)                                                                                                                                                                                                              | 34                                                                                                                                                                                                                 |                                                                                                                                                                                                                    |
| Infections and infestations, overall                                                                                                                                                                               | 5 (2.3)                                                                                                                                                                                                            | 6                                                                                                                                                                                                                  | 7                                                                                                                                                                                                                  | (3.2)                                                                                                                                                                                                              | 7                                                                                                                                                                                                                  | 12                                                                                                                                                                                                                 | (2.8)                                                                                                                                                                                                              | 13                                                                                                                                                                                                                 |                                                                                                                                                                                                                    |
| Conjunctivitis                                                                                                                                                                                                     | 5 (2.3)                                                                                                                                                                                                            | 6                                                                                                                                                                                                                  | 6                                                                                                                                                                                                                  | (2.8)                                                                                                                                                                                                              | 6                                                                                                                                                                                                                  | 11                                                                                                                                                                                                                 | (2.5)                                                                                                                                                                                                              | 12                                                                                                                                                                                                                 |                                                                                                                                                                                                                    |
| Injury, poisoning and procedural complications, overall                                                                                                                                                            | 3 (1.4)                                                                                                                                                                                                            | 4                                                                                                                                                                                                                  | 3                                                                                                                                                                                                                  | (1.4)                                                                                                                                                                                                              | 3                                                                                                                                                                                                                  | 6                                                                                                                                                                                                                  | (1.4)                                                                                                                                                                                                              | 7                                                                                                                                                                                                                  |                                                                                                                                                                                                                    |
| Generaldisordersandadministrationsite conditions,overall                                                                                                                                                           | 1 (0.5)                                                                                                                                                                                                            | 3                                                                                                                                                                                                                  | 4                                                                                                                                                                                                                  | (1.8)                                                                                                                                                                                                              | 4                                                                                                                                                                                                                  | 5                                                                                                                                                                                                                  | (1.2)                                                                                                                                                                                                              | 7                                                                                                                                                                                                                  |                                                                                                                                                                                                                    |
| Sensation of foreign body                                                                                                                                                                                          | 0 (0.0)                                                                                                                                                                                                            | 0                                                                                                                                                                                                                  | 3                                                                                                                                                                                                                  | (1.4)                                                                                                                                                                                                              | 3                                                                                                                                                                                                                  | 3                                                                                                                                                                                                                  | (0.7)                                                                                                                                                                                                              | 3                                                                                                                                                                                                                  |                                                                                                                                                                                                                    |
| Ev = number of TEAEs of specified AE type, MedDRA = medical dictionary for regulatory activities, N = total number ofpatients,n=number ofpatients with at least 1 adverse event of specified AE type, SAF = safety | Ev = number of TEAEs of specified AE type, MedDRA = medical dictionary for regulatory activities, N = total number ofpatients,n=number ofpatients with at least 1 adverse event of specified AE type, SAF = safety | Ev = number of TEAEs of specified AE type, MedDRA = medical dictionary for regulatory activities, N = total number ofpatients,n=number ofpatients with at least 1 adverse event of specified AE type, SAF = safety | Ev = number of TEAEs of specified AE type, MedDRA = medical dictionary for regulatory activities, N = total number ofpatients,n=number ofpatients with at least 1 adverse event of specified AE type, SAF = safety | Ev = number of TEAEs of specified AE type, MedDRA = medical dictionary for regulatory activities, N = total number ofpatients,n=number ofpatients with at least 1 adverse event of specified AE type, SAF = safety | Ev = number of TEAEs of specified AE type, MedDRA = medical dictionary for regulatory activities, N = total number ofpatients,n=number ofpatients with at least 1 adverse event of specified AE type, SAF = safety | Ev = number of TEAEs of specified AE type, MedDRA = medical dictionary for regulatory activities, N = total number ofpatients,n=number ofpatients with at least 1 adverse event of specified AE type, SAF = safety | Ev = number of TEAEs of specified AE type, MedDRA = medical dictionary for regulatory activities, N = total number ofpatients,n=number ofpatients with at least 1 adverse event of specified AE type, SAF = safety | Ev = number of TEAEs of specified AE type, MedDRA = medical dictionary for regulatory activities, N = total number ofpatients,n=number ofpatients with at least 1 adverse event of specified AE type, SAF = safety | Ev = number of TEAEs of specified AE type, MedDRA = medical dictionary for regulatory activities, N = total number ofpatients,n=number ofpatients with at least 1 adverse event of specified AE type, SAF = safety |

analysis set, TEAE = treatment-emergent adverse event

Source: Table 14.3.2.2.15

For local TEAEs (ocular, study eye) until Week 56, the event numbers were comparable with FYB203 and Eylea treatment. Also, they were in line with known undesirable effects of Eylea [Eylea SmPC, 2024; Elyea EPAR, 2024]. 125 events occurred in 67 (31.2%) patients treated with FYB203 versus 157 events in  75  (34.4%) patients treated with Eylea. The most frequent PT under the SOC Eye disorders was Conjunctival haemorrhage with 4 events in 4 (1.9%) patients with FYB203 versus 24 events in 14 (6.4%) patients with Eylea. Other notable PTs included PT Cataract with 9 events in 8 (3.7%) patients with FYB203  versus  7  events  in  7  (3.2%)  patients  with  Eylea  and  PT  Neovascular  age-related  macular degeneration with 9 events in 7 (3.3%) patients with FYB203 versus 9 events in 7 (3.2%) patients with Eylea.  The  events  of  Neovascular  age-related  macular  degeneration  in  the  study  eye  were  mild  or moderate and majority of the outcomes were recorded as resolved and unrelated to study procedure or study treatment. The most frequent PT under the SOC Investigations was IOP increased occurring with 9 events in 7 (3.3%) patients with FYB203 versus 25 events in 9 (4.1%) patients with Eylea.

<div style=\"page-break-after: always\"></div>

Table 35: Frequency of local (ocular, fellow eye) treatment-emergent adverse events (SAF, N=433)

| System Organ Class PreferredTerm(MedDRA23.0Mixed)   | FYB203 N=215   | FYB203 N=215   | FYB203 N=215   | Eylea N=218   | Eylea N=218   | Eylea N=218   | Total N=433   | Total N=433   |
|-----------------------------------------------------|----------------|----------------|----------------|---------------|---------------|---------------|---------------|---------------|
|                                                     |                | (%)            | Ev             | n             | (%)           | Ev            | (%)           | Ev            |
| Any local(ocular) TEAE in fellow eye                | 45             | (20.9)         | 53             | 48            | (22.0)        | 58 93         | (21.5)        | 111           |
| Eye disorders,overall                               | 40             | (18.6)         | 46             | 45            | (20.6)        | 55 85         | (19.6)        | 101           |
| Neovascular age-related macular degeneration        | 22             | (10.2)         | 22             | 24            | (11.0)        | 26 46         | (10.6)        | 48            |
| Cataract                                            | 7              | (3.3)          | 7              | 4             | (1.8) 4       | 11            | (2.5)         | 11            |
| Visual acuity reduced                               | 2              | (0.9)          | 2              | 2             | 2             | 4             | (0.9)         | 4             |
| Age-relatedmaculardegeneration                      | 2              | (0.9)          | 2              | (0.9) 1 (0.5) | 1             | 3             | (0.7)         | 3             |
| Chalazion                                           | 2              | (0.9)          | 2              | 1 (0.5)       | 1             | 3             | (0.7)         | 3             |
| Choroidal neovascularization                        | 1              | (0.5)          | 1              | 2 (0.9)       | 2             | 3             | (0.7)         | 3             |
| Cataract cortical                                   | 1              | (0.5)          | 1              | 1 (0.5)       | 1             | 2             | (0.5)         | 2             |
| Cataract nuclear                                    | 1              | (0.5)          | 1              | 1 (0.5)       | 1             | 2             | (0.5)         | 2             |
| Dry eye                                             | 2              | (0.9)          | 2              | 0 (0.0)       | 0             |               | 2 (0.5)       | 2             |
| Eye pruritus                                        | 1              | (0.5)          | 1              | 1 (0.5)       |               | 1             | 2 (0.5)       | 2             |
| Keratitis                                           | 2              | (0.9)          | 2              | 0 (0.0)       | 0             | 0             | 2 (0.5)       | 2             |
| Blepharitis                                         | 1              | (0.5)          | 1              | 0 (0.0)       |               |               | 1 (0.2)       | 1             |
| Blepharitis allergic                                | 0              | (0.0)          | 0              | 1 (0.5)       |               | 1             | 1 (0.2)       | 1             |
| Conjunctival haemorrhage                            | 1              | (0.5)          | 1              | 0 (0.0)       | 0             | 1             | (0.2)         | 1             |
| Conjunctival suffusion                              | 0              | (0.0)          | 0              | 1 (0.5)       |               | 1             | 1 (0.2)       | 1             |
| Conjunctivitis allergic                             | 0              | (0.0)          | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Detachment of macular retinal pigment epithelium    | 0              | (0.0)          | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Glaucoma                                            | 0              | (0.0)          | 0              | 1 (0.5)       | 2             | 1             | (0.2)         | 2             |
| Lacrimationincreased                                | 0              | (0.0)          | 0              | 1 (0.5)       | 1             |               | 1 (0.2)       | 1             |
| Lens dislocation                                    | 0              | (0.0)          | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Macular degeneration                                | 0              | (0.0)          | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Photopsia                                           | 1              | (0.5)          | 1              | 0 (0.0)       | 0             |               | 1 (0.2)       | 1             |
| Retinal degeneration                                | 0              | (0.0)          | 0              | 1 (0.5)       | 1             |               | 1 (0.2)       | 1             |
| Retinal depigmentation                              | 0              | (0.0)          | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Retinal haemorrhage                                 | 0              | (0.0)          | 0              | 1 (0.5)       |               | 1             | 1 (0.2)       | 1             |
| Retinal pigment epithelial tear                     | 0              | (0.0)          | 0              | 1 (0.5)       | 1             | 1             | (0.2)         |               |
| Vision blurred                                      | 0              | (0.0)          | 0              | 1 (0.5)       |               | 1             | 1 (0.2)       | 1             |
| Vitreous floaters                                   | 0              | (0.0)          | 0              | 1 (0.5)       | 1             | 1             | (0.2)         | 1             |
| Vitreous haemorrhage                                | 0              | (0.0)          | 0              | 1             | (0.5)         | 1             | 1 (0.2)       | 1             |
| Infections and infestations, overall                | 5              | (2.3)          | 5              | 1             | (0.5)         | 1             | 6 (1.4)       | 6             |
| Conjunctivitis                                      | 5              | (2.3)          | 5              | 0             | (0.0)         | 0             | 5 (1.2)       | 5             |
| Conjunctivitis bacterial                            | 0              | (0.0)          |                | 1             | (0.5)         | 1             | (0.2)         | 1             |
| Investigations, overall                             | 乙              |                | 0              |               |               | 1 1           |               |               |
| Intraocular pressure increased                      | 2              | (0.9) (0.9)    | 2 2            | 1 (0.5) 1     | (0.5)         | 1 3           | 3 (0.7) (0.7) | 3 3           |
| Neoplasms benign, malignant and unspecified         | 0              | (0.0)          | 0              | 1             | (0.5)         | 1             | 1 (0.2)       | 1             |
| (incl cysts and polyps), overall                    | 0              |                | 0              | 1             |               | 1             |               |               |
| Fibroma                                             |                | (0.0)          |                |               | (0.5)         | 1             | (0.2)         |               |

Ev = number of TEAEs of specified adverse events type, MedDRA = medical dictionary for regulatory activities, N = total number of patients, n = number of patients with at least 1 adverse event of specified

adverse event type, SAF = safety analysis set, TEAE = treatment-emergent adverse event

Source:Table14.3.2.2.20

For local TEAEs (ocular, fellow eye) until Week 56, the occurrences were similar in the two treatment groups: 53 events in 45 (20.9%) patients with FYB203 and 58 events in 48 (22.0%) patients with Eylea. The most frequent PT that occurred in the fellow eye was Neovascular age-related macular degeneration: in total, 48 events in 46 (10.6%) patients. The occurrences were similar between the groups: 22 events in 22 (10.2%) patients from the FYB203 group and 26 events in 24 (11.0%) patients from the Eylea treatment group. A slight imbalance in frequencies has been reported for the PT conjunctivitis for FYB203 vs. Eylea (5 (2.3%) subjects vs. none). Nevertheless, reported events of conjunctivitis in the fellow eye were of mild or moderate severity. All events did recover/resolve. Incidence was low and none of the cases reported were considered related either to study treatment or study procedure. Therefore, no safety concerns are raised regarding this imbalance.

Of note, the fellow eye could be treated with Eylea, which was allowed after Visit 3 and was to be timely separated by at least 14 days from study eye treatment. The TEAEs in the fellow eyes were mild or moderate in nature and started after Visit 3. The outcomes were recorded as ongoing (not recovered/not resolved) at the time of the study completion. The TEAEs in the fellow eyes were judged as unrelated to the study procedure or treatment in the study eye.

<div style=\"page-break-after: always\"></div>

## 2.5.8.3. Serious adverse event/deaths/other significant events

## AESI

The following AEs were classified as Adverse Events of Special Interest (AESIs):

- Any case of new onset IOP of &gt; 21 mmHg that does not respond to treatment, except the transient pressure rise observed within an hour after IVT injection of IMP;
- Any case of IOP ≥ 35 mmHg, at any time, that required treatment;
- Any case of intraocular infection such as endophthalmitis;
- Any case of intraocular inflammation such as iritis, vitritis, and iridocyclitis;
- Iatrogenic traumatic cataract;
- Arterial  thromboembolic events defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death;
- Death of unknown cause.

Table 36: Treatment-emergent adverse events of special interest (SAF, N=433)

| System Organ Class Preferred Term (MedDRA 23.0 Mixed)   | FYB203 N=215   | FYB203 N=215   | FYB203 N=215   | Eylea N=218   | Eylea N=218   | Eylea N=218   | Total N=433   | Total N=433   | Total N=433   |
|---------------------------------------------------------|----------------|----------------|----------------|---------------|---------------|---------------|---------------|---------------|---------------|
|                                                         | n              | (%)            | Ev             | n             | (%)           | Ev            | n             | (%)           | Ev            |
| Any TEAE of special interest'                           | 6              | (2.8)          | 10             | 7             | (3.2)         | 12            | 13            | (3.0)         | 22            |
| Eye disorders, overall                                  | 4              | (1.9)          | 7              | 4             | (1.8)         | 6             | 8             | (1.8)         | 13            |
| Iritis                                                  | 1              | (0.5)          | 1              | 3             | (1.4)         | 4             | 4             | (0.9)         | 5             |
| Iridocyclitis                                           | 乙              | (0.9)          | 3              | 1             | (0.5)         | 1             | 3             | (0.7)         | 4             |
| Vitritis                                                | 1              | (0.5)          | 1              | 1             | (0.5)         | 1             | 2             | (0.5)         | 2             |
| Uveitis                                                 | 1              | (0.5)          | 2              | 0             | (0.0)         | 0             | 1             | (0.2)         | 2             |
| Investigations, overall                                 | 1              | (0.5)          | 2              | 3             | (1.4)         | 5             | 4             | (0.9)         | 7             |
| Intraocular pressure increased                          | 1              | (0.5)          | 2              | 3             | (1.4)         | 5             | 4             | (0.9)         | 7             |
| Nervous system disorder's, overall                      | 1              | (0.5)          | 1              | 1             | (0.5)         | 1             | 2             | (0.5)         | 2             |
| Cerebrovascular accident                                | 1              | (0.5)          | 1              | 0             | (0.0)         | 0             | 1             | (0.2)         | 1             |
| Ischaemic stroke                                        | 0              | (0.0)          | 0              | 1             | (0.5)         | 1             | 1             | (0.2)         |               |

Ev = number of adverse events of the specified preferred term or system organ class, MedDRA = medical dictionary for regulatory activities, N = total number of patients in analysis set, n = number of patients with at least 1 TEAE of the specified preferred term or system organ class, SAF = safety analysis set, TEAE = treatment-emergent adverse event

1 TEAEs of special interest are TEAEs documented as adverse events of special interest by the Investigator in the eCRF according to study protocol criteria

Source: Table 14.3.2.2.28

A total of 13 (3.0%) patients reported AESIs until Week 56: 10 events in 6 (2.8%) patients treated with FYB203 and 12 events in 7 (3.2%) patients treated with Eylea.

Regarding local AESIs, the most frequent TEAEs belonged to the SOC Eye disorders and were classified as  ocular  inflammatory  AESIs:  a  total  of  13  events  in  8  (1.8%)  patients  were  reported.  Frequently reported PTs were Iridocyclitis, Iritis, Vitritis and Uveitis. These events occurred in the study eye.

Of the PTs, Iritis with 5 events (in one patient treated with FYB203 and in three patients treated with Eylea) was reported as possibly related to the study treatment in 4 of these cases. PT Iridocyclitis with 4 events (in two patients treated with FYB203 and one patient treated with Eylea) was reported as probably related to the study treatment for 2 events or unrelated to the study treatment for the other 2 events.

<div style=\"page-break-after: always\"></div>

PT Vitritis with 2 events (in one patient treated with FYB203 and in one patient treated with Eylea) was reported as possibly related to the study treatment. PT Uveitis with 2 events (in 1 patient treated with FYB203) was reported as possibly related to the study treatment (1 event) and probably related to the study treatment (1 event).

AESIs grouped under the SOC Investigations included the PT IOP increased: Two events in one (0.5%) patient treated with FYB203 where one event affected the study eye and one event affected the fellow eye. The events were reported as unrelated to the study procedure or study treatment and the outcome was recorded as resolved. Both events were moderate in severity. PT IOP increased was observed with 5 events in 3 (1.4%) patients treated with Eylea where all 5 events affected the study eye. Three of the events were reported as possibly/probably related to study treatment and the outcome was recorded as resolved. The events were mild or moderate in severity.

The  frequency  of  AESIs  reported  for  both  treatment  arms  was  comparable.  With  exception  to  one moderate ocular AESI of the fellow eye reported by one patient of the FYB203 arm (PT: IOP increased), ocular AESIs were reported for the study eye. Most ocular AESIs were of mild or moderate severity. One severe event of iridocyclitis and one severe event of uveitis, were both reported by one patient in the FYB203 arm. Non-ocular AESIs were reported as one mild event of ischaemic stroke by one patient in the Eylea arm and one severe event of cerebrovascular accident reported by one patient in the FYB203 arm. All AESIs recovered/resolved (with sequelae). Type and frequency of AESIs is in line with Eylea SmPC and/or EPAR [2024]. This is considered acceptable. Most of the AESIs reported were considered probably or possibly related to study procedure or study treatment. All related AESIs recovered/resolved (with sequelae). Reported AESIs were all in line with the Eylea SmPC/EPAR. Most events were of mild or moderate severity. Therefore, no safety concerns are raised regarding the occurrence of AESIs related to study procedure or study treatment.

## SAEs

Table 37: Overview of serious systemic treatment-emergent adverse events (SAF, N=433)

| SystemOrganClass PreferredTerm(MedDRA 23.0Mixed)   | FYB203 N=215   | FYB203 N=215   | FYB203 N=215   | Eylea N=218   | Eylea N=218   | Total N=433   | Total N=433   | Total N=433   |
|----------------------------------------------------|----------------|----------------|----------------|---------------|---------------|---------------|---------------|---------------|
|                                                    |                | (%)            | Ev             | n             | (%)           | Ev n          | (%)           | Ev            |
| AnyserioussystemicTEAE                             | 17             | (7.9)          | 35             | 23            | (10.6)        | 35 40         | (9.2)         | 70            |
| Infectionsandinfestations,overall                  | 8              | (3.7)          | 13             | 7             | (3.2)         | 8 15          | (3.5)         | 21            |
| COVID-19                                           | 4              | (1.9)          | 4              | 1             | (0.5)         | 1 5           | (1.2)         | 5             |
| COVID-19pneumonia                                  | 1              | (0.5)          | 1              | 2             | (0.9)         | 2 3           | (0.7)         | 3             |
| Appendicitis                                       | 0              | (0.0)          | 0              | 乙             | (0.9)         | 乙 2           | (0.5)         | 乙             |
| Pneumonia                                          | 1              | (0.5)          | 3              | 1             | (0.5)         | 1 2           | (0.5)         | 4             |
| Bronchitis                                         | 1              | (0.5)          | 1              | 0             | (0.0)         | 0 1           | (0.2)         | 1             |
| Colonic abscess                                    | 0              | (0.0)          | 0              | 1             | (0.5)         | 1 1           | (0.2)         | 1             |
| Coronavirusinfection                               | 1              | (0.5)          | 1              | 0             | (0.0)         | 0 1           | (0.2)         | 1             |
| Gallbladderempyema                                 | 1              | (0.5)          | 1              | 0             | (0.0)         | 0 1           | (0.2)         | 1             |
| Peritonitis                                        | 0              | (0.0)          | 0              | 1             | (0.5)         | 1 1           | (0.2)         | 1             |
| Toxicshocksyndrome                                 | 1              | (0.5)          | 1              | 0             | (0.0)         | 0 1           | (0.2)         | 1             |

<div style=\"page-break-after: always\"></div>

| System Organ Class Preferred Term (MedDRA 23.0 Mixed)               | FYB203 N=215   | FYB203 N=215   | FYB203 N=215   |    | Eylea N=218   |     | Total N=433   |    |
|---------------------------------------------------------------------|----------------|----------------|----------------|----|---------------|-----|---------------|----|
|                                                                     |                | (%)            | Ev             | n  | (%) Ev        |     | (%)           | Ev |
| Urosepsis                                                           | 1              | (0.5)          | 1              | 0  | (0.0) (1.8)   | 1   | (0.2)         | 1  |
| Neoplasms benign, maliguant and uspecified (incl cysts and polyps), | 4              | (1.9)          | 4              | 4  | 0             | 8   | (1.8)         | 9  |
| overall                                                             |                |                |                |    |               |     |               |    |
| Acute myeloid leukaemia                                             | 1              | (0.5)          | 1              | 0  | (0.0) 0       | 1   | (0.2)         | 1  |
| Adenocarcinoma gastric                                              | 0              | (0.0)          | 0              | 1  | (0.5) 1 (0.0) | 1   | (0.2)         | 1  |
| Adenocarcinoma of colon                                             | 1              | (0.5)          | 1              | 0  | 0             | 1   | (0.2)         | 1  |
| Colon cancer                                                        | 0              | (0.0)          | 0              | 1  | (0.5) 1       | 1   | (0.2)         | 1  |
| Gallbladder cancer                                                  | 0              | (0.0)          | 0              | 1  | (0.5) 2       | 1   | (0.2)         | 2  |
| Gastric cancer                                                      | 1              | (0.5)          | 1              | 0  | (0.0) 0       | 1   | (0.2)         | 一  |
| Oesophageal carcinoma stage 0                                       | 1              | (0.5)          | 1              | 0  | (0.0) 0       |     | (0.2)         |    |
| Parathyroid tumour benign                                           | 0              | (0.0)          | 0              | 1  | (0.5) 1       | 1 6 | (0.2)         | 1  |
| Cardiac disorders, overall                                          |                | (0.9)          | 2              | 4  | (1.8) 4       |     | (1.4)         | 6  |
| Cardiac failure                                                     | 2              | (0.9)          |                | 1  | (0.5) 1       |     | (0.7)         | 3  |
| Angina pectoris                                                     | 0              | (0.0)          | 0              | 1  | (0.5) 1       | 1   | (0.2)         |    |
| Tachycardia                                                         | 0              | (0.0)          | 0              | 1  | (0.5) 1       | 1   | (0.2)         | 1  |
| Ventricular tachycardia                                             | 0              | (0.0)          | 0              | 1  | (0.5) 1       | 1   | (0.2)         | 1  |
| Gastrointestinal disorders,overall                                  | 4              | (1.9)          |                |    | (0.9) 4       | 6   | (1.4)         | 9  |
| Abdominal adhesions                                                 | 1              | (0.5)          |                | 1  | (0.5) 1       |     | (0.5)         | 2  |
| Diverticulum intestinal                                             | 1              | (0.5)          | 1              | 0  | (0.0) 0       | 1   | (0.2)         |    |
| Gastitis                                                            | 0              | (0.0)          | 0              | 1  | 1 0           | 1   | (0.2)         |    |
| leus                                                                | 1              | (0.5)          | 1              | 0  | (0.5) (0.0)   | 1   | (0.2)         |    |
| Intestinal obstruction                                              | 0              | (0.0)          | 0              | 1  | 1 0           | 1   | (0.2)         |    |
| Large intestinal stenosis                                           | 1              | (0.5)          | 1              | 0  | (0.5) (0.0)   | 1   | (0.2)         |    |
| Oesophageal obstruction                                             | 1              | (0.5)          | 1              | 0  | 0             | 1   | (0.2)         |    |
| Small intestinal obstruction                                        | 0              | (0.0)          | 0              | 1  | (0.0) (0.5) 1 | 1   | (0.2)         | 1  |
| Nervous systemdisorders,overall                                     | 1              | (0.5)          | 1              | 4  | (1.8) 4       |     | (1.2)         | 5  |
| Cerebrovascular accident                                            | 1              | (0.5)          | ■              | 0  | (0.0) 0       | 1   | (0.2)         |    |
| Dementia                                                            | 0              | (0.0)          | 0              | 1  | (0.5) 1       | 1   | (0.2)         | 1  |
| Ischaemic stroke                                                    | 0              | (0.0)          | 0              | 1  | (0.5) 1       | 1   | (0.2)         |    |
| Transient global amnesia                                            | 0              | (0.0)          | 0              | 1  | (0.5) 1       | 1   | (0.2)         |    |
| Transient ischaemic attack                                          | 0              | (0.0)          | 0              | 1  | (0.5) 1       | 1   | (0.2)         | 1  |
| Musculoskeletalandconnectivetissue                                  | 2              | (0.9)          | 2              |    | (0.9) 2       | 4   | (0.9)         | 4  |
| disorders,overall                                                   |                |                |                |    |               |     |               |    |
| Intervertebral disc disorder                                        | 0              | (0.0)          | 0              | 1  | (0.5)         | 1   | (0.2)         |    |
| Myalgia                                                             | 1              | (0.5)          | 1              | 0  | 1 (0.0) 0     | 1   | (0.2)         |    |
| Osteoarthritis                                                      | 1              | (0.5)          | 1              | 0  | (0.0) 0       | 1   | (0.2)         |    |
| Rheumatoid arthritis                                                | 0              | (0.0)          | 0              | 1  | (0.5) 1       | 1   | (0.2)         |    |
| Injuy, poisoning and procedural                                     | 1              | (0.5)          | 1              | 2  | 2             | 3   | (0.7)         | 3  |
| complications,overall                                               |                |                |                |    | (0.9)         |     |               |    |
| Clavicle fiacture                                                   | 0              | (0.0)          | 0              | 1  | 1             | 1   | (0.2)         | 1  |
| Ligament injuy                                                      | 1              | (0.5)          | ■              | 0  | (0.5) (0.0)   | 1   | (0.2)         |    |
| Nerve root injury                                                   | 0              | (0.0)          | 0              | 1  | 0 1 2         | 1   | (0.2)         | 1  |
| Metabolism and nutrition disorders,                                 | 1              | (0.5)          | 1              | 2  | (0.5) (0.9)   | 3   | (0.7)         | 3  |
| overall                                                             |                |                |                |    |               |     |               |    |
| Diabeticmetabolic decompensation                                    | 0              | (0.0)          | 0              | 1  | (0.5) 1       | 1   | (0.2)         |    |
| Hyponatraemia                                                       | 1              | (0.5)          | 1              | 0  | (0.0) 0       | 1   | (0.2)         |    |

| SystemOrganClass Preferred Term(MedDRA 23.0 Mixed)   | FYB203 N=215   | FYB203 N=215   | Eylea N=218   | Eylea N=218       | Total N=433   | Total N=433   |
|------------------------------------------------------|----------------|----------------|---------------|-------------------|---------------|---------------|
|                                                      | (%)            | Ev             | n             | (%) Ev            | n (%)         | Ev            |
| Type 2 diabetes mellitus                             | 0 (0.0)        | 0              | 1             | (0.5) 1           | 1 (0.2)       | 1             |
| Hepatobiliary disorders, overall                     | 2 (0.9)        | 乙              | 0             | (0.0) 0           | 2 (0.5)       | 2             |
| Biliary dilatation                                   | 1 (0.5)        |                | 0             | (0.0) 0           | 1 (0.2)       |               |
| Gallbladder disorder                                 | 1 (0.5)        |                | 0             | (0.0) 0           | 1 (0.2)       | 1             |
| Respiratory,thoracic and mediastinal                 | 2 (0.9)        | 2              | 0             | (0.0) 0           | 2 (0.5)       | 2             |
| disorder's, overall                                  |                |                |               |                   |               |               |
| Aspiration                                           | 1 (0.5)        | 1              | 0             | (0.0) 0           | 1 (0.2)       | 1             |
| Puimonary fibrosis                                   | 1 (0.5)        | 1              | 0             | (0.0) 0 (0.9)     | 1 (0.2)       | 1             |
| Vascuar disorders,overall                            | 0 (0.0)        | 0              | 乙             | 2                 | 2 (0.5)       | 2             |
| Aortic aneurysm                                      | 0 (0.0)        | 0              | 1             | 1 1               | 1 (0.2)       | 一             |
| Varicose vein                                        | 0 (0.0)        | 0              | 1             | (0.5) (0.5) (0.5) | 1 (0.2)       | 一             |
| Blood and lynphatic system disorders, overall        | 0 (0.0)        | 0              | 1             | 2                 | 1 (0.2)       | 2             |
| Anaemia                                              | 0 (0.0)        | 0              | 1             | (0.5) 1           | 1 (0.2)       | 1             |
| Iron deficiency anaemia                              | 0 (0.0)        | 0              | 1             | (0.5) 1           | 1 (0.2)       |               |
| Renaland winary disorders, overall                   | 1 (0.5)        |                | 0             | (0.0) 0           | 1 (0.2)       | 2             |
| Calculus uwinary                                     | 1 (0.5)        | 1              | 0             | 0 0               | 1 (0.2)       | 1             |
| Renal failure                                        | 1 (0.5)        | 1              | 0             | (0.0) (0.0)       | 1 (0.2)       |               |

dictionary forregulatory activities,N=total number ofpatients in analysis set, n=number ofpatients with at

Ev = number of adverse events of the specified preferred tem or system organ class, MedDRA = medical least 1 TEAE of the specified preferred tem or system organ class, SAF = safety analysis set,

Source:Table 14.3.2.2.26

TEAE = treatment-emergent adverse event

<div style=\"page-break-after: always\"></div>

The most frequently recorded SOC was Infections and infestations with a total of 15 (3.5%) patients: 13 events in 8 (3.7%) patients treated with FYB203 and 8 events in 7 (3.2%) patients treated with Eylea. The most frequently reported PT under SOC Infections and infestations was COVID-19: 4 events in 4 (1.9%) patients treated with FYB203 and 1 event in 1 (0.5%) patient treated with Eylea.

Other systemic SAEs were recorded more than once in the following SOCs, but with PTs occurring in mostly single patients only: Neoplasms benign, malignant and unspecified (incl. cysts and polyps) in 8 (1.8%) patients; Cardiac disorders in 6 (1.4%) patients; Gastrointestinal disorders in 6 (1.4%) patients; Nervous system disorders in 5 (1.2%) patients; Musculoskeletal and connective tissue disorders in 4 (0.9%) patients; Injury, poisoning and procedural complications in 3 (0.7%) patients; Metabolism and nutrition  disorders  in  3  (0.7%)  patients;  Hepatobiliary  disorders  in  2  (0.5%)  patients;  Respiratory, thoracic and mediastinal disorders in 2 (0.5%) patients; and Vascular disorders in 2 (0.5%) patients.

All systemic SAEs reported until Week 56 were unrelated to study procedure or to study treatment except for 1 event (Cerebrovascular accident, patient treated with FYB203: possibly related to treatment).

Table 38: Serious treatment-emergent adverse events affecting eye (local) per patient

| Patient               | Age / Sex             | MedDRAPT/ (Start day-Stop day)                                  | Eye Affected          | AESI/ Severity        | Related to Study Procedure/ Study Treatment   | Outcome                           |
|-----------------------|-----------------------|-----------------------------------------------------------------|-----------------------|-----------------------|-----------------------------------------------|-----------------------------------|
| TreatmentGroup:FYB203 | TreatmentGroup:FYB203 | TreatmentGroup:FYB203                                           | TreatmentGroup:FYB203 | TreatmentGroup:FYB203 | TreatmentGroup:FYB203                         | TreatmentGroup:FYB203             |
|                       | 78/ Male              | Iridocyclitis/ (Day 237-Day 252)                                | Study Eye             | Yes/ severe           | Probably related/ Probably related /          | Recovered/ Resolved with sequelae |
|                       |                       | Uveitis / (Day 237-Day 252)                                     | Study Eye             | Yes/ severe           | Probably related/ Probably related            | Recovered/ Resolved with sequelae |
|                       | 65 / Male             | Rhegmatogenous retinal detachment/ (Day 44-Day 51)              | Study Eye             | No / moderate         | Possibly related / unrelated                  | Recovered/ Resolved with sequelae |
| TreatmentGroup:Eylea  | TreatmentGroup:Eylea  | TreatmentGroup:Eylea                                            | TreatmentGroup:Eylea  | TreatmentGroup:Eylea  | TreatmentGroup:Eylea                          | TreatmentGroup:Eylea              |
|                       | 81/ Female            | Neovascular age- related macular degeneration/ (Day 57-Day 113) | Fellow eye            | No / severe           | Unrelated/ Unrelated                          | Recovered/ Resolved with sequelae |
|                       | 71/ Female            | Visualimpairment/ (Day 58-Day 225)                              | Study Eye             | No / moderate         | Unrelated/ Unrelated                          | Recovered/ Resolved with sequelae |
|                       | 67/ Male              | Corneal dystrophy/ (Day 337-Day 375)                            | Study Eye             | No / mild No /        | Unrelated/ unrelated Unrelated/               | Recovered/ Resolved               |
|                       | 79 / Female           | Retinal degeneration/ (Day 400-Ongoing)                         | Fellow Eye            | moderate              | unrelated                                     | 10N recovered/ Not resolved       |
|                       | 80/ Male              | Glaucoma/ (Day 386-Ongoing)                                     | Fellow Eye            | No / severe           | Unrelated/ unrelated                          | Not recovered/ Not resolved       |

AESI= adverse event of special interest,MedDRA =medical dictionary for regulatory activities,PT =preferrec term

Source:Listing16.2.7.3,Listing16.2.4.1

Overall, the nonfatal SAE occurrences until Week 56 were comparable in the 2 treatment groups: 38 events in 19 (8.8%) patients treated with FYB203 and 40 events in 28 (12.8%) patients treated with Eylea. The SAEs were mostly systemic and rarely local.

For the study eye, local SAEs until Week 56 were observed in a total of 4 patients: 2 patients in the FYB203 group (PT Iridocyclitis, PT Uveitis and PT Rhegmatogenous retinal detachment) and 2 patients in the Eylea group (PT Visual impairment and PT Corneal dystrophy, both unrelated to study treatment or study procedure). The Investigator judged PT Iridocyclitis and PT Uveitis as probably related to study treatment  and  to  study  procedure.  PT  Rhegmatogenous  retinal  detachment  was  judged  as  possibly related to study procedure but unrelated to study treatment. Local SAEs in the study eyes were resolved or resolved with sequelae. The SAE Rhegmatogenous retinal detachment led to study discontinuation and study treatment withdrawal in one patient. Additionally, PT Iridocyclitis and PT Uveitis in one patient were considered as a TEAE of special interest.

<div style=\"page-break-after: always\"></div>

For the fellow eye, local SAEs until Week 56 were observed in 3 patients (PTs Neovascular age-related macular  degeneration,  Retinal  degeneration  and  Glaucoma).  PT  Neovascular  age-related  macular degeneration resolved or resolved with sequelae while the other 2 PTs were not resolved. Local SAEs in the fellow eyes were unrelated to study treatment or study procedure.

## Deaths

All fatal outcomes were considered as unrelated to study treatment or study procedure.

Table 39: Occurrence of death by patient during treatment

| Patient               | Age / Sex             | MedDRA PT / (Startday-Stop/Death day)                                    | AESI/ Severity/ Serious         | Related to Study Procedure/ StudyTreatment   | Outcome               |
|-----------------------|-----------------------|--------------------------------------------------------------------------|---------------------------------|----------------------------------------------|-----------------------|
| TreatmentGroup:Eylea  | TreatmentGroup:Eylea  | TreatmentGroup:Eylea                                                     | TreatmentGroup:Eylea            | TreatmentGroup:Eylea                         | TreatmentGroup:Eylea  |
|                       | 69/ Male              | Cardiac failure/ (Day 41-Day 41)                                         | No/Severe/ Yes                  | Unrelated/ unlikely to be related            | Fatal                 |
| TreatmentGroup:FYB203 | TreatmentGroup:FYB203 | TreatmentGroup:FYB203                                                    | TreatmentGroup:FYB203           | TreatmentGroup:FYB203                        | TreatmentGroup:FYB203 |
|                       | 86/ Female            | Pulmonary fibrosis/ (Day 296-Day 325) Cardiac failure/ (Day 321-Day 325) | No/Severe/ Yes No/Moderate/ Yes | Unrelated/ unrelated Unrelated/ unrelated    | Fatal Fatal           |
|                       | 70/                   | COVID-19/                                                                | No/Severe/ Yes                  | Unrelated/ unrelated                         | Fatal                 |
|                       | Male                  | (Day 260-Day 265) COVID-19pneumonia/ (Day 261-Day 265)                   | No/Severe/ Yes                  | Unrelated/ unrelated                         | Fatal                 |
|                       |                       | Cardiacfailure/ (Day 265-Day 265)                                        | No/Severe/ Yes                  | Unrelated/ unrelated                         | Fatal                 |
|                       | 72/                   | Toxic shock syndrome/                                                    | No/Severe/                      | Unrelated/ unrelated                         | Fatal                 |
|                       | Male                  | (Day 273-Day 274) Ileus/ (Day 273-Day 274)                               | Yes No/Severe/ Yes              | Unrelated / unrelated                        | Fatal                 |
|                       | 77/ Male              | Acutemyeloidleukaemia/ (Day 243-Day 270)                                 | No/Severe/ Yes                  | Unrelated/ unrelated                         | Fatal                 |

AESI = adverse event of special interest, MedDRA = medical dictionary for regulatory activities, PT = preferred term

Source: Listing 16.2.7.10, Listing 16.2.4.1

## 2.5.8.4. Discontinuation due to adverse events

Overall, 18 events in 10 (4,7%) patients treated with FYB203 and 2 events in 2 patients (0,9%) treated with Eylea led to discontinuation of treatment.

The  TEAEs  leading  to  study  treatment  withdrawal  were  the  same  as  TEAEs  leading  to  study discontinuation, except for 3 single events - overall, 16 events in 9 patients (4,2%) vs. 1 event in 1 patient (0,5%) led to completely discontinuation of the study.

FYB203 - The local (ocular) TEAEs leading to discontinuation in the FYB203 group included macular hole, rhegmatogenous retinal detachment and subretinal fluid while the rest were systemic TEAEs (cardiac failure, COVID-19, COVID-19, pneumonia, toxic shock syndrome, acute myeloid leukaemia, oesophageal carcinoma  stage  0,  aspiration,  pulmonary  fibrosis,  abdominal  adhesions,  ileus  and  cerebrovascular accident).

Eylea - The TEAEs leading to discontinuation in the Eylea group were cardiac failure (fatal) and eye disorder (not related).

None of the TEAEs occurred in more than 1 patient except for cardiac failure reported by a total of 3 (0.7%) patients and COVID-19 reported by a total of 2 (0.5%) patients.

Most  events  reported  in  the  FYB203  arm  were  not  related  to  study  procedure  or  treatment  (12/18 events). None of the events reported in the Eylea arm were considered related to study treatment or procedure.

<div style=\"page-break-after: always\"></div>

TEAEs  leading to study treatment withdrawal or to discontinuation of the study judged as possibly/probably related to the study treatment or to study procedure are described below:

Macular hole (moderate event) was reported by one patient treated with FYB203 and was judged as possibly related to study procedure but unlikely to be related to study treatment and the outcome was recorded as not recovered or not resolved. The reported TEAE led to withdrawal of study treatment, however, the study was completed on day 393.

Rhegmatogenous  retinal  detachment led  to  premature  study  discontinuation  in  one  patient  (3 moderate events) and was recorded as an SAE. The Investigator suspected the TEAE as possibly related to  the  study  procedure  and  unrelated  to  the  study  treatment.  The  treatment  discontinued  after  1 administration on day 1 and the study discontinued on day 37.

Subretinal fluid (moderate event) was reported by one patient treated with FYB203 a was judged as probably related to study treatment. The outcome was recorded as not recovered/not resolved. The study treatment was discontinued on day 225 and the study on day 267.

Cerebrovascular  accident  (stroke) occurred  in  one  patient  treated  with  FYB203  was  judged  as possibly related to study treatment. The TEAE cerebrovascular accident was considered as severe and the outcome was resolved with sequelae. The treatment was discontinued on day 169 (5 th  IVT injection) and the study on day 221.

In the terms of severity, in the FYB203 arm, 12 TEAEs leading to study treatment withdrawal or study discontinuation were considered as severe and 6 as moderate. In the Eylea arm, 1 TEAE was considered as severe, 1 as mild.

## 2.5.8.5. Laboratory findings

The applicant states that the results of clinical safety laboratory evaluation, vital signs and physical examination did not indicate any relevant differences between the 2 treatment groups. Furthermore, the results from other safety assessments resulting from ophthalmological examinations and tonometry were also  well  balanced  between  the  2  treatment  groups  and  no  relevant  safety-related  differences  were identified.

Regarding haematology, the mean and median changes during the study until Week 56 were minimal. No clinically relevant differences between the treatment groups have been observed in any haematology parameter throughout the study. Clinically significant abnormal values for clinical chemistry were slightly more prominent in the FYB203 vs. Eylea treatment group up to Week 40 (V7) and comparable at Week 56 (V9). Clinically significant abnormal urinalysis values were comparable between treatment groups throughout the study. Also, no clinically relevant differences between the treatment groups have been observed  for  the  patients'  coagulation  profile.  In  general,  no  substantial  differences  were  observed regarding vital  signs,  or  physical  examination  parameters  between  the  treatment  groups  during  the study.

Full data regarding to laboratory evaluation, vital signs and physical examination is to be found in module 5.

In the SOC investigations, 16 treatment-related events in 7 (1.6%) patients were observed overall. The most frequently reported treatment-related PT was IOP increased with a total of 14 events in 6 (1.4%) patients: 2 events in 1 (0.5%) patient treated with FYB203 and 12 events in 5 (2.3%) patients treated with Eylea. A total of 30 events in 14 (3.2%) patients were reported as being related to study procedure indicating that increase in IOP was judged as either related to study treatment or to study procedure.

<div style=\"page-break-after: always\"></div>

The incidence of IOP in Eylea arm is slightly higher than in the FYB203 arm (FYB203 vs. Eylea: 8 (3.7%) vs.  9  (4.1%)  patients),  this  is  acceptable.  According  to  Eylea  SmPC,  the  frequency  for  Intraocular pressure increase is determined as common (≥1/100 to &lt;1/10). Increase in IOP was classified as an AESI for 1 patient from the FYB203 group and 3 patients from the Eylea group.

One patient experienced one moderate episode in the study eye and the fellow eye each. Both events recovered and were not considered related to study procedure or treatment. The patient completed the study without any treatment interruption.

One patient had 3 moderate episodes of IOP increased in the study eye. All episodes did recover/resolve. Two episodes were considered related to study procedure and/or treatment. The patient completed the study.

One patient experienced one moderate episode of IOP increased in the study eye. The event resolved on the same day. The episode was considered related to study procedure and treatment. The patient completed the study without any treatment interruption.

One patient experienced one mild episode of IOP increased in the study eye. The event resolved on the same day. The episode was considered related to study procedure and treatment. The patient completed the study.

## 2.5.8.6. In vitro biomarker test for patient selection for safety

Not applicable

## 2.5.8.7. Safety in special populations

Not applicable

## 2.5.8.8. Immunological events

See Immunogenicity in section 2.5.3

## 2.5.8.9. Safety related to drug-drug interactions and other interactions

Not applicable

## 2.5.8.10. Post marketing experience

Not applicable

## 2.5.9. Discussion on clinical safety

No Summary of clinical safety was provided by the applicant (document contained only reference to the specific section of the Clinical study report). This is not fully in accordance with the ICH Topic M4E. The safety assessment is based on data provided in the Clinical overview and Clinical study report.

## Data collection:

The clinical safety assessment of FYB203 is based on one phase III parallel-group, 1:1 randomised, double-masked, multicentre completed study (MAGELLAN-AMD). The study compares the efficacy and safety  of  the  FYB203  biosimilar  with  EU  Eylea  in  patients  with  neovascular  Age-Related  Macular

<div style=\"page-break-after: always\"></div>

Degeneration (AMD). According to the CHMP advice, it was agreed that a naive nAMD population is a sensitive and reasonable patient population to assess clinical biosimilarity between Eylea and FYB203.

## Patient exposure:

A total of 433 patients have received at least one dose of test product FYB203 or reference product Eylea. The patients were randomised in ratio 1:1 approximately (215/218 patients) in two comparable arms.

A total  of  196  (91.2%)  patients  in  the  FYB203  group  and  206  (94.1%)  patients  in  the  Eylea  group completed the study until Week 56.

A total  of  183  patients  (85.1%)  in  the  FYB203  group  and  199  patients  (91.3%)  in  the  Eylea  group completed the treatment - they received all 8 scheduled injections.

The exposure to study treatment between these two arms seems to be comparable, there are no relevant differences.

The last assessment was done after 56 weeks. The mean (SD) treatment duration was 323.1 (58.97) days and the mean (SD) study duration was 398.7 (53.03) days.

In general, the treatment and study duration were well balanced between both treatment groups and no relevant differences were observed.

## Adverse events:

## TEAEs

Overall incidence for TEAEs was slightly higher in the FYB203 arm vs. Eylea arm (76.7 % vs 72.5 %). Incidence of ocular TEAEs in study eye were slightly lower in FYB203 arm vs Eylea arm (31.2 % vs 34.4 %) and also in fellow eye (20.9 % vs 22.0%).

Systemic TEAEs were observed in FYB203 arm (57.7 %) with higher incidence compared to Eylea arm (51.8 %). Incidence of serious TEAEs is lower in FYB203 arm compared to Eylea arm (7.9 % vs 10.6 %) as well as the incidence of severe TEAEs (3.7 % vs 5.0 %).  Regarding PTs, incidences have been higher for  the  FYB203  arm  vs.  Eylea  arm  regarding  nasopharyngitis  (10  (4.7%)  vs.  6  (2.8%)  subjects); Coronavirus infection (6 (2.8%) vs. 1 (0.5%) subjects); and osteoarthritis (10 (4.7%) vs. 1 (0.5%) subjects). With exception to one event of severe coronavirus infection reported for one patient in the FYB203 arm, whose outcome is unknown, all these events were of mild or moderate severity, considered not or unlikely related to study procedure or treatment and recovered/resolved. Therefore, no safety concerns are raised regarding this imbalance.

Based  on  Eylea  SmPC,  systemic  adverse  events  including  non-ocular  haemorrhages  and  arterial thromboembolic events have been reported following intravitreal injection of VEGF inhibitors and there is a theoretical risk that these may relate to VEGF inhibition. This information is provided in the PI of the reference medicinal product Eylea and also in the proposed PI (sections 4.4 and 4.8). According to the information  provided  in  the  section  related  to  SAE,  all  systemic  SAEs  reported  until  Week  56  were unrelated to study procedure or to study treatment except for 1 event (Cerebrovascular accident, patient treated with FYB203: possibly related to treatment, see section AESI for more details). Given the FYB203 related  systemic  TEAEs,  the  following  were  reported  within  the  study  -related  to  study  treatment (FYB203) - headache, cerebrovascular accident, somnolence, hypertension, anaemia, asthenia; related to study procedure (FYB203) - headache, somnolence, pain in extremity. For more details, please see the section TEAEs by relationship below.

Based on the size of the patients included in clinical study, such a study can generally not well inform on the rare (and less frequent) AEs. Nevertheless, the provided safety database is considered sufficient to

<div style=\"page-break-after: always\"></div>

assess the comparability of common (≥1/100 to &lt;1/10) and very common (≥1/10) adverse events. This is considered acceptable for biosimilar medicinal product.

The  most  frequently  reported  TEAEs  were  under  the  SOCs  Eye  disorders  and  SOC  Infections  and infestations. The number of events for TEAEs under the SOC Eye disorders was lower in the FYB203 group - 149 events/ 84 patients (39.1%) than in Eylea group -171 events/ 95 patients (43.6%).

The most frequently reported PTs under the SOCs Eye disorders were neovascular age-related macular degeneration  (13.0  %  FYB203  vs  12.8  %  Eylea),  cataract  (5.1  %  FYB203  vs  4.6  %  Eylea)  and conjunctival haemorrhage (2.3 % FYB203 vs 6.4 % Eylea). The observed PTs are in accordance with the known safety profile of aflibercept (proposed indication - neovascular AMD ; cataract and conjunctival haemorrhage are listed ADRs). No clinically significant disbalances were noted.

The number of events for TEAEs under the SOC Infections and infestations was slightly higher in the FYB203 - (27.0 %) than in Eylea group (25.2 %). The most frequently reported PTs under the SOCs Infections  and  infestations  were  Covid-19  (8.8  %  FYB203  vs  8.3  %  Eylea),  Nasopharyngitis  (4.7  % FYB203 vs 2.8 % Eylea) and Conjunctivitis (2.8 % FYB203 vs 2.8 % Eylea). No clinically significant disbalances were noted.

Higher disbalances in observed PT osteoarthritis (4.7 % FYB203 vs 0.5 % Eylea) and PT hypertension (7.0 %, 15 patients FYB203 vs 4.1 %, 9 patients Eylea) and SOC Gastrointestinal disorders (10.2 % vs 6.9 %) were noted. It is acknowledged that hypertension was assessed as related to study treatment only in 1 patient in each group but considering the fact that a systemic VEGF inhibition is described to cause dose-related increases in systolic and diastolic blood pressure and since none of these risks is listed in Eylea and also in proposed PI, the applicant is asked to discuss the proposed disbalances further. The applicant provided additional data on the higher incidence of medical history of gastrointestinal disorders in the study - 17.2% in the FYB203 group (37 of 215 patients) and 14.7% in the Eylea group (32 of 218 patients) and also on incidence of a pre-existing and ongoing hypertension -72.1% in the FYB203 group (155 patients) and 70.6% in the Eylea group (154 patients). Moreover, the provided details did not show any observed trends. Thus, the issue has been considered sufficiently justified and solved.

Except the requested discussion on osteoarthritis and hypertension and GIT disorders, both arms are considered to be comparable, and no safety concern has been identified.

According to the intensity of reported TEAEs, both arms (FYB203 and Eylea) are considered comparable. The majority of TEAEs were mild (44.7 % FYB203 vs 39.0 % Eylea) or moderate (27.4 % FYB203 vs 26.6 % Eylea) intensity. Severe TEAEs were observed in lower incidence in FYB203 arm (10 patients/4.7 % vs 15 patients/6.9 %).

Severe TEAEs were most frequently observed in SOC Eye disorders (6 patients in total), Infection and infestations (5 patients in total) and Neoplasms benign, malignant and unspecified incl. cysts and polyps (5 patients in total). No PT was reported more than 2 times. In FYB203, PT with severe intensity were iridocyclitis, retinal pigment epithelial tear and uveitis.  All 3 PTs were observed in the study eye and were probably related to study treatment. All 3 PT are listed in the Eylea and proposed SmPC.

Additionally, PT Cerebrovascular accident under SOC Nervous system disorders was reported as possibly related to study treatment. Please see above section AESI for further details.

TEAE was considered to be related to the study treatment if the Investigator had judged the relationship as  'probably  related'  or  'possibly  related'  or  if  the  relationship  to  study  treatment  was  missing  or unknown.

<div style=\"page-break-after: always\"></div>

Incidence of related TEAEs to the treatment were slightly higher in FYB203 arm compared to Eylea (9.3 % vs 7.3 %). The most frequently reported related TEAEs were from SOC Eye disorders (26 patients in total - FYB203 15 patients vs Eylea 11 patients) and Investigations (7 patients in total- FYB203 1 patient vs Eylea 6 patients).  Majority of related PTs occurred with similar frequencies in both treatment groups and/or mostly in single patients.

Incidence of related TEAEs to the IVT injection were slightly lower in FYB203 arm compared to Eylea (13.0 % vs 17.0 %). The most frequently reported related TEAEs were from SOC Eye disorders (54 patients - FYB203 23 patients vs Eylea 31 patients) and Investigations (14 patients in total- FYB203 6 patients vs Eylea 8 patients).  Majority of related PTs occurred with similar frequencies in both treatment groups  and/or  mostly  in  single  patients.  PT  conjunctival  haemorrhage  was  observed  with  higher frequency in Eylea arm (6.4 % vs 1.9 % in FYB203 arm). PT Vision blurred was observed in slightly higher frequency in FYB203 arm (2.3 % vs 0 %). A notable PT related to study procedure was IOP increased: 8 events in 6 (2.8%) patients with FYB203 versus 22 events in 8 (3.7%) patients treated with Eylea. Increased intraocular pressure, vision blurred and conjunctival haemorrhage are listed ADRs with frequency common or very common, which corresponds with observed TEAEs.

No clinical difference between reported related TEAEs arms or discrepancies from known safety profile of aflibercept were noted.

Ocular TEAE in study eye were observed with lower incidence in FYB203 arm (31.2 % vs 34.4 % in Eylea arm). The most frequently reported related TEAEs were from SOC Eye disorders (126 patients in total FYB203 60 patients vs Eylea 66 patients) and Investigations (16 patients in total - FYB203 7 patients vs Eylea  9  patients).  The  most  frequently  reported  PTs  were  conjunctival  haemorrhages,  cataract, neovascular AMD, eye pain, visual acuity reduced, visual blurred and increased intraocular pressure. These PTs correspond with known safety profile of aflibercept.

Ocular TEAEs in fellow eye were observed with lower incidence in FYB203 arm (20.9 % vs 22.0 % in Eylea arm). The most frequently reported related TEAEs were from SOC Eye disorders (85 patients in total  -  FYB203  40  patients  vs  Eylea  45  patients)  and  Investigations  (6  patients  in  total  -  FYB203  5 patients vs Eylea 1 patient). The most frequently reported PTs were neovascular AMD, cataract, visual acuity reduced, AMD and conjunctivitis. The observed TEAEs are considered comparable between both arms.

## ADRs:

## TEAEs

TEAEs related to study treatment were reported in a total of 36 (8.3%) patients. The occurrence of related TEAEs was similar in both treatment groups: 34 events in 20 (9.3%) patients treated with FYB203 and 32 events in 16 (7.3%) patients treated with Eylea.

The most frequently reported TEAEs related to study treatment in FYB203 arm were:  Neovascular agerelated macular degeneration (6), Retinal pigment epithelial tear (3), Eye pain (3).  The most frequently reported TEAEs related to study treatment in Eylea arm were:  Intraocular pressure increased (5) and Neovascular age-related macular degeneration (3). Other PT were reported once or two times.

The  most  frequently  reported  TEAEs  related  to  study  procedure  in  FYB203  arm  were:  Intraocular pressure  increased  (6),  Vision  blurred  (5),  Conjunctival  haemorrhage  (4),  Eye  pain  (4).  The  most frequently reported TEAEs related to study treatment in Eylea arm were: Conjunctival haemorrhage (14), Intraocular pressure increased (8), Eye pain (5), Swelling of eyelid (3) and Sensation of foreign body (3). Other PT were reported once or two times.

Given the FYB203 related systemic TEAEs, the following were reported within the study:

<div style=\"page-break-after: always\"></div>

-  related  to  study  treatment  (FYB203  arm)  -  headache  2  patients,  cerebrovascular  accident  1, somnolence 1, hypertension 1, anaemia 1, asthenia 1

- related to study procedure (FYB203 arm) - headache 2, somnolence 1, pain in extremity 1

No clinical difference between reported related TEAEs arms or discrepancies from known safety profile of aflibercept were noted.

## Ocular SAEs

Frequencies of ocular serious TEAEs in the study eye have been comparable between treatment groups.

Two patients in FYB203 arm with coded ocular SAEs were assessed as related to study procedure and study  treatment.  One  patient  (iridocyclitis-  probably  related  and  uveitis  -  possibly  related)  and  one patient  (rhegmatogenous  retinal  detachment  -possible  related  to  study  procedure).  All  coded  SAEs affected study eye. Ocular SAEs in Eylea arm occurred in 5 patients (2 in study eye and 3 in fellow eye) and none of reported events was assessed as related. (For further detail please see table 10-12).

## Systemic SAEs

All systemic SAEs reported until Week 56 were unrelated to study procedure or to study treatment except for 1 event (Cerebrovascular accident, patient treated with FYB203: possibly related to treatment).

## AESI

A total of 13 (3.0%) patients reported AESIs until Week 56. 10 events in 6 (2.8%) patients treated with FYB203 and 12 events in 7 (3.2%) patients treated with Eylea. 3 patients treated with FYB203 had coded events  as  related  to  treatment/study  procedure  (patient  -  63  yo  female  experienced  mild  vitritis  possibly  related,  patient  -  77  yo  female  experienced  mild  iritis  -  possibly  related  and  patient  with iridocyclitis- probably related and uveitis - possibly related).

## Deaths

None of the 5 patients treated with aflibercept with fatal outcome was assessed as related to the study procedure or study treatment.

## Discontinuation

Only 2 reported TEAEs leading to study discontinuation were judged as possibly/probably related to the study  treatment  -  subretinal  fluid,  reported  by  one  patient  and  cerebrovascular  accident  (stroke), reported by one patient. Both TEAEs were observed in the FYB203 arm. Further 2 TEAEs leading to study discontinuation observed in FYB203 arm were judged as possibly related to the study procedure (one patient - macular hole, one patient - rhegmatogenous retinal detachment).

The  reported  ADRs  in  FYB203  are  considered  comparable  with  reported  ADR  in  reference  medicinal product (Eylea) arm. TEAEs related to study treatment were reported in slightly lower incidence than in Eylea arm. The observed ADRs are considered in accordance with known safety profile of aflibercept. Observed  incidences  of  all  reported  ADRs  do  not  significantly  differ  between  both  arms  and  are considered in line with the provided frequencies stated in proposed Product Information (PI).  No safety concern is raised regarding the reported and assessed ADRs.

The provided data is considered relevant and support the proposed product information. The proposed ADRs (in accordance with reference medicinal product Eylea) are considered justified.

## SAEs

Three serious TEAEs considered related to study treatment have been reported by 2 (0.9%) patients in the FYB203 arm vs. none in the Eylea arm.

<div style=\"page-break-after: always\"></div>

Ocular SAEs - 2 patients in FYB203 arm experienced ocular SAEs.

78 y/o male patient experienced severe iridocyclitis and uveitis in study eye on days 237-252 (considered to be AESI). SAEs were assessed as probable related to study procedure and also study treatment. These risks are listed in Product Information.  Outcome is described as resolved with sequelae (decreased visual acuity). 65 y/o male patient experienced moderate rhegmatogenous retinal detachment in study eye on days 44-51. SAE was assessed as possibly related to study procedure but unrelated to study treatment. SAE recovered due to surgery, but still needed follow-up observation and medicine. This SAE led to discontinuation of study. This risk is described in section 4.4 of SmPC and retinal detachment is listed in section 4.8 of SmPC. In Eylea arm 5 ocular SAEs were reported (all assessed as not related). Coded SAEs were neovascular age related macular degeneration, visual impairment, corneal dystrophy, retinal degeneration and glaucoma. With exception to the event of uveitis, all events recovered/resolved (with sequelae).

Systemic SAEs incidence is slightly lower in FYB203 arm than in Eyla arm (7.9% vs 10.6%). The most frequently were reported SAEs in SOC Infections and Infestations (FYB203 3.7 % vs Eylea 3.2 %). All systemic SAEs reported until Week 56 were unrelated to study procedure or to study treatment except for 1 event (Cerebrovascular accident, patient treated with FYB203: possibly related to treatment, see section  AESI  for  more  details).  Additional  PTs  occur  in  mostly  single  patients  only.  Both  arms  are considered  comparable.  Most  systemic  serious  TEAEs  were  of  moderate  or  severe  severity.  Overall, reported SAEs were in line with known undesirable effects of Eylea [Eylea SmPC and EPAR, 2024]. This is  considered  acceptable.  Therefore,  no  safety  concerns  are  raised  regarding  the  occurrence  of  the serious TEAEs.

According to the theoretical risk that non-ocular haemorrhages and arterial thromboembolic events may relate to VEGF inhibition, increased focus was given to all SAEs from SOC Cardiac disorders (2 patients, 2 cardiac failures in FYB203 arm) and SOC Nervous system disorders (1 case of cerebrovascular accident in FYB203 arm) and SOC Vascular disorders (no SAEs in FYB203 arm). No safety concern was raised regarding the systemic SAEs.

## AESI

A total of 13 (3.0%) patients reported AESIs until Week 56. 10 events in 6 (2.8%) patients treated with FYB203 and 12 events in 7 (3.2%) patients treated with Eylea. The most frequent AESI belonged to the SOC Eye disorders and were classified as ocular inflammatory AESIs in study eye (4 patients in FYB203 arm vs 4 patients in Eylea arm). The coded PTs were iritis, iridocyclitis, vitritis and uveitis. All PTs are listed in product information with frequency uncommon (rare for vitritis), this corresponds with known safety profile of aflibercept. Further, intraocular pressure increased and cerebrovascular accident were reported in 1 patient each in FYB203 arm compared to 3 patients with increased intraocular pressure and 1 patient with ischaemic stroke in Eylea arm. Below are provided summaries of patients with coded AESI in FYB203 arm.

Patient - 73 yo male experienced mild iridocyclitis in a study eye on day 56 (duration 24 days). The drug was  interrupted  and  medication  was  given.  Outcome  is  coded  as  resolved  (day  79)  and  causality unrelated. The patient completed study. Patient - 63 yo female experienced mild vitritis in a study eye on day 227 (duration 57 days). Dose was not changed and no treatment was given. Outcome is coded as recovered with possible causality. Patient completed study.

Patient - 77 y/o female experienced mild iritis in study eye on day 113 (duration 15 days). Dose was not changed and treatment was given.  Outcome is coded as recovered with possible causality.  Patient completed study.

<div style=\"page-break-after: always\"></div>

Patient - 81 y/o female experienced intraocular pressure increased (26mmHg) with moderate severity in study and also in fellow eye on day 109 (duration 5 days). Dose was not changed and treatment was given.  Outcome is coded as recovered with unrelated causality.

Patient - 84 y/o male (with history of hypertension, coronary artery disease, hypercholesterolaemia, atrial fibrillation and carotid artery stenosis) experienced severe cerebrovascular accident on days 201 (duration 23 days). Drug was withdrawn and treatment was given. Outcome is coded as recovered with sequelae (slight paresis of the left limbs). Causality is coded as unrelated to study procedure but possibly related to study treatment.

Patient - 78 y/o male experienced severe/mild uveitis (on day 237, duration 16 days and on day 253, duration  85  days)  and  moderate/severe  iridocyclitis  (on  day  228,  duration  9  days  and  on  day  237, duration  16  days).  Drug  was  interrupted  and  adequate  treatment  was  given.  Outcome  is  coded  as recovered with sequelae (panuveitis, decreased visual acuity). Causality is coded as probably related. The patient completed study.

The applicant provided brief information on the fact that the subgroup of 15 patients received injections with different syringes than the original ones provided by the Sponsor and total of 5 (33.3%) patients in this  group  experienced  ocular  inflammatory  AESIs  (according  to  the  CSR  -  2  patients  in  FYB203 experienced 1 iritis and 1 vitritis and 3 patients in Eylea arm experienced iritis (2) and vitritis (1). The other subgroup of 418 patients received injections with the original syringes provided by the Sponsor and  an  ocular  inflammatory  AESI  was  observed  in  3  (0.7%)  patients.  The  applicant  was  asked  for thorough discussion of the evident difference between observed higher incidence of ocular inflammatory AESIs with different syringes (reasons for usage of different syringes, characterisation of their differences and discussion on causation of such a difference in incidence in AESI - 1/3 of patients with different syringe suffered from ocular inflammatory). The provided reason for the usage of different syringes with observed higher incidence of ocular inflammatory AESIs was justified by the deviation of the single site. The deviation was caused by the preference of the single site due to the smaller size of the injection syringe allowing for easier handling and not blocking the injector's visual field to the cornea during the injection.  The  main  differences  in  the  devices  and  procedure  at  site  14008  included  the  use  of  two siliconised syringes instead of one, different syringe material and additional handling steps. According to the provided tables, filter  needles  were  identical,  differences  were  in  the  usage  of  sterile  syringes  syringe n.1 - polycarbonate vs polypropylene, luer slip instead of luer lock, syringe n.2 (only in the 14008 site)  -  polypropylene  +  different  needle  design  (staked-in)  with  same  dimensions.  The  applicant discussed the causation of such difference and explained it by the possible increased particulate matter release  from  the  siliconised  devices  or  by  potential  bending  or  dulling  of  the  injection  needle  (from insertion into the tip of the transfer syringe). The applicant's justification is acknowledged and as the issues was caused by the deviation of the single site. The concern is not further pursued.

Ocular TEAEs in the study eye have been reported in higher frequency in the FYB203 arm vs. Eylea arm for  subjects  injected  with  'other  syringes'  (7  (100.0%)  subjects  reported  25  events  vs.  7  (87.5%) subjects reported 47 events). While eye disorders were more frequent in the FYB203 arm (7 (100.0%) subjects/19 events vs. 7 (87.5%) subjects/24 events), investigations were reported in higher frequency in the Eylea group. Only PT for the latter reported was IOP increased (3 (42.9%) subjects/4 events vs. 5 (62.5%) subjects/18 events). In comparison, frequencies of reported ocular TEAEs in the study eye for the subgroup 'original syringes' were comparable to the overall data as discussed above. The low number of subjects in the subgroup 'other syringes' may hamper interpretability of data presented.

To address the notable imbalances in the number of events for IOP increased, as shown for the 'other syringes' subgroup vs. 'original syringes', the applicant provided a summary of the number of events and patients by treatment group and eye affected by increased IOP. Also, a table of tonometry results for  the  'IOP  increased'-TEAEs  in  the  study  eye  has  been  presented,  categorised  by  syringe  used,

<div style=\"page-break-after: always\"></div>

treatment group and patient. All events of 'IOP increased' for patients in the Eylea group receiving treatment  via  'other  syringes'  were  of  mild  or  moderate  severity  and  did  recover/resolve  or  were recovering/resolving.

Furthermore, it was reported that all 15 patients receiving injections with 'other syringes' than provided by the sponsor were treated at this same site. Major differences of the medical devices and application procedure used at this one site vs. devices provided by the sponsor were:

- use of a separate transfer syringe in addition to the injection syringe
- syringe material ('other syringes' vs. 'provided by sponsor'): polypropylene vs. polycarbonate
- connections and dimensions of the needles ('other syringes' vs. 'provided by sponsor'): staked-in needle (30G x ½', 0.3 mm x 12.7 mm) vs. Luer-lock needle (30G x ½', 0.3 mm x 13 mm)

Dimensions  of  the  listed  filter  needles  and  injection  needles  are,  nevertheless,  in  line  with  the recommendations given in the product information of the originator [Eylea SmPC, 2024]: a 18 G, 5micron filter needle is provided together with the vial. A 30 G x ½ inch injection needle and a 1-ml sterile, Luer-lock syringe are recommended for the intravitreal injection procedure.

However, application procedure as recommended in the Eylea SmPC has not been followed for the use of  the  'other  syringes'.  The  vials  were  emptied  using  a  separate  Luer-slip  transfer  syringe.  After removing the filter needle, the plunger was moved up and down several times to expel air bubbles. This was followed by inserting the staked-in needle of the injection syringe in the Luer-slip tip of the transfer syringe  to  withdraw  the  contents.  Remaining  steps  were  in  accordance  with  the  Eylea  SmPC.  The applicant hypothesises that the cumulative agitation from the additional plunger movements, could have increased particulate matter release from the siliconised devices or may have resulted in bending or dulling of the injection needle. This is plausible.

These discrepancies have affected only a small number of study participants. Also, all events of IOP increased in the 'other syringe' subgroup were of moderate or mild severity and did resolve/recover or were  resolving/recovering.  Furthermore,  recommended  syringe  and  needles  for  the  application procedure listed in the Ahzantive SmPC as well as the description of the application procedure itself are in line with the originator. Therefore, in summary, the concern regarding the imbalances in the number of events for IOP increased reported for the 'other syringes' subgroup is considered resolved.

The applicant justified the selection of the AESI by the collaboration between the applicant and the CROs. The selection of  AESIs  was  based  on  the  applicant's  and  CRO's  earlier  experience  with  ranibizumab biosimilars taking into account the EMA SmPC and FDA Prescribing information and considering the listed AESIs as typical for both aflibercept and ranibizumab products.

## TEAEs leading to discontinuation

Overall, 18 events in 10 (4,7%) patients treated with FYB203 and 2 events in 2 patients (0,9%) treated with Eylea led to discontinuation of treatment. 16 events in 9 patients (4,2%) in the FYB203 arm vs. 1 event in 1 patient (0,5%) the Eylea arm led to completely discontinuation of the study.

As possibly/probably related to study treatment were judged following TEAEs:

Subretinal fluid was reported by one patient treated with FYB203 a was judged as probably related to study treatment. The outcome was recorded as not recovered/not resolved. The study treatment was discontinued on day 225 and the study on day 267.

Cerebrovascular accident (stroke) occurred in one patient treated with FYB203 was judged as possibly related  to  study  treatment.  The  TEAE  cerebrovascular  accident  was  considered  as  severe  and  the

<div style=\"page-break-after: always\"></div>

outcome was resolved with sequelae. The treatment was discontinued on day 169 (5 th  IVT injection) and the study on day 221.

As possibly related to study procedure were judged following TEAEs observed in the FYB203 arm:

Macular hole was reported by one patient treated with FYB203 and was judged as possibly related to study procedure but unlikely to be related to study treatment and the outcome was recorded as not recovered or not resolved. The reported TEAE led to withdrawal of study treatment, however, the study was completed on day 393.

Rhegmatogenous retinal detachment led to premature study discontinuation in one patient (3 events) and was recorded as an SAE. The Investigator suspected the TEAE as possibly related to the study procedure and unrelated to the study treatment. The treatment discontinued after 1 administration on day 1 and the study discontinued on day 37.

In term of severity, in the FYB203 arm, 12 TEAEs were considered as severe (7 of them were fatal, 3 were not recovered/not resolved and 2 resolved with sequelae) and in the Eylea arm, 1 TEAE was considered as severe (fatal).The incidence of severe TEAEs leading to discontinuation is higher in the FYB203 arm (12 TEAEs vs. 1 TEAE), however, the overall incidence of severe TEAEs observed in both arms is comparable (23 TEAEs vs 20 TEAEs). Only one severe TEAE cerebrovascular accident (stroke) reported in one patient was assessed as possibly related to study treatment FYB203 and none to study treatment Eylea.

Most events considered related to study procedure or treatment were of moderate severity and in line with the Eylea SmPC/EPAR [2024] or reasonably connected to the application procedure.

The incidence of TEAEs leading to withdrawal of study treatment (4,7% vs.0,9%) or to complete discontinuation of study (4,2% vs. 0,5%) is higher in the FYB203 arm.

The discussion regarding the imbalance between the incidence of TEAEs leading to discontinuation of the treatment, resp. to discontinuation of the study has been provided.

## Deaths

In  total  7  deaths  were  reported  within  the  study.  2  patients  did  not  receive  any  treatment  product (screening period), 1 patient died when treated with Eylea (cardiac failure, day 41 of treatment, assessed as unrelated). 4 patients died when treated with FYB203.

One patient (86 y/o female) died due to pulmonary fibrosis and cardiac failure on Day 325. Death was assessed as not related to FYB203. The patient was several times hospitalised, had positive microbiology sampling for pseudomonas, decreased kidney function values, breathing difficulties and was treated with antibiotics and oxygen therapy.

One patient (70 y/o male) died due to COVID-19/pneumonia and heart failure on Day 265. Death was assessed as not related to FYB203.

One patient (72 y/o male) died due to toxic shock syndrome caused by ileus on day 274. Death was assessed as not related to FYB203. One patient (77 y/o male) died due to acute myeloid leukaemia on day  270.  Concomitantly  patient  suffered  from  coronavirus  infection  and  kidney  failure.  Death  was assessed as not related to FYB203.

All causes of death were of non-ocular nature. The narratives for all patients have been provided by the applicant. All patients had prior/concomitant co-morbidities and the causes of most of the deaths are consistent with the age of the study population. None of the reported deaths were considered related to the study drug. No safety concerns are raised from reported fatal cases.

<div style=\"page-break-after: always\"></div>

## Immunogenicity

The percentage of ADA-positive patients from the first IP administration through Week 56 was generally low in both treatment arms and ranged between 1.0% and 2.7% in the FYB203 group and between 0.5% and 1.5% for the Eylea overall treatment group. 2 patients at week 40 and 3 patients at week 56 had Nab positive in FYB203 arm and no patient with positive Nab was observed in Eylea arm. The percentage of ADA patients was slightly higher with FYB203 compared to Eylea across all timepoints up to Week 56 and the number of patients with treatment-induced ADA is also slightly higher in FYB203 arm - 4 patients vs 2 patients in Eylea arm. No treatment-boosted ADAs were observed between treatments. Based on the provided data and due to overall low incidence of ADAs, the impact of immunogenicity on safety is very limited and no concerns arise regarding the impact of immunogenicity on safety. Information on the  risk  of  immunogenicity  is  described  in  sections  4.4  and  4.8  of  SmPC  in  line  with  the  reference medicinal product.

## Laboratory and other findings

In the SOC Investigations, 16 treatment-related events in 7 (1.6%) patients were observed overall. The most frequently reported treatment-related PT was IOP increased with a total of 14 events in 6 (1.4%) patients: 2 events in 1 (0.5%) patient treated with FYB203 and 12 events in 5 (2.3%) patients treated with Eylea. A total of 30 events in 14 (3.2%) patients were reported as being related to study procedure indicating that increase in IOP was judged as either related to study treatment or to study procedure.

No safety concerns are raised regarding the observed changes in laboratory findings. Full data regarding to laboratory evaluation, vital signs and physical examination is to be found in module 5, however, some summary or broad discussion from the applicant is missing. No summary of clinical safety was provided and even in the clinical overview such a discussion is not to be found.

A thorough discussion regarding to abnormalities in haematology, chemical and urinalysis parameters, their clinical significance and their relationship to the drug treatment has been provided. The summary of the laboratory parameters, vital signs and other monitored parameters has been also provided No safety concerns have been identified regarding the observed changes in laboratory and other findings.

including increased PT IOP.

## 2.5.10. Conclusions on the clinical safety

The overall safety profile of FYB203 is in line with known adverse events of the reference medicinal product  Eylea  [SmPC  2024].    No  safety  concerns  (regarding  assessed  AEs,  clinically  meaningful differences  in  laboratory  findings  and  immunogenicity)  were  seen  compared  to  reference  medicinal product. Overall, FYB203 and Eylea demonstrated comparable safety profiles. Biosimilarity is supported from a safety perspective.

<div style=\"page-break-after: always\"></div>

## 2.6. Risk Management Plan

## 2.6.1. Safety concerns

| Summary of safetyconcerns   | Summary of safetyconcerns                                                                                                                                                             |
|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks  | Endophthalmitis (likely infectious origin) Intraocular inflammation Transient intraocular pressure increase Retinal pigment epithelia tears Cataract (especially of traumatic origin) |
| Important potential risks   | Medication errors Off-label use and misuse Embryo-fetotoxicity                                                                                                                        |
| Missing information         | None                                                                                                                                                                                  |

## 2.6.2. Pharmacovigilance plan

No additional pharmacovigilance activities.

## 2.6.3. Risk minimisation measures

Table 40: Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

| Safety concern                             | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Pharmacovigilance activities                                                                                                                                                                                                                                                                     |
|--------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endophthalmitis (likely infectious origin) | Routine risk minimisation measures: SmPC sections 4.2, 4.3, 4.4, and 4.8 Package Leaflet sections 2,3 and 4 Other routine risk minimisation measures beyond the Product Information: Medicinal product subject to restricted medical prescription. Ahzantive must only be administered by a qualified physician experienced in administering intravitreal injections. Additional risk minimisation measures : Educational programme: Beyond routine minimisation activities, additional measures are currently needed to raise patients' and physicians' awareness on identified | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection Specific questionnaire to be used for any post-marketing or study reports suspicious for endophthalmitis and intraocular inflammation (see Annex 4.1) Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

| Safety concern                          | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Pharmacovigilance activities                                                                                                                                                                                                                                                                      |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                         | and potential risks (prescriber guide and video; patient guide 'Your guide to Ahzantive', and its audio version).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                   |
| Intraocular inflammation                | Routine risk minimisation measures: SmPC sections 4.2, 4.3, 4.4, and 4.8 Package Leaflet sections 2,3 and 4 Other routine risk minimisation measures beyond the Product Information: Medicinal product subject to restricted medical prescription. Ahzantive must only be administered by a qualified physician experienced in administering intravitreal injections. Additional risk minimisation measures: Educational programme: Beyond routine minimisation activities, additional measures are currently needed to raise patients' and physicians' awareness on identified and potential risks (prescriber guide and video; patient guide 'Your guide | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Specific questionnaire to be used for any post-marketing or study reports suspicious for endophthalmitis and intraocular inflammation (see Annex 4.1) Additional pharmacovigilance activities: None |
| Transient intraocular pressure increase | Routine risk minimisation measures: SmPC sections 4.2, 4.4, 4.8, and 4.9 Package Leaflet sections 2 and 4 Other routine risk minimisation measures beyond the Product Information: Medicinal product subject to restricted medical prescription. Ahzantive must only be administered by a qualified physician experienced in administering intravitreal injections. Additional risk minimisation measures: Educational programme: Beyond routine minimisation activities, additional measures are currently                                                                                                                                                | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Not applicable. Additional pharmacovigilance activities: None                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| Safety concern                            | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Pharmacovigilance activities                                                                                                                                |
|-------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                           | needed to raise patients' and physicians' awareness on identified and potential risks (prescriber guide and video; patient guide 'Your guide to Ahzantive', and its audio version).                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                             |
| Retinal pigment epithelial tears          | Routine risk minimisation measures: SmPC sections 4.4, and 4.8 Package Leaflet sections 2 and 4 Other routine risk minimisation measures beyond the Product Information: Medicinal product subject to restricted medical prescription. Ahzantive must only be administered by a qualified physician experienced in administering intravitreal injections. Additional risk minimisation measures: Educational programme: Beyond routine minimisation activities, additional measures are currently needed to raise patients' and physicians' awareness on identified and potential risks (prescriber guide and video; patient guide 'Your guide | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Not applicable. Additional pharmacovigilance activities: None |
| Cataract (especially of traumatic origin) | Routine risk minimisation measures: SmPC sections 4.2, 4.4, and 4.8 Package Leaflet sections 2, 3 and 4 Other routine risk minimisation measures beyond the Product Information: Medicinal product subject to restricted medical prescription. Ahzantive must only be administered by a qualified physician experienced in administering intravitreal injections. Additional risk minimisation measures:                                                                                                                                                                                                                                       | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Not applicable. Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

| Safety concern           | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Pharmacovigilance activities                                                                                                                                |
|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                          | Educational programme: Beyond routine minimisation activities, additional measures are currently needed to raise patients' and physicians' awareness on identified and potential risks (prescriber guide and video; patient guide 'Your guide to Ahzantive', and its audio version).                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                             |
| Medication errors        | Routine risk minimisation measures: SmPC sections 4.2, 4.9, and 4.6 Package Leaflet sections 1 and 3 Other routine risk minimisation measures beyond the Product Information: Medicinal product subject to restricted medical prescription. Ahzantive must only be administered by a qualified physician experienced in administering intravitreal injections. Additional risk minimisation measures: Educational programme: Beyond routine minimisation activities, additional measures are currently needed to raise physicians' awareness on medication error (prescriber guide and video; patient guide 'Your guide to Ahzantive', and | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Not applicable. Additional pharmacovigilance activities: None |
| Off-label use and misuse | Routine risk minimisation measures: SmPC sections 4.1. 4.3, 4.4 and 4.6 Package Leaflet sections 1, 2 and 3 Other routine risk minimisation measures beyond the Product Information: Medicinal product subject to restricted medical prescription. Ahzantive must only be administered by a qualified physician experienced in administering intravitreal injections.                                                                                                                                                                                                                                                                      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Not applicable. Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

| Safety concern       | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Pharmacovigilance activities                                                                                                                                |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                      | Additional risk minimisation measures: Educational programme: Beyond routine minimisation activities, additional measures are currently needed to raise patients' and physicians' awareness on off-label use (prescriber guide and video; patient guide 'Your guide to Ahzantive', and its audio version).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                             |
| Embryo- fetotoxicity | Routine risk minimisation measures: SmPC sections 4.4, 4.6 and 5.3 Package Leaflet section 2 Other routine risk minimisation measures beyond the Product Information: Medicinal product subject to restricted medical prescription. Ahzantive must only be administered by a qualified physician experienced in administering intravitreal injections. Additional risk minimisation measures: Educational programme: Beyond routine minimisation activities, additional measures are currently needed to raise patients' and physicians' awareness on the potential risk of embryo-toxicity and to underline information on treatment of women of child-bearing potential, and the need for appropriate contraception in women of childbearing potential (prescriber guide and video; patient guide 'Your guide to Ahzantive', and its audio version). | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Not applicable. Additional pharmacovigilance activities: None |

## 2.6.4. Conclusion

The CHMP considers that the risk management plan version 1.0 is acceptable.

<div style=\"page-break-after: always\"></div>

## 2.7. Pharmacovigilance

## 2.7.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.7.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.8. Product information

## 2.8.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the applicant and has been found acceptable for the following reasons:

No full user consultation with target patient groups on the package leaflet has been performed on the basis of a bridging report making reference to Eylea 40 mg/mL solution for injection in a vial. The bridging report submitted by the applicant has been found acceptable.

## 2.8.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Ahzantive (aflibercept) is included in the additional monitoring list as it is a biological product authorised after 1 January 2011.

Therefore, the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Biosimilarity assessment

## 3.1. Comparability exercise and indications claimed

Ahzantive (also referred to as FYB203) 40 mg/mL solution for injection in a vial has been developed as a biosimilar to the reference product Eylea.

The reference product Eylea is authorised in 3 presentations: Eylea 40 mg/mL solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in a vial and Eylea 114.3 mg/ml solution for injection. The approved Eylea indications differ for respective presentations as follows:

- -Eylea 40 mg/mL solution for injection in pre-filled syringe: nAMD, branch RVO or central RVO, DME, myopic CNV in adults. This presentation has an additional indication in preterm infants which is not authorised for  other  presentation:  the  treatment  of  retinopathy  of  prematurity  (ROP)  with  zone  I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease.

<div style=\"page-break-after: always\"></div>

- -Eylea 40 mg/mL solution for injection in a vial: nAMD, branch RVO or central RVO, DME, myopic CNV in adults
- -Eylea 114.3 mg/ml solution for injection: nAMD and DME in adults.

The applicant applied only for one presentation, i.e. Ahzantive 40 mg/mL solution for injection in a vial.

The administration route (intravitreal), posology, and the claimed indications of Ahzantive 40 mg/mL solution for injection in a vial are identical to the reference product Eylea 40 mg/mL solution for injection in a vial. The treatment of retinopathy of prematurity (ROP) with zone I (stage1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease of ROP in preterm infants, approved for Eylea 40 mg/mL solution for injection in pre-filled syringe, has not been claimed.

In  this  case,  not  claiming  the  full  range  of  indications  approved  for  Eylea,  is  deemed  acceptable, considering  the  unavailability  of  respective  pre-filled  syringe  presentation  for  which  an  additional indication is approved and distinct Summary of Product Characteristics for these.

A comprehensive analytical exercise was performed to evaluate Ahzantive (FYB203) similarity with EUEylea  reference  medicinal  product  in  all  relevant  physical  and  chemical  attributes  and  functional characteristics. Analysis covered primary and higher order structure, product related substances and impurities,  variants  related  to  cysteine  chemistry,  charge,  isoaspartate  formation,  glycosylation,  or molecular size, and DP related attributes. Functional activity was compared by a large panel of binding assays and cell-based biological assays covering the mode of action for the targeted indications as well as  Fc-related  functions.  In  addition  to  initial  characterisation  study,  comparative  forced  degradation study and stability  study  under  accelerated  and  stress  conditions  were  performed  and  study  results provide supportive information with regard to totality of evidence.

The in vitro comparability data was provided in quality part of the dossier. The in vitro data support the similarity of FYB203 to the reference products EU-Eylea.

A  repeat-dose  toxicology  study  was  performed  for  the  proposed  aflibercept  biosimilar  FYB203 manufactured using process I to evaluate the toxicological effects of repeated IVT injections of FYB203 in comparison with EU-approved Eylea over a 5-week period in albino NZW rabbits. The overall ocular and systemic toxicological properties of FYB203 were similar to those of EU-approved Eylea. The FYB203 alternative formulation, as well as differences in quality attributes (specifically degree of sialylation), were shown not to impact the safety profile of FYB203.

The clinical development comprised one pivotal phase III clinical study (FYB203-03-01), a parallel-group, randomised, active-controlled, double-masked, multi-centre study to demonstrate therapeutic equivalence  of  FYB203  to  Eylea  and  to  compare  the  safety  and  immunogenicity  in  subjects  with neovascular age-related macular degeneration (nAMD).

The design of the clinical study has been partly discussed in a CHMP Scientific Advice [EMA/CHMP/SAWP/398725/2019].

## 3.2. Results supporting biosimilarity

For most quality attributes including multiple attributes covering the mechanism of action and other functional activities, FYB203 was demonstrated to be highly similar to the reference products EU-Eylea. Results  for  comprehensive  analytical  exercise  of  FYB203  and  EU-Eylea  reference  medicinal  product generally  support  similarity  with  regard  to  primary  and  higher  order  structure  and  functional characterisation. Profile of product related variants (charged and size variants, N-glycosylation variants) is  considered  qualitatively  comparable  and  no  new  variants  were  identified  for  FYB203  however, differences were observed in relative content of the individual variants. Size variants (HMW, LMW) and

<div style=\"page-break-after: always\"></div>

various oxidation/deamidation forms were found generally lower for FYB203 which does not preclude similarity conclusion. Force degradation studies revealed similar degradation pathways and comparative accelerated/stress  stability  showed  similar  degradation  trends  and  rates  in  tested  quality  attributes. Characterisation of potency by orthogonal analytical methods confirmed similarity. Generally comparable results  were  also  found  for  additional  functional  characterisation  regarding  FcRn  and  FcgR  binding properties,  affinity  to  VEGF-B,  VEGF-C,  VEGF-D,  PlGF-1,  PlGF-2,  Galectin-1  and  absence  of  the  Fcmediated  effector  functions  tested  by  relevant  bioassays.  The  observed  differences  in  glycosylation variants  and  minor  analytical  differences  have  been  adequately  justified  regarding  their  impact  on potency of the product.

No dedicated human PK study was conducted, instead the comparability was evaluated in supportive PK analysis in the subset of patients enrolled in phase III study FYB203-03-01. A total of 57 patients were included in the PK subgroup (31 in FYB203 and 26 in Eylea group) and the post-dose plasma levels were evaluated at Week 0 and at Week 8 after IVT injection. The levels of free aflibercept were in the similar range as previously reported.

The systemic exposure was low and there were no significant differences between FYB203 and Eylea treatment groups.

The percentage of ADA-positive patients from the first IP administration through Week 56 was generally low in both treatment arms and ranged between 1.0% and 2.7% in the FYB203 group and between 0.5% and 1.5% for the Eylea overall treatment group. There were 2 patients at week 40 and 3 patients at week 56 who were Nab positive in FYB203 arm and no patient with positive Nab was observed in Eylea arm. The percentage of ADA-positive patients was slightly higher with FYB203 compared to Eylea across all timepoints up to Week 56 and the number of patients with treatment-induced ADA was also slightly higher in FYB203 arm - 4 patients vs 2 patients in Eylea arm. No treatment-boosted ADAs were observed in either treatment group. Based on the provided data and due to overall low incidence of ADAs, the impact of immunogenicity on efficacy and safety is very limited and no concerns arise regarding the impact of immunogenicity on efficacy and safety.

Primary endpoint: The least squares (LS) mean observed for change from baseline in BCVA at Week 8 was  similar  in  both  treatment  groups,  i.e.,  6.6  letters  and  5.6  letters  in  FYB203  and  Eylea  group, respectively in the FAS. The LS mean difference in BCVA of the change from baseline between FYB203 and Eylea at Week 8 was 1.0 letter with 95.2% confidence interval (CI) of [-0.6 letter; 2.5 letters] and was completely contained within the predefined equivalence range (ER) of [-3.5 letters, 3.5 letters].

The  sensitivity  analyses  for  the  primary  endpoint  were  performed  using  linear  mixed  effects  model (MMRM) and analysis of covariance  (ANCOVA)  model  and  results  of  these  analyses  for  the  primary efficacy endpoint supported the robustness of the equivalence between FYB203 and Eylea based on FAS.

Secondary endpoints: (e.g., change in BCVA by ETDRS letters; foveal (centre point and central subfield) thickness at different time points and over time; the proportion of subjects who gained or lost ≥5, 10, or 15 ETDRS letters compared to baseline; percentage of subjects with fluid-free macula; change in lesion size compared to baseline and quality of life assessment) were overall comparable between the FYB203 and Eylea treatment groups.

A total of 433 nAMD patients (215 patients in FYB203 arm vs. 218 patients Eylea arm) have received at least one dose of study treatment.

A total of 196 (91.2%) patients in the FYB203 group and 206 (94.1%) patients in the Eylea group completed the study until Week 56. Until Week 56, 183 patients (85.1%) in the FYB203 group and 199 patients (91.3%) in the Eylea group received all 8 scheduled injections (88.2% in total). The mean

<div style=\"page-break-after: always\"></div>

(SD) treatment duration was 323.1 (58.97) days and the mean (SD) study duration was 398.7 (53.03) days.

The number of scheduled IVT injections and the duration of exposure to one of the study treatments were comparable between both treatment groups.

Overall, the incidence of TEAEs was slightly higher in the FYB203 arm vs. Eylea arm (76.7 % vs 72.5 %). Incidence of ocular TEAEs in study eye were slightly lower in FYB203 arm vs Eylea arm (31.2 % vs 34.4 %) and also in fellow eye (20.9 % vs 22.0%).  Systemic TEAEs were observed in FYB203 arm (57.7 %) with higher incidence compared to Eylea arm (51.8 %). Incidence of serious TEAEs is lower in FYB203 arm compared to Eylea arm (7.9 % vs 10.6 %) as well as the incidence of severe TEAEs (3.7 % vs 5.0 %).

According to the intensity of reported TEAEs, both arms (FYB203 and Eylea) are considered comparable. The majority of TEAEs were mild (44.7 % FYB203 vs 39.0 % Eylea) or moderate (27.4 % FYB203 vs 26.6 % Eylea) intensity. Severe TEAEs were observed in lower incidence in FYB203 arm (10 patients/4.7 % vs 15 patients/6.9 %).

Incidence of TEAEs related to the treatment were slightly higher in FYB203 arm compared to Eylea (9.3 %  vs  7.3  %).  The  most  frequently  reported  related  TEAEs  were  from  SOC  Eye  disorders  and Investigations.  Majority of related PTs occurred with similar frequencies in both treatment groups and/or mostly in single patients.

Incidence of TEAEs related to the study procedure were slightly lower in FYB203 arm compared to Eylea (13.0 % vs 17.0 %). The most frequently reported related TEAEs were from SOC Eye disorders and Investigations.

Overall,  the  SAEs  occurrences  (excluding  deaths)  until  Week  56  are  comparable  in  the  2  treatment groups: 30 events in 18 (8.4%) patients treated with FYB203 and 39 events in 27 (12.4%) patients treated with Eylea. All systemic SAEs reported until Week 56 were unrelated to study procedure or to study treatment except for 1 event treated with FYB203.

A total of 13 (3.0%) patients reported AESIs until Week 56. 10 events in 6 (2.8%) patients treated with FYB203 and 12 events in 7 (3.2%) patients treated with Eylea. The most frequent AESI belonged to the SOC Eye disorders and were classified as ocular inflammatory AESIs in study eye (4 patients in FYB203 arm vs 4 patients in Eylea arm).

TEAEs cerebrovascular accident and subretinal fluid leading to discontinuation of the study treatment were judged as possibly/probably related to study treatment.

All the events leading to death were considered not related to the study drug or study procedure.

The overall safety profile of FYB203 is in line with known adverse events of the reference medicinal product Eylea [Eylea SmPC, 2024].  Overall, FYB203 and Eylea demonstrated comparable safety profiles.

## 3.3. Uncertainties and limitations about biosimilarity

The differences between FYB203 and EU-Eylea reference medicinal product have been identified in Nglycosylation profile with regard to overall fucosylation, galactosylation, mannosylation and sialylation content.  Primarily  differences  in  sialylation  content  contributed  to  different  relative  content  and distribution of charged variants. It was demonstrated that observed differences in N-glycosylation profile do  not  impact  the  primary  or  secondary  mechanism  of  action  of  aflibercept.  Potential  impact  of differences  in  N-glycosylation  profile  to  pharmacokinetic  properties  is  not  expected  in  regard  to  the intravitreal application which is supported by scientifically sound discussion. Additional sporadic findings

<div style=\"page-break-after: always\"></div>

of results outside of the quality ranges of the EU-Eylea product for various quality attributes in initial characterisation study do not preclude the similarity conclusion. All residual uncertainty with regard to demonstration of analytical similarity has been sufficiently resolved.

A repeat-dose toxicology study was performed with the aflibercept biosimilar FYB203 to evaluate the toxicological effects of repeated IVT injections of FYB203 in comparison with EU-approved Eylea over a 5-week period in albino NZW rabbits. However, nonclinical in vivo data in the context of a biosimilar development are regarded of supportive value only and no conclusions on similarity can be drawn due to general lack of sensitivity of in vivo (animal) models regarding biosimilarity assessment.

There were minor differences in aflibercept plasma levels between the treatment arms, at Week 0, the plasma  concentrations  of  aflibercept  were  slightly  higher  in  the  FYB203  group  (GM  21.667  ng/mL) compared to Eylea group (GM 14.235 ng/mL), but with large variability (CV 58.9% vs 119.3%).

The percentage of ADA-positive patients was slightly higher with FYB203 compared to Eylea across all timepoints up to Week 56 and the number of patients with treatment-induced ADA was also slightly higher in FYB203 arm - 4 patients vs 2 patients in Eylea arm.

No subject in the PK subset had positive ADA result so the impact of ADA on pharmacokinetics cannot be assessed. Also due to overall low incidence of ADAs, the impact of immunogenicity on efficacy and safety is very limited but no concerns arise in this context.

A simulation study had been conducted prior to the initiation of the study to assess the impact of a masked sample size review (MSSR) on possible inflation of overall type 1 error probability. Results of simulations suggested a necessary adjustment of alpha to 2.4% for all EU-specific statistical analyses which corresponded to consideration of two-sided 95.2% confidence interval (CI) instead of nominal 95% CI. It was pointed out by the assessor that simulation may not exhaust all possible scenarios and analytical calculation of OT1EP should be performed to justify that the 95.2% CI was appropriate. Despite existence of analytical solution for evaluation of OT1EP inflation in case of equivalence trials (see Friede and Kieser (2003): Blinded sample size reassessment in non-inferiority and equivalence), the applicant found analytical  calculation  imprecise.  Instead,  the  applicant  performed  tipping  point  analysis  which searched for maximum confidence level (CL) when equivalence would still be concluded across primary endpoint and key secondary endpoint and both for full analysis set and per protocol set considered for these  endpoints.  Maximum  value  of  CL  is  99.90%.  Consequently,  99.90%  CI  can  be  considered  as sufficient to cover possible OT1EP inflation due to MSSR. Hence issue with MSSR is resolved.

The safety database is considered sufficient to assess the comparability regarding common (≥1/100 to &lt;1/10) and very common (≥1/10) adverse events. However, it is too small to inform on less frequently occurring adverse events.

## 3.4. Discussion on biosimilarity

A  comprehensive  analytical  exercise  was  performed  to  evaluate  FYB203  similarity  with  EU-Eylea reference medicinal product in all relevant physical and chemical attributes and functional characteristics. In addition to initial characterisation study, comparative forced degradation study and stability study under accelerated and stress conditions were performed and study results provide supportive information with regard to totality of evidence.

Overall, the differences between FYB203 and EU-Eylea reference medicinal product have been identified in  N-glycosylation  profile  with  regard  to  overall  fucosylation,  galactosylation,  mannosylation  and sialylation  content.  Also,  lower  levels  of  oxidation  and  deamidation  was  observed  in  FYB203.  These findings contributed to different relative content and distribution of charged variants and lower Fc γ RIIIA affinity.  Nonetheless,  it  has  been  justified  that  this  heterogeneity  does  not  significantly  impact  the

<div style=\"page-break-after: always\"></div>

primary or secondary mechanism of action of aflibercept as generally robust functional characterisation supports the similarity between FYB203 and EU-Eylea. Also, it is concluded that observed differences presumably  do  not  have  impact  on  safety  and  immunogenicity  of  the  FYB203.  Potential  impact  of differences  in  N-glycosylation  profile  to  pharmacokinetic  properties  is  not  expected  in  regard  to  the intravitreal application which is supported by scientifically sound discussion. Available non-clinical data for all tested FYB203 batches showed a high degree of similarity to treatment with Eylea in the relevant ocular  matrices  (vitreous  humor,  aqueous  humor,  retina/choroid  tissue)  which  further  support  this conclusion.  All  residual  uncertainty  with  regard  to  demonstration  of  analytical  similarity  has  been sufficiently  resolved.  FYB203  is  considered  similar  to  EU-Eylea  in  relevant  physical  and  chemical attributes and functional characteristics and identified differences in quality profile are not expected to affect clinical performance.

Based on the PK data in subset of patients with nAMD there were no significant differences in systemic exposure between FYB203 and Eylea treatment groups identified.

The incidence of ADA-positive patients from the first IP administration through Week 56 was generally low and comparable in both treatment arms.

The PK and immunogenicity data are considered supportive of biosimilarity between FYB203 and Eylea.

The pivotal clinical study FYB203-03-01 was adequately designed to demonstrate clinical equivalence between FYB203 and Eylea on both with respect to efficacy and safety. The selected study population, consisting  of  patients  with  nAMD  as  well  as  primary  and  secondary  efficacy  endpoints  are  deemed appropriate for this biosimilarity exercise.

The primary efficacy endpoint, change in BCVA from baseline to Week 8, was well within the pre-defined equivalence range of +/- 3.5 letters both for PPS and FAS and demonstrated equivalent efficacy in the primary endpoint.

The overall safety profile of FYB203 is in line with known adverse events of Eylea (SmPC). Only few disbalances  were  observed  within  the  study  (PTs  Hypertension,  Osteoarthritis,  SOC  Gastrointestinal Disorders) and in higher incidence of observed TEAEs leading to withdrawal of study treatment or to complete discontinuation of study in the FYB203 arm. These imbalances were discussed by the applicant. The  provided  justification  is  considered  adequate  and  the  overall  safety  biosimilarity  is  considered comparable between both arms. No differences in expected adverse events in each indication of use in adult patient population is expected.

## 3.5. Extrapolation of safety and efficacy

In the EU, the reference product Eylea is approved in adults for the treatment of nAMD, RVO, DME and myopic  CNV  in  adults.  The  clinical  development  programme  for  the  proposed  biosimilar  FYB203 comprised a single pivotal phase III study (FYB203-03-01) to investigate Eylea and FYB203 regarding efficacy,  safety,  pharmacokinetics  (in  a  subset  of  patients)  and  immunogenicity  in  the  treatment  of subjects with nAMD.

The applicant claimed the same indication as approved for the respective presentation of the reference product, Eylea 40 mg/mL solution for injection in a vial (nAMD, branch RVO or central RVO, DME, myopic CNV in adults), based on the common mechanism of action across all indications and comparable PK, safety,  and  immunogenicity  profiles  of  aflibercept  (Eylea)  across  the  approved  indications.  The pathogenesis of all approved indications involves angiogenesis mediated by the members of the VEGF family  of  angiogenic  factors,  and  the  mechanism  of  action  of  aflibercept  in  nAMD  is  considered representative of the mechanism of action of aflibercept in all other approved indications for Eylea.

<div style=\"page-break-after: always\"></div>

Thus, the justification presented to allow extrapolation from nAMD to all approved indications of Eylea in adults is considered adequate.

Clinical comparability of the overall safety profile of FYB203 with Eylea has been shown. Safety profile is in  line  with  known  adverse  events  of  the  reference  medicinal  product  Eylea  [Eylea  SmPC,  2024]. Biosimilarity is supported from a safety perspective.

## 3.6. Additional considerations

Most neovascular and VEGF dependent retina diseases including particularly AMD are diseases seen in adults. Therefore, the potential for off-label use in the paediatric population is expected to be very limited due to the nature of paediatric ophthalmic diseases. Aflibercept may be also used to treat some cases of retinopathy  of  prematurity  (ROP).  Compared  to  the  reference  medicinal  product  Eylea  (40  mg/mL solution for injection in pre-filled syringe), Ahzantive (40 mg/mL solution for injection in a vial) is not proposed to be approved for preterm infants for the treatment of ROP. Risk of off-label use and misuse is considered to be important potential risk in the risk management plan (RMP); thus it is expected to be routinely monitored. The number of such cases is considered very low and their care is provided by paediatric ophthalmologists who are tertiary care-based and experienced in the care of these infants. An educational programme is proposed to be performed as an additional risk minimisation measure to raise patients' awareness on identified and potential risks.

Intentional misuse, as such, is difficult to prevent because of the user's deliberate decision to deviate from the provided instructions. However, intravitreal injections must be carried out according to medical standards and applicable guidelines by a qualified physician experienced in administering intravitreal injections.

No safety additional comments on the potential for misuse and off label use have been raised.

## 3.7. Conclusions on biosimilarity and benefit risk balance

Based on the review of the submitted data, Ahzantive is considered biosimilar to Eylea.

Therefore, a benefit/risk balance comparable to the reference product can be concluded.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Ahzantive is favourable in the following indication(s):

- neovascular (wet) age-related macular degeneration (AMD) (see section 5.1),
- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),
- visual impairment due to diabetic macular oedema (DME) (see section 5.1),
- visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1).

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product

<div style=\"page-break-after: always\"></div>

Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## · Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## · Additional risk minimisation measures

The MAH has agreed to provide EU Educational Material for Ahzantive.

Prior to launch in each Member State the MAH shall agree the final educational material with the National Competent Authority.

The MAH ensures that, following discussions and agreements with the National Competent Authorities in each Member State where Ahzantive is marketed, ophthalmological clinics where Ahzantive is expected to be used for the treatment of adult patients are provided with an updated physician information pack containing the following elements:

- Physician information booklet
- Intravitreal injection procedure video
- Intravitreal injection procedure pictogram
- Patient information pack

The physician information in the educational material contains the following key elements:

- Techniques for the intravitreal injection including use of a 30 G needle, and angle of injection
- Confirmation that the vial is for single use in adults only
- The need to expel excess volume of the syringe before injecting Ahzantive to avoid overdose
- Patient monitoring after intravitreal injection including monitoring for visual acuity and increase of intraocular pressure post-injection
- Key signs and symptoms of intravitreal injection related adverse events including endophthalmitis, intraocular inflammation, increased intraocular pressure, retinal pigment epithelial tear and cataract
- Female patients of childbearing potential have to use effective contraception and pregnant women should not use Ahzantive

The patient information pack of the educational material includes a patient information guide 'Your

<div style=\"page-break-after: always\"></div>

guide to Ahzantive' and its audio version. The patient information guide contains following key elements:

- Patient information leaflet
- Who should be treated with Ahzantive
- How to prepare for Ahzantive treatment
- What are the steps following treatment with Ahzantive
- Key signs and symptoms of serious adverse events including endophthalmitis, intraocular inflammation, intraocular pressure increased, retinal pigment epithelial tear, and cataract
- When to seek urgent attention from their health care provider
- Female patients of childbearing potential have to use effective contraception and pregnant women should not use Ahzantive